

Comprehensive genomic characterization of squamous

Nature

489, 519-525

DOI: [10.1038/nature11404](https://doi.org/10.1038/nature11404)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. <i>Science</i> , 1978, 202, 975-977.	6.0	185
2	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. <i>Revue De Gestion Des Ressources Humaines</i> , 2012, N° 83, 20-30.	0.1	8
3	Tendon injuries of the hand in athletes. <i>Türk Ortopedi Ve Travmatoloji Birliđi Derneđi</i> , 2012, 11, 201-213.	0.0	1
4	Targeted therapy for squamous cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 293-300.	1.5	41
6	Using MicroRNAs to Inform Clinical Decision Making in Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1077-1079.	2.5	1
7	The Role of Sulfhydryl Reactivity of Small Molecules for the Activation of the KEAP1/NRF2 Pathway and the Heat Shock Response. <i>Scientifica</i> , 2012, 2012, 1-19.	0.6	24
8	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. <i>Cell</i> , 2012, 150, 1107-1120.	13.5	1,591
9	What are we learning from the cancer genome?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 621-630.	12.5	50
10	Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers. <i>Cell</i> , 2012, 150, 1121-1134.	13.5	1,038
11	Bringing the genomic landscape of small-cell lung cancer into focus. <i>Nature Genetics</i> , 2012, 44, 1074-1075.	9.4	51
12	The Transcriptional Consequences of Somatic Amplifications, Deletions, and Rearrangements in a Human Lung Squamous Cell Carcinoma. <i>Neoplasia</i> , 2012, 14, 1075-IN16.	2.3	16
13	DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. <i>Genome Biology</i> , 2012, 13, R124.	13.9	247
14	Studies offer a "panoramic view" of lung cancer. <i>Nature</i> , 2012, , .	13.7	0
15	Integrated analysis of recurrent properties of cancer genes to identify novel drivers. <i>Genome Biology</i> , 2013, 14, R52.	13.9	33
16	Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. <i>Genome Biology</i> , 2013, 14, R24.	13.9	65
17	Tailored management of advanced squamous non-small cell lung cancer (NSCLC). <i>Current Respiratory Care Reports</i> , 2013, 2, 10-16.	0.6	0
18	Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. <i>Frontiers of Medicine</i> , 2013, 7, 157-171.	1.5	34
19	The Impact of Genomic Changes on Treatment of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 770-775.	2.5	91

#	ARTICLE	IF	CITATIONS
20	Multiplicity of Hormone-Secreting Tumors: Common Themes About Cause, Expression, and Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3139-3148.	1.8	9
21	Role of ABL family kinases in cancer: from leukaemia to solid tumours. <i>Nature Reviews Cancer</i> , 2013, 13, 559-571.	12.8	371
22	The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. <i>Nature</i> , 2013, 500, 207-211.	13.7	302
23	Next generation sequencing in cancer research and clinical application. <i>Biological Procedures Online</i> , 2013, 15, 4.	1.4	102
24	Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. <i>BMC Genomics</i> , 2013, 14, S8.	1.2	12
25	Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. <i>BMC Genomics</i> , 2013, 14, 440.	1.2	21
26	Update in Lung Cancer and Mesothelioma 2012. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 157-166.	2.5	29
27	New Targets in Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2013, 15, 411-423.	1.8	12
28	Systems Biology. , 2013, , .		9
29	DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies. <i>American Journal of Human Genetics</i> , 2013, 93, 439-451.	2.6	67
30	Harnessing the genome for characterization of Gâ€protein coupled receptors in cancer pathogenesis. <i>FEBS Journal</i> , 2013, 280, 4729-4738.	2.2	28
31	Next Generation Sequencing in Cancer Research. , 2013, , .		5
32	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. <i>British Journal of Cancer</i> , 2013, 109, 827-835.	2.9	91
33	The Cellâ€™s Nucleolus: an Emerging Target for Chemotherapeutic Intervention. <i>ChemMedChem</i> , 2013, 8, 1441-1449.	1.6	51
35	Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. <i>Current Opinion in Chemical Biology</i> , 2013, 17, 369-378.	2.8	21
36	New Advances in the Precision Medicine of Lung Cancer. <i>Current Pathobiology Reports</i> , 2013, 1, 1-8.	1.6	4
37	Identification of thresholds for dichotomizing DNA methylation data. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , 2013, 2013, 8.	1.4	12
38	Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics. <i>Science</i> , 2013, 342, 1235587.	6.0	341

#	ARTICLE	IF	CITATIONS
39	Genomic insights into cancer-associated aberrant CpG island hypermethylation. <i>Briefings in Functional Genomics</i> , 2013, 12, 174-190.	1.3	105
40	Targeted therapy for NSCLC with driver mutations. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1401-1412.	1.4	42
41	Inferring tumour purity and stromal and immune cell admixture from expression data. <i>Nature Communications</i> , 2013, 4, 2612.	5.8	5,788
42	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1381-1397.	2.5	6
43	Genetic alterations defining NSCLC subtypes and their therapeutic implications. <i>Lung Cancer</i> , 2013, 82, 179-189.	0.9	262
44	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. <i>Nature Biotechnology</i> , 2013, 31, 1023-1031.	9.4	1,785
45	YEATS4 Is a Novel Oncogene Amplified in Non-Small Cell Lung Cancer That Regulates the p53 Pathway. <i>Cancer Research</i> , 2013, 73, 7301-7312.	0.4	38
46	A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4140-4147.	0.8	250
47	A Genomics-Based Classification of Human Lung Tumors. <i>Science Translational Medicine</i> , 2013, 5, 209ra153.	5.8	365
48	Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed. <i>Science</i> , 2013, 339, 1563-1566.	6.0	142
49	OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. <i>Bioinformatics</i> , 2013, 29, 2238-2244.	1.8	397
50	DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. <i>Nature Communications</i> , 2013, 4, 1502.	5.8	100
51	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. <i>Journal of Clinical Pathology</i> , 2013, 66, 839-846.	1.0	27
52	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	13.5	3,979
53	Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2167-2172.	0.8	170
54	Next-generation sequencing for lung cancer. <i>Future Oncology</i> , 2013, 9, 1323-1336.	1.1	38
55	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 5195-5205.	0.4	153
56	Pan-cancer patterns of somatic copy number alteration. <i>Nature Genetics</i> , 2013, 45, 1134-1140.	9.4	1,616

#	ARTICLE	IF	CITATIONS
57	Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. , 2013, , 359-371.		0
58	ROS1 fusions in Chinese patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 1822-1827.	0.6	77
59	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. <i>Respiratory Medicine</i> , 2013, 107, 1755-1762.	1.3	30
60	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. <i>Lancet Respiratory Medicine</i> , 2013, 1, 251-261.	5.2	74
61	High-quality biobanking for personalized precision medicine: BioSpecimen Sciences at the helm. <i>Diagnostic Histopathology</i> , 2013, 19, 447-456.	0.2	10
62	Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. <i>Lung Cancer</i> , 2013, 82, 171-172.	0.9	56
63	Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy. <i>Clinical Lung Cancer</i> , 2013, 14, 627-635.	1.1	12
64	Strategies for improving outcomes in NSCLC: A look to the future. <i>Lung Cancer</i> , 2013, 82, 375-382.	0.9	29
65	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. <i>Cell</i> , 2013, 155, 552-566.	13.5	151
66	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , 2013, 45, 1113-1120.	9.4	6,265
67	NPEBseq: nonparametric empirical bayesian-based procedure for differential expression analysis of RNA-seq data. <i>BMC Bioinformatics</i> , 2013, 14, 262.	1.2	28
68	Sister chromatid cohesion defects are associated with chromosome instability in Hodgkin lymphoma cells. <i>BMC Cancer</i> , 2013, 13, 391.	1.1	19
69	Characterization of aberrant pathways across human cancers. <i>BMC Systems Biology</i> , 2013, 7, S1.	3.0	11
70	Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data. <i>Human Genomics</i> , 2013, 7, 23.	1.4	55
71	Relative impact of multi-layered genomic data on gene expression phenotypes in serous ovarian tumors. <i>BMC Systems Biology</i> , 2013, 7, S9.	3.0	24
72	Integrated molecular portrait of non-small cell lung cancers. <i>BMC Medical Genomics</i> , 2013, 6, 53.	0.7	51
73	Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung. <i>Current Treatment Options in Oncology</i> , 2013, 14, 568-579.	1.3	6
74	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. <i>Genome Medicine</i> , 2013, 5, 91.	3.6	146

#	ARTICLE	IF	CITATIONS
75	Emerging patterns of somatic mutations in cancer. <i>Nature Reviews Genetics</i> , 2013, 14, 703-718.	7.7	442
76	Integration of cancer genomics with treatment selection. <i>Cancer</i> , 2013, 119, 3914-3928.	2.0	15
77	Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. <i>British Journal of Cancer</i> , 2013, 109, 1599-1608.	2.9	25
78	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. <i>American Journal of Human Genetics</i> , 2013, 92, 974-980.	2.6	239
79	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. <i>Future Oncology</i> , 2013, 9, 377-386.	1.1	18
80	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	6.6	700
81	Emerging landscape of oncogenic signatures across human cancers. <i>Nature Genetics</i> , 2013, 45, 1127-1133.	9.4	1,190
82	Lung Cancer Biomarkers: Present Status and Future Developments. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1191-1198.	1.2	105
83	Gelsius: A Literature-Based Workflow for Determining Quantitative Associations between Genes and Biological Processes. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2013, 10, 619-631.	1.9	2
84	Tumor subtype identification with weighted sparse non-negative matrix factorization for multiple heterogeneous data integration. , 2013, , .		2
85	Pattern discovery and cancer gene identification in integrated cancer genomic data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4245-4250.	3.3	361
86	Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. <i>European Journal of Cancer</i> , 2013, 49, 1216-1225.	1.3	87
87	Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. <i>Nature Genetics</i> , 2013, 45, 131-132.	9.4	500
88	The Gasotransmitter Hydrogen Sulfide Induces Nrf2-Target Genes by Inactivating the Keap1 Ubiquitin Ligase Substrate Adaptor Through Formation of a Disulfide Bond Between Cys-226 and Cys-613. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 465-481.	2.5	189
89	New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 992-1001.	0.8	458
90	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
91	Network, nodes and nexus: systems approach to multitarget therapeutics. <i>Current Opinion in Biotechnology</i> , 2013, 24, 1129-1136.	3.3	7
92	Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 462-467.	0.9	66

#	ARTICLE	IF	CITATIONS
93	Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. <i>Cancer Cell</i> , 2013, 24, 710-724.	7.7	252
94	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 485-497.	1.2	16
95	Tight junction proteins: From barrier to tumorigenesis. <i>Cancer Letters</i> , 2013, 337, 41-48.	3.2	178
96	An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. <i>Lung Cancer</i> , 2013, 81, 487-490.	0.9	33
98	PPAPDC1B and WHSC1L1 Are Common Drivers of the 8p11-12 Amplicon, Not Only in Breast Tumors But Also in Pancreatic Adenocarcinomas and Lung Tumors. <i>American Journal of Pathology</i> , 2013, 183, 1634-1644.	1.9	32
99	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. <i>European Journal of Cancer</i> , 2013, 49, 3076-3082.	1.3	26
100	The era of big trials is over. <i>Lancet Oncology</i> , The, 2013, 14, 12-14.	5.1	4
101	Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination. <i>Cancer Research</i> , 2013, 73, 2199-2210.	0.4	209
102	Other signalization targets. <i>Targeted Oncology</i> , 2013, 8, 69-77.	1.7	6
103	Personalized therapy on the horizon for squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2013, 80, 249-255.	0.9	60
104	Biomarkers and Molecular Testing for Early Detection, Diagnosis, and Therapeutic Prediction of Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2013, 23, 211-224.	0.4	34
105	Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 58-65.	1.0	47
106	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nature Biotechnology</i> , 2013, 31, 213-219.	9.4	3,934
107	Surgery for NSCLC in the era of personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 235-244.	12.5	85
108	Mechanistic links between COPD and lung cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 233-245.	12.8	342
109	Interplay between the Cancer Genome and Epigenome. <i>Cell</i> , 2013, 153, 38-55.	13.5	733
110	Lessons from the Cancer Genome. <i>Cell</i> , 2013, 153, 17-37.	13.5	1,133
111	The future of epigenetic therapy in solid tumours—lessons from the past. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 256-266.	12.5	299

#	ARTICLE	IF	CITATIONS
112	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. <i>Nature Genetics</i> , 2013, 45, 478-486.	9.4	671
113	Cancer genome-sequencing study design. <i>Nature Reviews Genetics</i> , 2013, 14, 321-332.	7.7	100
114	Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. <i>OncoTargets and Therapy</i> , 2013, 6, 223.	1.0	38
115	The Pivotal Role of IKK β in the Development of Spontaneous Lung Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2013, 23, 527-540.	7.7	100
116	Understanding genomic alterations in cancer genomes using an integrative network approach. <i>Cancer Letters</i> , 2013, 340, 261-269.	3.2	70
117	Identification of driver mutations in lung cancer: first step in personalized cancer. <i>Targeted Oncology</i> , 2013, 8, 3-14.	1.7	26
118	Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. <i>Science Signaling</i> , 2013, 6, p1.	1.6	11,344
119	End-joining, translocations and cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 443-454.	12.8	311
120	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> , 2013, 499, 214-218.	13.7	4,761
121	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. <i>Journal of Human Genetics</i> , 2013, 58, 346-352.	1.1	52
122	Genotype analysis of the NRF2 gene mutation in lung cancer. <i>International Journal of Molecular Medicine</i> , 2013, 31, 1135-1138.	1.8	26
123	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013, 45, 791-798.	9.4	394
124	Lung cancer chemoprevention: current status and future prospects. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 334-343.	12.5	123
125	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. <i>Nature Genetics</i> , 2013, 45, 592-601.	9.4	1,082
126	Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. <i>Lung Cancer</i> , 2013, 79, 215-220.	0.9	30
127	Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 908-913.	3.6	524
128	Cancer systems biology in the genome sequencing era: Part 1, dissecting and modeling of tumor clones and their networks. <i>Seminars in Cancer Biology</i> , 2013, 23, 279-285.	4.3	69
129	Cancer systems biology in the genome sequencing era: Part 2, evolutionary dynamics of tumor clonal networks and drug resistance. <i>Seminars in Cancer Biology</i> , 2013, 23, 286-292.	4.3	64

#	ARTICLE	IF	CITATIONS
130	The genetic landscape of high-risk neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 279-284.	9.4	990
131	Chromosomal instability and transcriptome dynamics in cancer. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 391-402.	2.7	46
132	Identification of recurrent <i>FGFR3</i> fusion genes in lung cancer through kinome-centred RNA sequencing. <i>Journal of Pathology</i> , 2013, 230, 270-276.	2.1	113
133	Biopsies: next-generation biospecimens for tailoring therapy. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 437-450.	12.5	110
134	Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes. <i>Cell</i> , 2013, 153, 919-929.	13.5	308
135	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 25.	0.4	30
136	AQP4 (aquaporin 4). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2013, , .	0.1	0
137	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 415-453.	1.2	397
138	Genomics-Driven Oncology: Framework for an Emerging Paradigm. <i>Journal of Clinical Oncology</i> , 2013, 31, 1806-1814.	0.8	315
139	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 828-860.	1.2	415
140	A categorical network approach for discovering differentially expressed regulations in cancer. <i>BMC Medical Genomics</i> , 2013, 6, S1.	0.7	4
142	From human genome to cancer genome: The first decade. <i>Genome Research</i> , 2013, 23, 1054-1062.	2.4	132
143	KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer. <i>Cancer Research</i> , 2013, 73, 5532-5543.	0.4	66
144	Reducing Sequence Artifacts in Amplicon-Based Massively Parallel Sequencing of Formalin-Fixed Paraffin-Embedded DNA by Enzymatic Depletion of Uracil-Containing Templates. <i>Clinical Chemistry</i> , 2013, 59, 1376-1383.	1.5	94
145	Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, 1858-1865.	0.8	116
146	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 823-859.	0.5	792
148	Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers. <i>International Journal of Oncology</i> , 2013, 43, 755-764.	1.4	19
149	Harnessing massively parallel DNA sequencing for the personalization of cancer management. <i>Personalized Medicine</i> , 2013, 10, 183-190.	0.8	2

#	ARTICLE	IF	CITATIONS
150	Meta-analysis of Genomic and Proteomic Features to Predict Synthetic Lethality of Yeast and Human Cancer. , 2013, , .		5
151	Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4532-4540.	3.2	307
152	Epidemiology of Lung Cancer. <i>Seminars in Interventional Radiology</i> , 2013, 30, 093-098.	0.3	248
153	Androgen Receptor-Target Genes in African American Prostate Cancer Disparities. <i>Prostate Cancer</i> , 2013, 2013, 1-15.	0.4	45
154	Personalizing Therapy in Advanced Non-“Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 822-836.	0.8	20
155	Too New for Textbooks. <i>American Biology Teacher</i> , 2013, 75, 480-485.	0.1	0
156	QPLOT: A Quality Assessment Tool for Next Generation Sequencing Data. <i>BioMed Research International</i> , 2013, 2013, 1-4.	0.9	17
157	Integrative Genomics Analysis Identifies Candidate Drivers at 3q26-29 Amplicon in Squamous Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2013, 19, 5580-5590.	3.2	56
158	Lung Cancer Gene Signatures and Clinical Perspectives. <i>Microarrays (Basel, Switzerland)</i> , 2013, 2, 318-339.	1.4	14
159	Targeting Genomic Alterations in Squamous Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 195.	1.3	16
160	The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment. <i>Science Signaling</i> , 2013, 6, pe13.	1.6	64
161	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). <i>Annals of Oncology</i> , 2013, 24, 2371-2376.	0.6	510
162	Genomics of Squamous Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 707-716.	1.9	27
163	Low-copy <i>piggyBac</i> transposon mutagenesis in mice identifies genes driving melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E3640-9.	3.3	28
164	Targeted therapies of solid cancers. <i>Current Opinion in Oncology</i> , 2013, 25, 296-304.	1.1	21
165	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 263-271.	1.0	4
166	Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomes. <i>Nucleic Acids Research</i> , 2013, 41, 7615-7624.	6.5	26
167	MYC Phosphorylation at Novel Regulatory Regions Suppresses Transforming Activity. <i>Cancer Research</i> , 2013, 73, 6504-6515.	0.4	33

#	ARTICLE	IF	CITATIONS
168	Identification of Transcriptional Subgroups in <i>EGFR</i> -Mutated and <i>EGFR</i> / <i>KRAS</i> Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 5116-5126.	3.2	21
169	COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. <i>Nucleic Acids Research</i> , 2013, 41, e117-e117.	6.5	101
170	BlackOPs: increasing confidence in variant detection through mappability filtering. <i>Nucleic Acids Research</i> , 2013, 41, e178-e178.	6.5	19
171	Re-thinking cell cycle regulators: the cross-talk with metabolism. <i>Frontiers in Oncology</i> , 2013, 3, 4.	1.3	65
172	Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. <i>Nucleic Acids Research</i> , 2013, 41, 6857-6869.	6.5	54
173	Nicotine Induces the Up-regulation of the $\alpha 7$ -Nicotinic Receptor ($\alpha 7$ -nAChR) in Human Squamous Cell Lung Cancer Cells via the Sp1/GATA Protein Pathway. <i>Journal of Biological Chemistry</i> , 2013, 288, 33049-33059.	1.6	74
174	Molecular Pathways: <i>Fumarate Hydratase</i> -Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3345-3352.	3.2	172
175	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer. <i>Cancer Research</i> , 2013, 73, 6289-6298.	0.4	108
176	Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11982-11987.	3.3	605
177	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. <i>Genome Biology</i> , 2013, 14, r106.	13.9	102
178	Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non—Small-Cell Lung Cancer: ECOG 5597. <i>Journal of Clinical Oncology</i> , 2013, 31, 4179-4187.	0.8	96
179	Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor. <i>Journal of Carcinogenesis</i> , 2013, 12, 16.	2.5	20
180	A Double-Edged Sword: How Oncogenes and Tumor Suppressor Genes Can Contribute to Chromosomal Instability. <i>Frontiers in Oncology</i> , 2013, 3, 164.	1.3	56
181	Forget Transcription: Translation Is Where the Action Is. <i>Molecular and Cellular Biology</i> , 2013, 33, 1884-1885.	1.1	5
182	Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci. <i>Journal of Internal Medicine</i> , 2013, 274, 414-424.	2.7	24
183	A potential new enriching trial design for selecting non—small—cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. <i>Cancer Medicine</i> , 2013, 2, 360-366.	1.3	9
184	The silent mutational landscape of infant <i>MLL</i> — <i>AF4</i> pro—acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 954-960.	1.5	50
185	Transforming Epidemiology for 21st Century Medicine and Public Health. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 508-516.	1.1	104

#	ARTICLE	IF	CITATIONS
186	The Complexity of Thyroid Transcription Factor 1 with Both Pro- and Anti-oncogenic Activities. <i>Journal of Biological Chemistry</i> , 2013, 288, 24992-25000.	1.6	29
187	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. <i>Clinical Cancer Research</i> , 2013, 19, 4315-4325.	3.2	32
188	The FAT epidemic: A gene family frequently mutated across multiple human cancer types. <i>Cell Cycle</i> , 2013, 12, 1011-1012.	1.3	28
189	Recurrent patterns of DNA methylation in the <i>ZNF154</i> , <i>CASP8</i> , and <i>VHL</i> promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. <i>Epigenetics</i> , 2013, 8, 1355-1372.	1.3	52
190	The mutational landscape of phosphorylation signaling in cancer. <i>Scientific Reports</i> , 2013, 3, 2651.	1.6	149
191	Cancer genome statistics lesson. <i>Science-Business EXchange</i> , 2013, 6, 676-676.	0.0	0
192	Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases. <i>Cell Research</i> , 2013, 23, 599-619.	5.7	71
193	RET, set, go. <i>Science-Business EXchange</i> , 2013, 6, 326-326.	0.0	0
194	Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes. <i>Scientific Reports</i> , 2013, 3, 3311.	1.6	8
195	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. <i>Nature Genetics</i> , 2013, 45, 1121-1126.	9.4	102
196	Drilling into big cancer-genome data. <i>Nature Methods</i> , 2013, 10, 293-297.	9.0	24
197	DNA polymerase ϵ and γ exonuclease domain mutations in endometrial cancer. <i>Human Molecular Genetics</i> , 2013, 22, 2820-2828.	1.4	319
198	Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 699-711.	1.1	23
199	Aberrant <i>Keap1</i> methylation in breast cancer and association with clinicopathological features. <i>Epigenetics</i> , 2013, 8, 105-112.	1.3	77
200	Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15259-15264.	3.3	301
201	TPL2 kinase is a suppressor of lung carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1470-9.	3.3	50
202	Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. <i>Genes and Development</i> , 2013, 27, 670-682.	2.7	50
203	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1441-1456.	3.0	51

#	ARTICLE	IF	CITATIONS
204	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. <i>Scientific Reports</i> , 2013, 3, 3544.	1.6	45
205	<i>EGFR</i> tyrosine kinase mutation testing methods in non-small-cell lung cancer: new diagnostic guidance is NICE. <i>Lung Cancer Management</i> , 2013, 2, 449-451.	1.5	1
206	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. <i>Lung Cancer Management</i> , 2013, 2, 381-390.	1.5	0
207	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1378-1388.	0.5	71
208	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. <i>Haematologica</i> , 2013, 98, 1689-1696.	1.7	10
209	CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 975-983.	0.6	130
210	Monitoring of Technical Variation in Quantitative High-Throughput Datasets. <i>Cancer Informatics</i> , 2013, 12, CIN.S12862.	0.9	47
211	Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. <i>Diagnostic Pathology</i> , 2013, 8, 201.	0.9	43
212	ATHENA: Identifying interactions between different levels of genomic data associated with cancer clinical outcomes using grammatical evolution neural network. <i>BioData Mining</i> , 2013, 6, 23.	2.2	64
213	Genetics and Genomics Nursing Has Arrived!. <i>Oncology Nursing Forum</i> , 2013, 40, 20-21.	0.5	5
214	Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1371-1377.	0.5	27
215	Comprehensive genomic characterization of squamous cell lung cancers. <i>Yearbook of Pathology and Laboratory Medicine</i> , 2013, 2013, 290-291.	0.0	2
216	<i>Saccharomyces cerevisiae</i> Genetics Predicts Candidate Therapeutic Genetic Interactions at the Mammalian Replication Fork. <i>G3: Genes, Genomes, Genetics</i> , 2013, 3, 273-282.	0.8	34
217	Pathology and personalized medicine in lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 35-46.	1.5	5
218	A Prediction Model for Pathologic N2 Disease in Lung Cancer Patients with a Negative Mediastinum by Positron Emission Tomography. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1170-1180.	0.5	63
219	The role of epithelial–mesenchymal transition programming in invasion and metastasis: a clinical perspective. <i>Cancer Management and Research</i> , 2013, 5, 187.	0.9	117
220	Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-7.	1.3	27
221	Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy. <i>Journal of Thoracic Oncology</i> , 2013, 8, 582-586.	0.5	26

#	ARTICLE	IF	CITATIONS
222	Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective. <i>Theranostics</i> , 2013, 3, 953-963.	4.6	18
223	Druggable Targets of Squamous Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 75, 231.	0.7	1
224	Whole Genome and Transcriptome Sequencing of a B3 Thymoma. <i>PLoS ONE</i> , 2013, 8, e60572.	1.1	28
225	The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target. <i>PLoS ONE</i> , 2013, 8, e67668.	1.1	56
226	Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes. <i>PLoS ONE</i> , 2013, 8, e69008.	1.1	148
227	Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2. <i>PLoS ONE</i> , 2013, 8, e73609.	1.1	173
228	Genome-Wide Promoter Methylome of Small Renal Masses. <i>PLoS ONE</i> , 2013, 8, e77309.	1.1	13
229	An Integrated Inspection of the Somatic Mutations in a Lung Squamous Cell Carcinoma Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e78823.	1.1	5
230	Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR. <i>PLoS ONE</i> , 2013, 8, e79820.	1.1	24
231	Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e67980.	1.1	27
232	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013, 8, e67306.	1.1	98
233	Synthetic Genetic Targeting of Genome Instability in Cancer. <i>Cancers</i> , 2013, 5, 739-761.	1.7	31
234	Using Aptamers for Cancer Biomarker Discovery. <i>Journal of Nucleic Acids</i> , 2013, 2013, 1-7.	0.8	47
235	The Involvement of NRF2 in Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-10.	1.9	41
236	Nrf2 in Host Defense: Over the Rainbow. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-3.	1.9	11
237	An Introduction to The Cancer Genome Atlas. , 0, , 31-53.		1
238	Lung Cancer in Developing Countries: Access to Molecular Testing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 327-331.	1.8	10
239	Genetically Engineered Mouse Models for Human Lung Cancer. , 2013, , .		3

#	ARTICLE	IF	CITATIONS
240	Molecular Pathology of Lung Cancer: Current Status and Future Directions. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 77, 49.	0.7	12
241	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. <i>OncoTargets and Therapy</i> , 2014, 7, 1689.	1.0	65
242	HDAC Inhibitors Increase NRF2-Signaling in Tumour Cells and Blunt the Efficacy of Co-Administered Cytotoxic Agents. <i>PLoS ONE</i> , 2014, 9, e114055.	1.1	21
243	Fusion Transcript Discovery in Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissues Reveals a Link to Tumor Progression. <i>PLoS ONE</i> , 2014, 9, e94202.	1.1	16
244	Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets. <i>PLoS ONE</i> , 2014, 9, e98293.	1.1	105
245	Integrating Multi-Omics for Uncovering the Architecture of Cross-Talking Pathways in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e104282.	1.1	21
246	CREB Targets Define the Gene Expression Signature of Malignancies Having Reduced Levels of the Tumor Suppressor Tristetraprolin. <i>PLoS ONE</i> , 2014, 9, e115517.	1.1	29
247	Toward a systematic understanding of cancers: a survey of the pan-cancer study. <i>Frontiers in Genetics</i> , 2014, 5, 194.	1.1	22
248	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. <i>Journal of Personalized Medicine</i> , 2014, 4, 386-401.	1.1	13
249	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. <i>Oncotarget</i> , 2014, 5, 12383-12397.	0.8	175
250	Mechanisms of Base Substitution Mutagenesis in Cancer Genomes. <i>Genes</i> , 2014, 5, 108-146.	1.0	49
251	Revealing Biological Pathways Implicated in Lung Cancer from TCGA Gene Expression Data Using Gene Set Enrichment Analysis. <i>Cancer Informatics</i> , 2014, 13s1, CIN.S13882.	0.9	8
252	Molecular pathways and therapeutic targets in lung cancer. <i>Oncotarget</i> , 2014, 5, 1392-1433.	0.8	171
253	Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e353-e365.	1.8	75
254	Algorithms for network-based identification of differential regulators from transcriptome data: a systematic evaluation. <i>Science China Life Sciences</i> , 2014, 57, 1090-1102.	2.3	7
255	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , 2014, 25, 552-563.	0.6	290
256	Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. <i>Bioinformatics</i> , 2014, 30, 2051-2059.	1.8	30
257	Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis. <i>Nature Communications</i> , 2014, 5, 4804.	5.8	48

#	ARTICLE	IF	CITATIONS
258	Insights into cancer biology through next-generation sequencing. <i>Clinical Medicine</i> , 2014, 14, s71-s77.	0.8	3
259	DNA Methylation Is Globally Disrupted and Associated with Expression Changes in Chronic Obstructive Pulmonary Disease Small Airways. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 912-922.	1.4	122
260	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1873-1883.	3.2	63
261	The emerging roles of ARID1A in tumor suppression. <i>Cancer Biology and Therapy</i> , 2014, 15, 655-664.	1.5	200
262	Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas. <i>Respiratory Research</i> , 2014, 15, 160.	1.4	28
263	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. <i>Genome Biology</i> , 2014, 15, 473.	3.8	69
264	Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. <i>Cancer Cytopathology</i> , 2014, 122, 822-832.	1.4	48
265	The Impact of miRNA-Based Molecular Diagnostics and Treatment of NRF2-Stabilized Tumors. <i>Molecular Cancer Research</i> , 2014, 12, 58-68.	1.5	64
266	Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. <i>BMC Genomics</i> , 2014, 15, 876.	1.2	29
267	Gene Silencing Associated with SWI/SNF Complex Loss during NSCLC Development. <i>Molecular Cancer Research</i> , 2014, 12, 560-570.	1.5	23
268	Biobank Bootstrapping: Is Biobank Sustainability Possible Through Cost Recovery?. <i>Biopreservation and Biobanking</i> , 2014, 12, 374-380.	0.5	40
269	Bioinformatics in otolaryngology research. Part two: other high-throughput platforms in genomics and epigenetics. <i>Journal of Laryngology and Otology</i> , 2014, 128, 942-947.	0.4	1
270	MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. <i>Oncogene</i> , 2014, 33, 5626-5636.	2.6	34
271	The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. <i>Cell Death and Disease</i> , 2014, 5, e1195-e1195.	2.7	96
272	Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. <i>Cell Death and Disease</i> , 2014, 5, e1108-e1108.	2.7	89
273	Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , 2014, 5, 3644.	5.8	86
274	G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4191-4196.	3.3	70
275	The PTEN/NRF2 Axis Promotes Human Carcinogenesis. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 2498-2514.	2.5	104

#	ARTICLE	IF	CITATIONS
276	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity. <i>Clinical Cancer Research</i> , 2014, 20, 5777-5786.	3.2	44
278	The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 2659-2674.	1.1	40
279	Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. <i>Postgraduate Medical Journal</i> , 2014, 90, 228-235.	0.9	4
280	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. <i>Genome Research</i> , 2014, 24, 743-750.	2.4	534
281	Characterization of the Usage of the Serine Metabolic Network in Human Cancer. <i>Cell Reports</i> , 2014, 9, 1507-1519.	2.9	136
282	Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 602-606.	0.6	2
283	Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line. <i>Frontiers in Oncology</i> , 2014, 4, 157.	1.3	41
284	Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 320.	1.3	5
285	EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. <i>Oncogene</i> , 2014, 33, 4464-4473.	2.6	41
286	The Mcm2-7 Replicative Helicase: A Promising Chemotherapeutic Target. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	63
287	Abnormal Dosage of Ultraconserved Elements Is Highly Disfavored in Healthy Cells but Not Cancer Cells. <i>PLoS Genetics</i> , 2014, 10, e1004646.	1.5	22
288	Tumour-associated mutations of PA-TM-RING ubiquitin ligases RNF167/RNF13 identify the PA domain as a determinant for endosomal localization. <i>Biochemical Journal</i> , 2014, 459, 27-36.	1.7	20
289	Thoracic Neoplasia: Carcinoma. , 2014, , 2677-2689.		0
290	Microbial Contamination in Next Generation Sequencing: Implications for Sequence-Based Analysis of Clinical Samples. <i>PLoS Pathogens</i> , 2014, 10, e1004437.	2.1	159
291	CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung. <i>Disease Markers</i> , 2014, 2014, 1-11.	0.6	22
292	SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. <i>Nucleic Acids Research</i> , 2014, 42, e113-e113.	6.5	17
293	Squamous carcinoma of the lung: still a long and winding road to successful treatment. <i>Lung Cancer Management</i> , 2014, 3, 365-368.	1.5	0
294	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 525-529.	0.8	5

#	ARTICLE	IF	CITATIONS
295	Milestones in Skin Carcinogenesis: The Biology of Multistage Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 2014, 134, E2-E7.	0.3	32
296	A global profile of gene promoter methylation in treatment-naïve urothelial cancer. <i>Epigenetics</i> , 2014, 9, 760-773.	1.3	31
297	PrimPol—A new polymerase on the block. <i>Molecular and Cellular Oncology</i> , 2014, 1, e960754.	0.3	35
298	Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations. <i>Cancer Research</i> , 2014, 74, 7217-7228.	0.4	43
299	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. <i>Nature Communications</i> , 2014, 5, 5893.	5.8	121
300	Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. <i>Oncogene</i> , 2014, 33, 3151-3160.	2.6	23
301	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. <i>Clinical Cancer Research</i> , 2014, 20, 3299-3309.	3.2	141
302	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6582-6592.	3.2	493
303	Nullifying the <i>CDKN2A</i> Locus Promotes Mutant K-ras Lung Tumorigenesis. <i>Molecular Cancer Research</i> , 2014, 12, 912-923.	1.5	39
304	Transdifferentiation of lung adenocarcinoma in mice with <i>Lkb1</i> deficiency to squamous cell carcinoma. <i>Nature Communications</i> , 2014, 5, 3261.	5.8	137
305	Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. <i>Nature Communications</i> , 2014, 5, 5469.	5.8	93
306	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. <i>Cancer Cell</i> , 2014, 26, 923-937.	7.7	851
307	Cancer beyond organ and tissue specificity: Next-generation sequencing gene mutation data reveal complex genetic similarities across major cancers. <i>International Journal of Cancer</i> , 2014, 135, 2362-2369.	2.3	36
308	Modeling Cutaneous Squamous Carcinoma Development in the Mouse. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a013623-a013623.	2.9	32
309	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, 85-117.	0.8	98
310	Redesigning the DNA-Targeted Chromophore in Platinum-Acridine Anticancer Agents: A Structure-Activity Relationship Study. <i>Chemistry - A European Journal</i> , 2014, 20, 16174-16187.	1.7	43
311	Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib. <i>Oncologist</i> , 2014, 19, 1100-1109.	1.9	27
312	The evolving genomic classification of lung cancer. <i>Journal of Pathology</i> , 2014, 232, 121-133.	2.1	87

#	ARTICLE	IF	CITATIONS
313	Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. <i>European Respiratory Journal</i> , 2014, 44, 1011-1022.	3.1	63
314	Emerging Research and Clinical Development Trends of Liposome and Lipid Nanoparticle Drug Delivery Systems. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 29-52.	1.6	437
315	Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice. <i>Human Mutation</i> , 2014, 35, 715-727.	1.1	27
316	Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. <i>Journal of Pathology</i> , 2014, 232, 522-533.	2.1	65
317	A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. <i>Nucleic Acids Research</i> , 2014, 42, 8258-8270.	6.5	40
318	Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. <i>EMBO Molecular Medicine</i> , 2014, 6, 539-550.	3.3	21
319	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 246-257.	7.7	93
320	BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization. <i>Cancer Research</i> , 2014, 74, 6486-6498.	0.4	104
321	Understanding Cancer at the Genomic Level. , 2014, , 89-112.		0
322	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
323	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. <i>Cancer Research</i> , 2014, 74, 4676-4684.	0.4	31
324	Advances in the Diagnosis and Treatment of Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 557-564.	1.9	18
325	DNA Methylation as a Biomarker in Cancer. , 2014, , 1-22.		0
328	The Cancer Genome Atlas Research Network: A Sight to Behold. <i>Endocrine Pathology</i> , 2014, 25, 362-365.	5.2	47
329	Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. <i>BMC Cancer</i> , 2014, 14, 786.	1.1	35
330	Synchronous Non-small Cell Lung Cancers: Diagnostic Yield can be Improved by Histologic and Genetic Methods. <i>Annals of Surgical Oncology</i> , 2014, 21, 4369-4374.	0.7	21
331	Activation of the NOTCH Pathway in Head and Neck Cancer. <i>Cancer Research</i> , 2014, 74, 1091-1104.	0.4	181
332	DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer. <i>Thorax</i> , 2014, 69, 451-457.	2.7	14

#	ARTICLE	IF	CITATIONS
333	Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2014, 23, 79-91.	3.0	51
334	State of the Art of Genetic Alterations in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S131-S136.	0.5	60
335	New developments in the treatment of squamous cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 152-158.	1.1	20
336	Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1324-1331.	0.5	150
337	Identification of a Subset of Human Non-Small Cell Lung Cancer Patients with High PI3K ^{Î²} and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 595-603.	3.2	27
338	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. <i>Nucleic Acids Research</i> , 2014, 42, 13557-13572.	6.5	102
339	Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 974-982.	0.5	79
340	Gallbladder cancers. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 562-569.	0.8	52
341	LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT. <i>Journal of Thoracic Oncology</i> , 2014, 9, 794-804.	0.5	65
342	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1031-1035.	0.5	44
343	A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277.	0.5	33
344	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database: the <i>Journal of Biological Databases and Curation</i> , 2014, 2014, bau015.	1.4	50
345	PDGF receptors in tumor biology: prognostic and predictive potential. <i>Future Oncology</i> , 2014, 10, 1695-1708.	1.1	84
346	TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal. <i>Clinical Cancer Research</i> , 2014, 20, 4419-4421.	3.2	25
347	The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. <i>Nucleic Acids Research</i> , 2014, 42, e172-e172.	6.5	33
348	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1495-1513.	1.1	8
349	Loss of Notch1-dependent p21 ^{Waf1/Cip1} expression influences the Notch1 outcome in tumorigenesis. <i>Cell Cycle</i> , 2014, 13, 2046-2245.	1.3	33
350	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246

#	ARTICLE	IF	CITATIONS
351	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. <i>Clinical Cancer Research</i> , 2014, 20, 6127-6140.	3.2	91
352	Could γ -5-GABA-A receptor activation be used as a target for managing medulloblastomas?. <i>CNS Oncology</i> , 2014, 3, 245-247.	1.2	3
353	Fibulin-3 suppresses Wnt/ β -catenin signaling and lung cancer invasion. <i>Carcinogenesis</i> , 2014, 35, 1707-1716.	1.3	53
354	Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel). <i>Frontiers in Oncology</i> , 2014, 4, 177.	1.3	6
355	The Robustness of Pathway Analysis in Identifying Potential Drug Targets in Non-Small Cell Lung Carcinoma. <i>Microarrays (Basel, Switzerland)</i> , 2014, 3, 212-225.	1.4	1
356	Integrated DNA Copy Number and Gene Expression Regulatory Network Analysis of Non-small Cell Lung Cancer Metastasis. <i>Cancer Informatics</i> , 2014, 13s5, CIN.S14055.	0.9	13
357	<i>nab</i> -paclitaxel for the management of patients with advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 129-141.	1.1	14
358	Oncogenic transformation of mesenchymal stem cells decreases Nrf2 expression favoring in vivo tumor growth and poorer survival. <i>Molecular Cancer</i> , 2014, 13, 20.	7.9	38
359	Using high-density DNA methylation arrays to profile copy number alterations. <i>Genome Biology</i> , 2014, 15, R30.	13.9	113
360	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3818-3829.	3.2	230
361	CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3260-8.	3.3	29
362	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. <i>Nucleic Acids Research</i> , 2014, 42, 12973-12983.	6.5	5
363	Systems Analysis of Chromatin-Related Protein Complexes in Cancer. , 2014, , .		0
364	Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients. <i>Cell Reports</i> , 2014, 7, 1310-1319.	2.9	22
365	ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN- β -STAT1-ISG15 Signaling Axis. <i>Cell Reports</i> , 2014, 7, 514-526.	2.9	47
366	Summary Report From the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. <i>Clinical Lung Cancer</i> , 2014, 15, 16-20.	1.1	1
367	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. <i>Seminars in Oncology</i> , 2014, 41, 110-125.	0.8	60
368	Signaling through cyclin D-dependent kinases. <i>Oncogene</i> , 2014, 33, 1890-1903.	2.6	251

#	ARTICLE	IF	CITATIONS
369	Omics-based nanomedicine: The future of personalized oncology. <i>Cancer Letters</i> , 2014, 352, 126-136.	3.2	75
370	Î±5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. <i>Acta Neuropathologica</i> , 2014, 127, 593-603.	3.9	39
371	Biallelic <i>DICER1</i> Mutations in Sporadic Pleuropulmonary Blastoma. <i>Cancer Research</i> , 2014, 74, 2742-2749.	0.4	67
372	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. <i>Lancet Oncology</i> , 2014, 15, 143-155.	5.1	823
373	Detection of a Recurrent <i>DNAJB1-PRKACA</i> Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma. <i>Science</i> , 2014, 343, 1010-1014.	6.0	388
374	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2630-2638.	0.3	287
375	Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2014, 74, 403-413.	4.9	84
376	General assessment of copy number variation in normal and tumor tissues of the domestic dog (<i>Canis</i>) Tj ETQq1 1 0,784314,rgBT /Over	1.0	1
377	Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. <i>BMC Cancer</i> , 2014, 14, 64.	1.1	20
378	Lung cancer in never smokers: a different disease. <i>Current Respiratory Care Reports</i> , 2014, 3, 26-34.	0.6	6
379	Monitoring Keap1-Nrf2 interactions in single live cells. <i>Biotechnology Advances</i> , 2014, 32, 1133-1144.	6.0	122
380	Chemical Warfare Among Invaders: A Detoxification Interaction Facilitates an Ant Invasion. <i>Science</i> , 2014, 343, 1014-1017.	6.0	48
381	MYCxing It Up with FGFR1 in Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 152-154.	7.7	4
382	Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature</i> , 2014, 507, 315-322.	13.7	2,496
383	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
384	Identification of genomic alterations in oesophageal squamous cell cancer. <i>Nature</i> , 2014, 509, 91-95.	13.7	903
385	Epistatic interactions and drug response. <i>Journal of Pathology</i> , 2014, 232, 255-263.	2.1	24
386	Prognostic value of microRNA expression in operable non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2014, 110, 991-1000.	2.9	33

#	ARTICLE	IF	CITATIONS
387	Molecular Testing in Cancer. , 2014, , .		2
388	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
389	Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nature Genetics, 2014, 46, 613-617.	9.4	211
390	Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors. Endocrine Pathology, 2014, 25, 151-164.	5.2	44
391	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. Journal of Pathology, 2014, 232, 274-282.	2.1	48
392	Identification of ZDHHC14 as a novel human tumour suppressor gene. Journal of Pathology, 2014, 232, 566-577.	2.1	44
393	Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology, 2014, 32, 973-982.	0.8	203
394	DNA Sequencing of Cancer: What Have We Learned?. Annual Review of Medicine, 2014, 65, 63-79.	5.0	41
395	Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination. Cancer Research, 2014, 74, 808-817.	0.4	121
396	Cause and Consequence of Cancer/Testis Antigen Activation in Cancer. Annual Review of Pharmacology and Toxicology, 2014, 54, 251-272.	4.2	201
397	Antioxidants Accelerate Lung Cancer Progression in Mice. Science Translational Medicine, 2014, 6, 221ra15.	5.8	663
398	Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opinion on Investigational Drugs, 2014, 23, 211-226.	1.9	35
399	Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia, 2014, 28, 1227-1234.	3.3	50
400	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	13.7	708
401	Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. Journal of Clinical Oncology, 2014, 32, 121-128.	0.8	176
402	Lung Stem and Progenitor Cells in Tissue Homeostasis and Disease. Current Topics in Developmental Biology, 2014, 107, 207-233.	1.0	68
403	Inactivating CUX1 mutations promote tumorigenesis. Nature Genetics, 2014, 46, 33-38.	9.4	111
404	Hedgehogâ€“GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer. Clinical Cancer Research, 2014, 20, 1566-1575.	3.2	99

#	ARTICLE	IF	CITATIONS
405	Section IV: Non-“small cell lung cancer and malignant melanoma. <i>Current Problems in Cancer</i> , 2014, 38, 180-198.	1.0	2
406	Characterization of HPV and host genome interactions in primary head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15544-15549.	3.3	317
408	Aspects biologiques des cancers bronchiques. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 311-319.	0.0	0
409	Improving Detection of Driver Genes: Power-Law Null Model of Copy Number Variation in Cancer. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2014, 11, 1260-1263.	1.9	1
410	Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by <i>DDR2</i> Gatekeeper Mutation and <i>NF1</i> Loss. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 475-482.	1.9	51
411	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2547-2558.	1.9	106
412	A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling. <i>Cancer Discovery</i> , 2014, 4, 1168-1181.	7.7	15
413	Personalized medicine: Special treatment. <i>Nature</i> , 2014, 513, S8-S9.	13.7	17
414	Pan-cancer patterns of DNA methylation. <i>Genome Medicine</i> , 2014, 6, 66.	3.6	149
415	A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. <i>Lung Cancer</i> , 2014, 86, 59-66.	0.9	50
416	Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells. <i>Cell Death and Differentiation</i> , 2014, 21, 1218-1228.	5.0	21
417	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468.	1.5	17
418	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. <i>Genome Medicine</i> , 2014, 6, 5.	3.6	186
419	Advancing clinical oncology through genome biology and technology. <i>Genome Biology</i> , 2014, 15, 427.	3.8	9
420	Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. <i>Cancer Letters</i> , 2014, 354, 12-20.	3.2	98
421	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. <i>Haematologica</i> , 2014, 99, 222-231.	1.7	52
423	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. <i>Nature Reviews Cancer</i> , 2014, 14, 455-467.	12.8	683
424	DNA copy number changes as diagnostic tools for lung cancer. <i>Thorax</i> , 2014, 69, 496-497.	2.7	21

#	ARTICLE	IF	CITATIONS
425	Lung Cancer Transcriptomes Refined with Laser Capture Microdissection. American Journal of Pathology, 2014, 184, 2868-2884.	1.9	22
426	Similarity network fusion for aggregating data types on a genomic scale. Nature Methods, 2014, 11, 333-337.	9.0	1,392
427	A novel cancer-germline transcript carrying pro-metastatic miR-105 and <i>TET</i> -targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics, 2014, 9, 1163-1171.	1.3	56
428	The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. Genes and Development, 2014, 28, 1929-1939.	2.7	69
429	Lean Big Data integration in systems biology and systems pharmacology. Trends in Pharmacological Sciences, 2014, 35, 450-460.	4.0	85
431	Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer. Cell Reports, 2014, 8, 40-49.	2.9	78
432	The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer—Differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer, 2014, 85, 125-130.	0.9	29
433	Tumour—stroma crosstalk in the development of squamous cell carcinoma. International Journal of Biochemistry and Cell Biology, 2014, 53, 450-458.	1.2	39
434	Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 2014, 14, 535-546.	12.8	1,375
435	Proteogenomic characterization of human colon and rectal cancer. Nature, 2014, 513, 382-387.	13.7	1,219
436	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251-1253.	6.0	348
437	Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treatment Reviews, 2014, 40, 980-989.	3.4	95
438	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Advances in Biological Regulation, 2014, 56, 66-80.	1.4	77
439	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. Molecular and Cellular Proteomics, 2014, 13, 1690-1704.	2.5	323
440	WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 188-200.	3.3	89
441	Personalized medicine in hematology — A landmark from bench to bed. Computational and Structural Biotechnology Journal, 2014, 10, 70-77.	1.9	10
442	Dynamic Changes in Intracellular ROS Levels Regulate Airway Basal Stem Cell Homeostasis through Nrf2-Dependent Notch Signaling. Cell Stem Cell, 2014, 15, 199-214.	5.2	236
443	Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014, 511, 543-550.	13.7	4,572

#	ARTICLE	IF	CITATIONS
444	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	13.5	1,242
445	Emerging approaches to target tumor metabolism. <i>Current Opinion in Pharmacology</i> , 2014, 17, 22-29.	1.7	18
446	nab-Paclitaxel for the Treatment of Advanced Squamous Non-Small-Cell Lung Cancer: A Comprehensive Update. <i>Clinical Lung Cancer</i> , 2014, 15, 391-397.	1.1	11
447	Brain Metastases from Non-Small Cell Lung Cancer. , 2014, , 141-155.		1
448	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. <i>American Journal of Gastroenterology</i> , 2014, 109, 1205-1214.	0.2	55
449	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. <i>Physiological Genomics</i> , 2014, 46, 699-724.	1.0	26
450	Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. <i>BMC Genomics</i> , 2014, 15, 419.	1.2	262
451	Validation of a blood protein signature for non-small cell lung cancer. <i>Clinical Proteomics</i> , 2014, 11, 32.	1.1	66
452	MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. <i>Genome Biology</i> , 2014, 15, 419.	3.8	87
453	Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. <i>Genome Biology</i> , 2014, 15, 429.	3.8	179
454	High-risk prostate cancer: A disease of genomic instability. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1101-1107.	0.8	29
455	DNA repair pathways and their therapeutic potential in lung cancer. <i>Lung Cancer Management</i> , 2014, 3, 159-173.	1.5	10
456	Next-generation sequencing technologies: breaking the sound barrier of human genetics. <i>Mutagenesis</i> , 2014, 29, 303-310.	1.0	106
457	Role of the Keap1-Nrf2 Pathway in Cancer. <i>Advances in Cancer Research</i> , 2014, 122, 281-320.	1.9	134
458	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256.	6.0	962
459	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 670-681.	1.2	165
460	Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. <i>Rna</i> , 2014, 20, 1356-1368.	1.6	47
461	In silico identification of potential targets and drugs for non-small cell lung cancer. <i>IET Systems Biology</i> , 2014, 8, 56-66.	0.8	13

#	ARTICLE	IF	CITATIONS
462	Where cancer genomics should go next: a clinician's perspective. <i>Human Molecular Genetics</i> , 2014, 23, R69-R75.	1.4	13
463	Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. <i>Genome Medicine</i> , 2014, 6, 18.	3.6	37
464	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. <i>Human Molecular Genetics</i> , 2014, 23, 1527-1537.	1.4	19
465	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , 2014, 32, 644-652.	9.4	257
466	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. <i>Nature Communications</i> , 2014, 5, 3963.	5.8	143
467	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	5.8	239
468	CGARS: cancer genome analysis by rank sums. <i>Bioinformatics</i> , 2014, 30, 1295-1296.	1.8	5
469	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. <i>Medical Oncology</i> , 2014, 31, 960.	1.2	19
470	Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. <i>BMC Genomics</i> , 2014, 15, 244.	1.2	136
471	The common ground of genomics and systems biology. <i>BMC Systems Biology</i> , 2014, 8, S1.	3.0	22
472	Patterns and processes of somatic mutations in nine major cancers. <i>BMC Medical Genomics</i> , 2014, 7, 11.	0.7	57
473	The global landscape of intron retentions in lung adenocarcinoma. <i>BMC Medical Genomics</i> , 2014, 7, 15.	0.7	32
474	MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors. <i>International Journal of Cancer</i> , 2015, 136, 593-602.	2.3	43
475	Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. <i>Cancer</i> , 2014, 120, 1394-1400.	2.0	27
476	Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. <i>Human Molecular Genetics</i> , 2014, 23, 6008-6021.	1.4	59
477	Understanding lung cancer molecular subtypes. <i>Clinical Practice (London, England)</i> , 2014, 11, 441-453.	0.1	2
478	Current concepts on the molecular pathology of non-small cell lung carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 306-313.	1.0	43
479	Genetic landscape of esophageal squamous cell carcinoma. <i>Nature Genetics</i> , 2014, 46, 1097-1102.	9.4	600

#	ARTICLE	IF	CITATIONS
480	Attack of the clones. <i>Science</i> , 2014, 346, 169-170.	6.0	21
482	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51
483	Cancer mouse models: Past, present and future. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 54-60.	2.3	46
485	From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling. <i>Cancer Cell</i> , 2014, 25, 318-334.	7.7	318
486	Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. <i>Nature Genetics</i> , 2014, 46, 736-741.	9.4	360
487	Emerging protein kinase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 51-65.	1.0	22
488	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887.	5.8	456
489	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. <i>Clinical Lung Cancer</i> , 2014, 15, 1-6.	1.1	79
490	Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315.	0.9	23
491	RNA sequencing identifies novel markers of non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 84, 229-235.	0.9	64
492	Survivin and YM155: How faithful is the liaison?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 202-220.	3.3	90
493	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. <i>Genomics</i> , 2014, 103, 189-203.	1.3	49
494	Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. <i>Methods</i> , 2014, 67, 344-353.	1.9	30
495	Collection, integration and analysis of cancer genomic profiles: from data to insight. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 92-98.	1.5	22
496	An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4660-4672.	3.2	81
497	The genomic landscape of nasopharyngeal carcinoma. <i>Nature Genetics</i> , 2014, 46, 866-871.	9.4	317
498	Genomic landscape of CD34 hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8589-8594.	3.3	52
499	Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 2914-2922.	2.9	75

#	ARTICLE	IF	CITATIONS
500	Functional Identification of Cancer-Specific Methylation of <i>CDO1</i> , <i>HOXA9</i> , and <i>TAC1</i> for the Diagnosis of Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1856-1864.	3.2	69
501	Smoking, p53 Mutation, and Lung Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 3-13.	1.5	205
502	Systems biology approaches to develop innovative strategies for lung cancer therapy. <i>Cell Death and Disease</i> , 2014, 5, e1260-e1260.	2.7	22
503	Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. <i>Carcinogenesis</i> , 2014, 35, 2224-2231.	1.3	40
504	Family matters: sibling rivalry and bonding between p53 and p63 in cancer. <i>Experimental Dermatology</i> , 2014, 23, 238-239.	1.4	5
505	The Molecular Balancing Act of p16INK4a in Cancer and Aging. <i>Molecular Cancer Research</i> , 2014, 12, 167-183.	1.5	220
506	Loss of <i>Lkb1</i> and <i>Pten</i> Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression. <i>Cancer Cell</i> , 2014, 25, 590-604.	7.7	332
507	DNA Replication and Oncogene-Induced Replicative Stress. <i>Current Biology</i> , 2014, 24, R435-R444.	1.8	320
508	Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. <i>Trends in Parasitology</i> , 2014, 30, 324-332.	1.5	78
509	Genes and Pathology of Non-Small Cell Lung Carcinoma. <i>Seminars in Oncology</i> , 2014, 41, 28-39.	0.8	59
510	From genomes to societies: a holistic view of determinants of human health. <i>Current Opinion in Biotechnology</i> , 2014, 28, 134-142.	3.3	7
511	Gene amplification of the histone methyltransferase <i>SETDB1</i> contributes to human lung tumorigenesis. <i>Oncogene</i> , 2014, 33, 2807-2813.	2.6	126
512	PELO negatively regulates HER receptor signalling and metastasis. <i>Oncogene</i> , 2014, 33, 1190-1197.	2.6	13
513	Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 567-571.	0.5	28
514	Characterizing DNA methylation alterations from The Cancer Genome Atlas. <i>Journal of Clinical Investigation</i> , 2014, 124, 17-23.	3.9	162
515	Harnessing the potential of epigenetic therapy to target solid tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 56-63.	3.9	130
516	Changing Histopathological Diagnostics by Genome-Based Tumor Classification. <i>Genes</i> , 2014, 5, 444-459.	1.0	12
517	Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 900-904.	0.5	40

#	ARTICLE	IF	CITATIONS
518	A novel somatic FGFR3 mutation in primary lung cancer. <i>Oncology Reports</i> , 2014, 31, 1219-1224.	1.2	12
522	Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report. <i>Oncology Letters</i> , 2014, 8, 589-593.	0.8	7
523	Text Mining in Cancer Gene and Pathway Prioritization. <i>Cancer Informatics</i> , 2014, 13s1, CIN.S13874.	0.9	32
524	BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. <i>Cancer Control</i> , 2014, 21, 221-230.	0.7	80
525	The potential of genome-wide analyses to improve non-small-cell lung cancer care. <i>Lung Cancer Management</i> , 2014, 3, 383-396.	1.5	0
526	Counterpoint: Should Ultrasonographic Endoscopy Be the Preferred Modality for Staging of Lung Cancer? No. <i>Chest</i> , 2014, 145, 449-451.	0.4	4
527	The biological and clinical challenge of liver cancer heterogeneity. <i>Hepatic Oncology</i> , 2014, 1, 349-353.	4.2	34
528	Personalized Therapy for Lung Cancer. <i>Chest</i> , 2014, 146, 1649-1657.	0.4	54
529	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. <i>Nucleic Acids Research</i> , 2014, 42, e107-e107.	6.5	76
530	Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015, 4, 174-181.	0.4	24
531	Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1430-1436.	0.5	40
532	Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2015, 90, 561-567.	0.9	8
533	The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer. <i>Medicine (United States)</i> , 2015, 94, e1400.	0.4	6
534	Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. <i>Genome Biology</i> , 2015, 16, 105.	13.9	178
535	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	1.4	105
536	Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. <i>Cancer Medicine</i> , 2015, 4, 201-211.	1.3	71
537	PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. <i>Cancer Medicine</i> , 2015, 4, 325-332.	1.3	25
538	Signaling pathways in HPV-associated cancers and therapeutic implications. <i>Reviews in Medical Virology</i> , 2015, 25, 24-53.	3.9	77

#	ARTICLE	IF	CITATIONS
539	Epidermal growth factor receptor variant <scp>lll</scp> mutation in <scp>C</scp>hinese patients with squamous cell cancer of the lung. <i>Thoracic Cancer</i> , 2015, 6, 319-326.	0.8	10
540	Differences in driver genes between smokingâ€related and nonâ€smokingâ€related lung cancer in the Chinese population. <i>Cancer</i> , 2015, 121, 3069-3079.	2.0	62
541	STIP overexpression confers oncogenic potential to humanâ€small cell lung cancer cells by regulating cell cycle and apoptosis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2806-2817.	1.6	7
542	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 505-512.	1.4	12
543	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	0.5	26
544	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 999-1006.	1.4	47
545	LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. <i>Scientific Reports</i> , 2015, 5, 13846.	1.6	15
547	Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. <i>Scientific Reports</i> , 2015, 5, 18616.	1.6	13
548	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. <i>Scientific Reports</i> , 2015, 5, 14237.	1.6	51
550	MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2015, 10, e113-e114.	0.5	42
551	Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling. <i>Scientific Reports</i> , 2014, 4, 5414.	1.6	73
552	Dysregulation of the Keap1â€Nrf2 pathway in cancer. <i>Biochemical Society Transactions</i> , 2015, 43, 645-649.	1.6	72
553	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 423-429.	1.4	15
554	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10641.	1.6	17
555	The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells. <i>Scientific Reports</i> , 2015, 5, 11305.	1.6	29
556	Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Nonâ€Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1020-1026.	0.5	38
557	Combined Mapping of Multiple clUsterINg ALgorithms (COMMUNAL): A Robust Method for Selection of Cluster Number, K. <i>Scientific Reports</i> , 2015, 5, 16971.	1.6	16
558	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <i>Cell Death Discovery</i> , 2015, 1, 15049.	2.0	37

#	ARTICLE	IF	CITATIONS
559	A Latent Variable Approach for Integrative Clustering of Multiple Genomic Data Types. , 0, , 155-173.		0
560	Analyzing Combinations of Somatic Mutations in Cancer Genomes. , 0, , 337-361.		0
561	Data Integration on Noncoding RNA Studies. , 0, , 403-424.		0
562	Integrating heterogeneous genomic data to accurately identify disease subtypes. BMC Medical Genomics, 2015, 8, 78.	0.7	3
563	A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. BMC Genomics, 2015, 16, S6.	1.2	12
564	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genomics, 2015, 16, S5.	1.2	29
565	Computational methods and resources for the interpretation of genomic variants in cancer. BMC Genomics, 2015, 16, S7.	1.2	18
566	The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression. Respiratory Research, 2015, 16, 67.	1.4	6
567	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clinical Epigenetics, 2015, 7, 57.	1.8	75
568	Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav022-bav022.	1.4	4
569	Microtubule affinityâ€regulating kinase 2 is associated with DNA damage response and cisplatin resistance in nonâ€small cell lung cancer. International Journal of Cancer, 2015, 137, 2072-2082.	2.3	38
570	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	2.1	98
571	Parameter optimization for constructing competing endogenous RNA regulatory network in glioblastoma multiforme and other cancers. BMC Genomics, 2015, 16, S1.	1.2	43
572	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	1.2	12
573	DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer, 2015, 15, 628.	1.1	23
574	Total Exposure Study Analysis consortium: a cross-sectional study of tobacco exposures. BMC Public Health, 2015, 15, 866.	1.2	2
575	Towards pathwayâ€centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clinical and Translational Medicine, 2015, 4, 66.	1.7	2
576	Targeting tumor suppressor genes for cancer therapy. BioEssays, 2015, 37, 1277-1286.	1.2	65

#	ARTICLE	IF	CITATIONS
577	From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 413-424.	1.0	3
578	Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer. <i>Head and Neck</i> , 2015, 37, 727-734.	0.9	56
579	Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics. <i>Chronic Diseases and Translational Medicine</i> , 2015, 1, 175-186.	0.9	36
580	Beyond Adenocarcinoma: Current Treatments and Future Directions for Squamous, Small Cell, and Rare Lung Cancer Histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 147-162.	1.8	10
582	Gallbladder carcinoma: Prognostic factors and therapeutic options. <i>World Journal of Gastroenterology</i> , 2015, 21, 12211.	1.4	201
583	MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30204-30222.	1.8	12
584	Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells. <i>Oncotarget</i> , 2015, 6, 27907-27922.	0.8	34
585	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 63.	0.4	24
586	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. <i>Wspolczesna Onkologia</i> , 2015, 1A, 78-91.	0.7	4
587	Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2015, 09, .	0.1	22
588	Novel Signal-Enhancing Approaches for Optical Detection of Nucleic Acids—Going beyond Target Amplification. <i>Chemosensors</i> , 2015, 3, 224-240.	1.8	11
589	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM ₂ Platform. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28765-28782.	1.8	35
590	Fine-tuning the ubiquitin code at DNA double-strand breaks: deubiquitinating enzymes at work. <i>Frontiers in Genetics</i> , 2015, 6, 282.	1.1	23
591	Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. <i>Frontiers in Oncology</i> , 2015, 5, 209.	1.3	48
592	Epiregulin as a therapeutic target in non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 91.	1.3	24
593	SPARCoC: A New Framework for Molecular Pattern Discovery and Cancer Gene Identification. <i>PLoS ONE</i> , 2015, 10, e0117135.	1.1	6
594	Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. <i>Wspolczesna Onkologia</i> , 2015, 1A, 68-77.	0.7	2,410
595	Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. <i>PLoS ONE</i> , 2015, 10, e0142433.	1.1	14

#	ARTICLE	IF	CITATIONS
596	A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. <i>PLoS Computational Biology</i> , 2015, 11, e1004518.	1.5	122
597	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqer for the Detection of Genetic Aberrations in NSCLC. <i>PLoS ONE</i> , 2015, 10, e0129280.	1.1	36
598	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. <i>PLoS ONE</i> , 2015, 10, e0132831.	1.1	9
599	Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. <i>PLoS ONE</i> , 2015, 10, e0137476.	1.1	12
600	The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	12
601	The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. <i>Cancers</i> , 2015, 7, 2094-2109.	1.7	19
602	Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?. <i>Oncotarget</i> , 2015, 6, 23905-23916.	0.8	49
604	Personalized targeted therapy for esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 7648.	1.4	43
605	Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment. <i>Ecanermedalscience</i> , 2015, 9, 598.	0.6	4
606	Squamous Non-small Cell Lung Cancer as a Distinct Clinical Entity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 220-226.	0.6	25
607	Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1. <i>Biochemical Journal</i> , 2015, 467, 141-151.	1.7	7
608	The emerging complexity of gene fusions in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 371-381.	12.8	544
609	Practical olefin hydroamination with nitroarenes. <i>Science</i> , 2015, 348, 886-891.	6.0	387
610	cMonkey ² : Automated, systematic, integrated detection of co-regulated gene modules for any organism. <i>Nucleic Acids Research</i> , 2015, 43, e87-e87.	6.5	45
611	High burden and pervasive positive selection of somatic mutations in normal human skin. <i>Science</i> , 2015, 348, 880-886.	6.0	1,431
612	The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer. <i>Molecular Cell</i> , 2015, 58, 690-698.	4.5	117
614	Long Noncoding RNAs in Lung Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 394, 57-110.	0.7	39
615	Role of LKB1-CRTC1 on Glycosylated COX-2 and Response to COX-2 Inhibition in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 358.	3.0	36

#	ARTICLE	IF	CITATIONS
616	Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15009.	18.1	653
617	Association of the chromodomain helicase DNA-binding protein 4 (<i>CHD4</i>) missense variation p.D140E with cancer: Potential interaction with smoking. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 122-128.	1.5	14
618	New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. , 2015, , 129-154.		0
619	Lung Cancer in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2213-2220.	3.2	148
620	FGFR1 Expression Levels Predict BGI398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 4356-4364.	3.2	75
621	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 425-449.	3.2	125
622	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2015, 11, 2175-2191.	1.1	5
623	Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. <i>Journal of Clinical Oncology</i> , 2015, 33, 1966-1973.	0.8	42
625	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. <i>Nature Communications</i> , 2015, 6, 6744.	5.8	879
626	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring <i>PIK3CA</i> Gene Alterations. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1916-1927.	1.9	43
627	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with <i>JAK3</i> Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	1.6	60
628	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1049-1057.	0.5	85
629	Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer. <i>Medicine (United States)</i> , 2015, 94, e1282.	0.4	7
631	Progress of cancer genomics. <i>Thoracic Cancer</i> , 2015, 6, 557-560.	0.8	1
632	Développement des adénocarcinomes bronchopulmonaires : le point de vue du pathologiste. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 290-305.	0.0	0
633	Molecular cancer prevention: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 345-383.	157.7	83
634	Multiple conformations are a conserved and regulatory feature of the <i>RB1</i> 5' UTR. <i>Rna</i> , 2015, 21, 1274-1285.	1.6	60
635	New insights into the molecular profile of lung adenocarcinoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 361-364.	1.1	1

#	ARTICLE	IF	CITATIONS
636	An Optimization-Based Framework for the Transformation of Incomplete Biological Knowledge into a Probabilistic Structure and Its Application to the Utilization of Gene/Protein Signaling Pathways in Discrete Phenotype Classification. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2015, 12, 1304-1321.	1.9	15
637	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
638	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.4	94
639	Primase-polymerases are a functionally diverse superfamily of replication and repair enzymes. <i>Nucleic Acids Research</i> , 2015, 43, 6651-6664.	6.5	79
640	Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2. <i>Cell</i> , 2015, 163, 1375-1387.	13.5	81
641	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 1477-1486.	3.2	13
642	Differential flux balance analysis of quantitative proteomic data on protein interaction networks. , 2015, , .		0
643	Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1172-1180.	0.5	33
644	Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1240-1242.	0.5	1,301
645	Unliganded EphA3 dimerization promoted by the SAM domain. <i>Biochemical Journal</i> , 2015, 471, 101-109.	1.7	45
646	Beyond antioxidant genes in the ancient Nrf2 regulatory network. <i>Free Radical Biology and Medicine</i> , 2015, 88, 452-465.	1.3	74
647	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1341-1348.	0.5	18
648	Thyroid genomics: refining diagnosis, prognosis and treatment. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 105-107.	0.4	0
649	Therapeutic options in advanced squamous cell lung carcinoma. <i>Lung Cancer Management</i> , 2015, 4, 75-86.	1.5	0
650	Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation. <i>Cancer Treatment Communications</i> , 2015, 4, 34-36.	0.4	14
651	Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. <i>Nature Communications</i> , 2015, 6, 8806.	5.8	30
652	Aquaporin 1 promotes the proliferation and migration of lung cancer cell in vitro. <i>Oncology Reports</i> , 2015, 34, 1440-1448.	1.2	52
653	Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction. <i>International Journal of Molecular Medicine</i> , 2015, 36, 473-484.	1.8	24

#	ARTICLE	IF	CITATIONS
654	Advances in Molecular Biology of Lung Disease. <i>Chest</i> , 2015, 148, 1063-1072.	0.4	18
655	The 2015 World Health Organization Classification of Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1243-1260.	0.5	3,313
656	Clinical potential of gene mutations in lung cancer. <i>Clinical and Translational Medicine</i> , 2015, 4, 33.	1.7	36
657	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. <i>Cancer Letters</i> , 2015, 357, 179-185.	3.2	81
658	Small cell lung cancer: Where do we go from here?. <i>Cancer</i> , 2015, 121, 664-672.	2.0	459
659	Identifying Predictive Features in Drug Response Using Machine Learning: Opportunities and Challenges. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 15-34.	4.2	64
660	Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 239-244.	7.7	80
661	Translating the transcriptome into tools for the early detection and prevention of lung cancer: Figure 1. <i>Thorax</i> , 2015, 70, 476-481.	2.7	20
662	Somatic Diseases (Cancer). , 2015, , 343-360.		0
663	Genetic Mutation of p53 and Suppression of the miR-17-92 Cluster Are Synthetic Lethal in Non-Small Cell Lung Cancer due to Upregulation of Vitamin D Signaling. <i>Cancer Research</i> , 2015, 75, 666-675.	0.4	39
664	Genomic profiling of small-cell lung cancer: the era of targeted therapies. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 513-9.	0.6	17
665	Emerging drugs for squamous cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 149-160.	1.0	18
666	Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 471-490.	1.5	18
667	Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM+ AFP+ hepatocellular carcinoma. <i>Oncogene</i> , 2015, 34, 5095-5104.	2.6	57
668	Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project. <i>Respiratory Medicine</i> , 2015, 109, 131-136.	1.3	9
669	Innovative Clinical Trials: The LUNG-MAP Study. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 488-491.	2.3	56
670	Lung Master Protocol (Lung-MAP) – A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015, 21, 1514-1524.	3.2	205
671	Cell-of-origin chromatin organization shapes the mutational landscape of cancer. <i>Nature</i> , 2015, 518, 360-364.	13.7	491

#	ARTICLE	IF	CITATIONS
672	Comprehensive genomic characterization of head and neck squamous cell carcinomas. <i>Nature</i> , 2015, 517, 576-582.	13.7	3,209
673	Sparse Overlapping Group Lasso for Integrative Multi-Omics Analysis. <i>Journal of Computational Biology</i> , 2015, 22, 73-84.	0.8	18
674	Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer. <i>Oncogene</i> , 2015, 34, 621-630.	2.6	37
675	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. , 2015, 149, 139-149.		27
676	Intrinsic cancer subtypes-next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 3-16.	2.1	24
677	Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2015, 87, 117-121.	0.9	9
678	Somatic Diseases (Cancer). , 2015, , 297-319.		2
679	Understanding and Using Information about Cancer Genomes. , 2015, , 357-368.e3.		0
680	Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. <i>Laboratory Investigation</i> , 2015, 95, 366-376.	1.7	54
681	<i>KEAP1</i> Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes. <i>Clinical Cancer Research</i> , 2015, 21, 1591-1601.	3.2	37
682	Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 704-712.	1.9	45
683	Epigenetic and transcriptional determinants of the human breast. <i>Nature Communications</i> , 2015, 6, 6351.	5.8	56
684	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132
685	Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. <i>Nucleic Acids Research</i> , 2015, 43, 1345-1356.	6.5	157
686	Molecular histology of lung cancer: From targets to treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 361-375.	3.4	142
687	Systems oncology: toward the clinical application of cancer systems biology. <i>Future Oncology</i> , 2015, 11, 553-555.	1.1	4
688	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1447-1456.	3.2	235
689	Therapeutic opportunities within the DNA damage response. <i>Nature Reviews Cancer</i> , 2015, 15, 166-180.	12.8	442

#	ARTICLE	IF	CITATIONS
690	Retinoblastoma Tumor Suppressor Gene. , 2015, , .		0
691	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015, 35, S55-S77.	4.3	95
692	Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis. <i>Cell</i> , 2015, 160, 1246-1260.	13.5	746
693	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
694	Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	31
695	Mutational Similarities Across Cancers: Implications for Research, Diagnostics, and Personalized Therapy Design. , 2015, , 57-65.		0
696	Personalised medicine in veterinary oncology: One to cure just one. <i>Veterinary Journal</i> , 2015, 205, 128-135.	0.6	17
697	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9990-9995.	3.3	31
698	Diagnostic yield of targeted next generation sequencing in various cancer types: An information-theoretic approach. <i>Cancer Genetics</i> , 2015, 208, 441-447.	0.2	9
699	Radiotherapy in the Era of Precision Medicine. <i>Seminars in Radiation Oncology</i> , 2015, 25, 227-236.	1.0	29
700	Cross-cancer profiling of molecular alterations within the human autophagy interaction network. <i>Autophagy</i> , 2015, 11, 1668-1687.	4.3	107
701	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	2.7	101
702	Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 11671.	1.6	29
703	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. <i>Cancer Discovery</i> , 2015, 5, 842-849.	7.7	514
704	Inflammation and Lung Cancer: Molecular Pathology. , 2015, , 69-93.		0
705	Inflammation and Lung Cancer: Prevention. , 2015, , 95-136.		0
706	DNA Methylation and Hydroxymethylation in Cancer. , 2015, , 9-30.		4
707	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	5.1	389

#	ARTICLE	IF	CITATIONS
708	Functional polymorphisms in Nrf2: implications for human disease. <i>Free Radical Biology and Medicine</i> , 2015, 88, 362-372.	1.3	63
709	EGFR tyrosine kinase inhibitors in squamous cell lung cancer. <i>Lancet Oncology</i> , The, 2015, 16, 872-873.	5.1	8
710	Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. <i>Cancers</i> , 2015, 7, 930-949.	1.7	83
711	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. <i>Nature Medicine</i> , 2015, 21, 946-954.	15.2	179
712	Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. <i>BioDrugs</i> , 2015, 29, 167-183.	2.2	59
713	Integrative Epigenomics. <i>Translational Bioinformatics</i> , 2015, , 127-139.	0.0	0
714	Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results. <i>Bioinformatics</i> , 2015, 31, 3666-3672.	1.8	196
715	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. <i>Journal of Biomolecular Screening</i> , 2015, 20, 810-820.	2.6	38
716	Current and future molecular diagnostics in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1061-1074.	1.5	14
717	An overview of new biomolecular pathways in pathogen-related cancers. <i>Future Oncology</i> , 2015, 11, 1625-1639.	1.1	12
718	Applications of the Keap1–Nrf2 system for gene and cell therapy. <i>Free Radical Biology and Medicine</i> , 2015, 88, 350-361.	1.3	41
719	MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types. <i>Bioinformatics</i> , 2015, 31, i284-i292.	1.8	87
720	The cancer COMPASS: navigating the functions of MLL complexes in cancer. <i>Cancer Genetics</i> , 2015, 208, 178-191.	0.2	122
721	Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. <i>Computational Biology and Chemistry</i> , 2015, 58, 104-119.	1.1	4
722	Human ortholog of <i>Drosophila</i> Melted impedes SMAD2 release from TGF- β 2 receptor I to inhibit TGF- β 2 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3000-9.	3.3	20
723	Functional cross-talk between Cdc42 and two downstream targets, Par6B and PAK4. <i>Biochemical Journal</i> , 2015, 467, 293-302.	1.7	24
724	Genomic aberrations guiding treatment of non-small cell lung cancer patients. <i>Cancer Treatment Communications</i> , 2015, 4, 23-33.	0.4	17
725	Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. <i>Free Radical Biology and Medicine</i> , 2015, 88, 108-146.	1.3	661

#	ARTICLE	IF	CITATIONS
726	Roles of Nrf2 in cell proliferation and differentiation. <i>Free Radical Biology and Medicine</i> , 2015, 88, 168-178.	1.3	189
727	Genomic alterations in lung adenocarcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e342-e351.	5.1	302
728	Monoallelic Loss of the Imprinted Gene Grb10 Promotes Tumor Formation in Irradiated Nf1+/- Mice. <i>PLoS Genetics</i> , 2015, 11, e1005235.	1.5	12
729	Best practice in the treatment of advanced squamous cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 224-235.	1.0	14
730	Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 589-596.	1.5	16
731	Bayesian nonparametric cross-study validation of prediction methods. <i>Annals of Applied Statistics</i> , 2015, 9, .	0.5	24
732	Lineage factors and differentiation states in lung cancer progression. <i>Oncogene</i> , 2015, 34, 5771-5780.	2.6	42
733	EGFR inhibition for recurrent or metastatic HNSCC. <i>Lancet Oncology</i> , The, 2015, 16, 488-489.	5.1	14
734	Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. <i>Lung Cancer</i> , 2015, 87, 226-231.	0.9	39
735	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 36-48.	0.4	8
736	ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis. <i>Cell Reports</i> , 2015, 10, 1599-1613.	2.9	70
737	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. <i>RNA Biology</i> , 2015, 12, 628-642.	1.5	85
738	Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer. <i>EBioMedicine</i> , 2015, 2, 583-590.	2.7	71
740	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 647-664.	1.5	40
741	Pancancer analysis of DNA methylation-driven genes using MethylMix. <i>Genome Biology</i> , 2015, 16, 17.	3.8	117
742	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. <i>Genome Biology</i> , 2015, 16, 45.	3.8	145
743	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015, 89, 76-79.	0.9	58
744	Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. <i>JAMA Oncology</i> , 2015, 1, 476.	3.4	177

#	ARTICLE	IF	CITATIONS
745	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
746	CT-Guided Percutaneous Transthoracic Needle Biopsies Using 10G Large-Core Needles: Initial Experience. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 1603-1610.	0.9	11
747	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. <i>Cancer Discovery</i> , 2015, 5, 610-621.	7.7	129
748	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. <i>Annals of Oncology</i> , 2015, 26, 1830-1837.	0.6	43
749	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
750	Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2015, 21, 2236-2243.	3.2	147
751	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255.	3.2	179
752	Dietary Diindolylmethane Suppresses Inflammation-Driven Lung Squamous Cell Carcinoma in Mice. <i>Cancer Prevention Research</i> , 2015, 8, 77-85.	0.7	16
753	9<i>H</i>-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2718-2736.	2.9	63
754	Nonâ€“small cell lung cancer is characterized by dramatic changes in phospholipid profiles. <i>International Journal of Cancer</i> , 2015, 137, 1539-1548.	2.3	143
755	Mighty mouse breakthroughs: a Sox2-driven model for squamous cell lung cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e969651.	0.3	0
756	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. <i>Oncogene</i> , 2015, 34, 5869-5878.	2.6	195
757	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1000-1007.	0.8	206
758	Applications of NGS to Screen FFPE Tumours for Detecting Fusion Transcripts. , 2015, , 155-177.		0
759	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1750-1760.	1.9	46
760	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. <i>Annals of Oncology</i> , 2015, 26, 1791-1798.	0.6	68
761	FGFR as potential target in the treatment of squamous non small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 527-539.	3.4	55
762	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. <i>Cancer Research</i> , 2015, 75, 1287-1297.	0.4	44

#	ARTICLE	IF	CITATIONS
763	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
764	MicroRNA control of protein expression noise. <i>Science</i> , 2015, 348, 128-132.	6.0	337
765	CMPD: cancer mutant proteome database. <i>Nucleic Acids Research</i> , 2015, 43, D849-D855.	6.5	13
766	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2499-2505.	3.2	48
767	Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions. <i>Cancer Research</i> , 2015, 75, 2264-2271.	0.4	38
768	Optimal Drug Prediction From Personal Genomics Profiles. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1264-1270.	3.9	43
769	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (<sc>NSCLC</sc>). <i>Respirology</i> , 2015, 20, 370-378.	1.3	119
770	Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. <i>Nucleic Acids Research</i> , 2015, 43, 3478-3489.	6.5	219
771	Epigenetic changes in the <i>CDKN2A</i> locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma. <i>Cancer Medicine</i> , 2015, 4, 342-353.	1.3	38
772	Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological Effectiveness of Proton Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 1081-1089.	0.4	77
773	Mutational landscape and clonal architecture in grade II and III gliomas. <i>Nature Genetics</i> , 2015, 47, 458-468.	9.4	729
774	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	7.7	426
775	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , 2015, 9, 1868-1876.	2.1	29
777	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.	13.5	346
778	Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. <i>Seminars in Oncology</i> , 2015, 42, 801-819.	0.8	75
779	The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2464-2469.	0.6	58
780	Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. <i>Carcinogenesis</i> , 2015, 36, 1314-1326.	1.3	15
781	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309.	4.9	34

#	ARTICLE	IF	CITATIONS
782	Biobanking for Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2015, 864, 55-68.	0.8	41
783	Intron retention is a widespread mechanism of tumor-suppressor inactivation. <i>Nature Genetics</i> , 2015, 47, 1242-1248.	9.4	322
784	Characterization of DDR2 Inhibitors for the Treatment of <i>DDR2</i> Mutated Nonsmall Cell Lung Cancer. <i>ACS Chemical Biology</i> , 2015, 10, 2687-2696.	1.6	43
785	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. <i>Nature Medicine</i> , 2015, 21, 1514-1520.	15.2	93
786	ATM rs189037 (G>A) polymorphism and risk of lung cancer and head and neck cancer: A meta-analysis. <i>Meta Gene</i> , 2015, 6, 42-48.	0.3	12
787	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. <i>BMC Cancer</i> , 2015, 15, 415.	1.1	116
788	The enemy of my enemy is my friend. <i>Nature</i> , 2015, 527, 170-171.	13.7	47
789	CD151 promotes $\beta 1$ integrin-dependent organization of carcinoma cell junctions and restrains collective cell invasion. <i>Cancer Biology and Therapy</i> , 2015, 16, 1626-1640.	1.5	14
790	The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 121.	3.5	20
791	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. <i>Cell Systems</i> , 2015, 1, 197-209.	2.9	94
792	Precision medicine in oncology drug development: a pharma perspective. <i>Drug Discovery Today</i> , 2015, 20, 1455-1463.	3.2	24
794	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2753-2762.	3.2	42
795	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. <i>Cell Research</i> , 2015, 25, 445-458.	5.7	36
796	Lung cancer nanomedicine: potentials and pitfalls. <i>Nanomedicine</i> , 2015, 10, 3203-3212.	1.7	53
797	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1284-1291.	0.7	7
798	Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. <i>ACS Chemical Biology</i> , 2015, 10, 2680-2686.	1.6	68
799	Deoxyxyboquinones as NQO1-Activated Cancer Therapeutics. <i>Accounts of Chemical Research</i> , 2015, 48, 2715-2723.	7.6	80
800	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. <i>Genome Biology</i> , 2015, 16, 193.	3.8	19

#	ARTICLE	IF	CITATIONS
801	Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor. <i>Molecular Cancer Research</i> , 2015, 13, 1238-1247.	1.5	47
802	Dysregulation of ubiquitin ligases in cancer. <i>Drug Resistance Updates</i> , 2015, 23, 1-11.	6.5	42
803	Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2015, 6, 508-516.	0.8	25
804	Hippo and TGF- β 2 interplay in the lung field. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L756-L767.	1.3	74
805	<i>RICTOR</i> Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 1262-1270.	7.7	84
806	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	9.4	233
807	Patterns of Chromosomal Aberrations in Solid Tumors. <i>Recent Results in Cancer Research</i> , 2015, 200, 115-142.	1.8	44
808	Reprint of "Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction". <i>Computational Biology and Chemistry</i> , 2015, 59, 123-138.	1.1	14
809	NSCLC Driven by <i>DDR2</i> Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2382-2389.	1.9	29
810	Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. <i>Cell Cycle</i> , 2015, 14, 2355-2361.	1.3	59
811	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
812	The impact of the Cancer Genome Atlas on lung cancer. <i>Translational Research</i> , 2015, 166, 568-585.	2.2	83
813	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43
814	Lung and Mediastinal Tumors. , 2015, , 221-268.		0
815	Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. <i>Drug Discovery Today</i> , 2015, 20, 1391-1397.	3.2	74
816	The genetic basis of intradural spinal tumors and its impact on clinical treatment. <i>Neurosurgical Focus</i> , 2015, 39, E3.	1.0	43
817	Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. <i>Cancer Biology and Therapy</i> , 2015, 16, 1341-1352.	1.5	16
818	Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3227-3234.	0.8	125

#	ARTICLE	IF	CITATIONS
819	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. <i>Cancer Gene Therapy</i> , 2015, 22, 417-430.	2.2	112
820	Identification of recurrent regulated alternative splicing events across human solid tumors. <i>Nucleic Acids Research</i> , 2015, 43, 5130-5144.	6.5	137
821	Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 109-120.	2.2	79
822	Histological tumor typing in the age of molecular profiling. <i>Pathology Research and Practice</i> , 2015, 211, 897-900.	1.0	10
823	An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. <i>Genome Biology</i> , 2015, 16, 140.	3.8	60
824	Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nature Biotechnology</i> , 2015, 33, 1152-1158.	9.4	573
825	Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1369-1381.	1.5	31
826	HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 729-739.	1.2	16
827	Screening for lung cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, C89-C93.	0.2	0
828	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. <i>Journal of Genetics and Genomics</i> , 2015, 42, 579-587.	1.7	3
829	The mathematics of cancer: integrating quantitative models. <i>Nature Reviews Cancer</i> , 2015, 15, 730-745.	12.8	539
830	The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical“ genomic driver associations. <i>Genome Medicine</i> , 2015, 7, 112.	3.6	80
831	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
832	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. <i>Molecular Oncology</i> , 2015, 9, 1936-1965.	2.1	64
833	The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. <i>Seminars in Oncology</i> , 2015, 42, 731-739.	0.8	17
834	Heightening Energetic Stress Selectively Targets LKB1-Deficient Non“Small Cell Lung Cancers. <i>Cancer Research</i> , 2015, 75, 4910-4922.	0.4	41
835	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. <i>Nature Genetics</i> , 2015, 47, 106-114.	9.4	830
836	ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138.		487

#	ARTICLE	IF	CITATIONS
837	Classification of lung cancer using ensemble-based feature selection and machine learning methods. <i>Molecular BioSystems</i> , 2015, 11, 791-800.	2.9	126
838	FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis. <i>Lung Cancer</i> , 2015, 87, 1-7.	0.9	60
839	The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. <i>Cancer Letters</i> , 2015, 356, 165-170.	3.2	289
840	Driver and Passenger Mutations in Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 25-50.	9.6	291
841	SWI/SNF Chromatin Remodeling and Human Malignancies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 145-171.	9.6	242
842	Clinical next-generation sequencing in patients with non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 631-639.	2.0	190
843	IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. <i>Nature</i> , 2015, 517, 626-630.	13.7	117
844	Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. <i>Oncogene</i> , 2015, 34, 2167-2177.	2.6	58
845	Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken. <i>Stem Cells and Development</i> , 2015, 24, 405-416.	1.1	58
846	Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. <i>Gut</i> , 2015, 64, 636-645.	6.1	163
847	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641.	3.2	525
848	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. <i>Oncogene</i> , 2015, 34, 2732-2740.	2.6	46
849	Refining the role for adult stem cells as cancer cells of origin. <i>Trends in Cell Biology</i> , 2015, 25, 11-20.	3.6	109
850	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. <i>Scientific Reports</i> , 2014, 4, 4186.	1.6	37
852	Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA. <i>Briefings in Bioinformatics</i> , 2015, 16, 291-303.	3.2	122
853	Epigenetics and Cancer. , 2015, , 67-78.e3.		0
854	<i>FGFR3-TACC3</i> fusion in solid tumors: mini review. <i>Oncotarget</i> , 2016, 7, 55924-55938.	0.8	103
855	The steady progress of targeted therapies, promising advances for lung cancer. <i>Ecanermedicalscience</i> , 2016, 10, 638.	0.6	6

#	ARTICLE	IF	CITATIONS
856	CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. <i>Oncotarget</i> , 2016, 7, 73845-73864.	0.8	16
857	Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2016, 8, 1639-1644.	0.6	13
858	Application of MATLAB in -Omics and Systems Biology. , 0, , .		0
859	NRF2 Rewires Cellular Metabolism to Support the Antioxidant Response. , 0, , .		24
860	Gene Therapy for Lung Cancer. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 115-124.	0.2	21
861	Genetic alteration profiling of patients with resected squamous cell lung carcinomas. <i>Oncotarget</i> , 2016, 7, 36590-36601.	0.8	20
862	Differential prognostic values of mRNA expression of >CEACAM gene family members in nonsmall cell lung cancer. <i>Current Biomarker Findings</i> , 0, Volume 6, 23-30.	0.4	2
863	Construction of a lncRNA-mediated feed-forward loop network reveals global topological features and prognostic motifs in human cancers. <i>Oncotarget</i> , 2016, 7, 45937-45947.	0.8	31
864	An appraisal of drug development timelines in the Era of precision oncology. <i>Oncotarget</i> , 2016, 7, 53037-53046.	0.8	29
865	The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20507-20519.	0.8	64
866	Exploring cancer genomic data from the cancer genome atlas project. <i>BMB Reports</i> , 2016, 49, 607-611.	1.1	64
867	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. <i>Current Protein and Peptide Science</i> , 2016, 17, 411-437.	0.7	25
868	Advances in targeted therapy and immunotherapy for treatment of lung cancer. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 1-6.	0.1	1
869	SOX2 in the Development and Maintenance of the Trachea, Lung, and Esophagus. , 2016, , 301-319.		3
870	Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. <i>Oncotarget</i> , 2016, 7, 64148-64167.	0.8	171
871	Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	5
872	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. <i>Disease Markers</i> , 2016, 2016, 1-14.	0.6	13
873	Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	7

#	ARTICLE	IF	CITATIONS
874	The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	80
875	META2: Intercellular DNA Methylation Pairwise Annotation and Integrative Analysis. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	0
876	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	36
877	Nrf2 Contributes to the Poor Prognosis and Chemoresistance. , 2016, , .		2
878	Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. <i>Oncotarget</i> , 2016, 7, 71013-71035.	0.8	69
879	Inducible Mouse Models for Cancer Drug Target Validation. <i>Journal of Cancer Prevention</i> , 2016, 21, 243-248.	0.8	10
880	Functions and mechanisms of long noncoding RNAs in lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4411-4424.	1.0	32
881	Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 60807-60822.	0.8	23
882	Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells. <i>Theranostics</i> , 2016, 6, 65-77.	4.6	15
883	Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4215-4224.	1.0	20
884	Clinical and genetic features of lung squamous cell cancer in never-smokers. <i>Oncotarget</i> , 2016, 7, 35979-35988.	0.8	22
885	Cartography of Pathway Signal Perturbations Identifies Distinct Molecular Pathomechanisms in Malignant and Chronic Lung Diseases. <i>Frontiers in Genetics</i> , 2016, 7, 79.	1.1	6
886	TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. <i>Frontiers in Genetics</i> , 2016, 07, 85.	1.1	76
887	Effects of Charged Particles on Human Tumor Cells. <i>Frontiers in Oncology</i> , 2016, 6, 23.	1.3	75
888	SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. <i>PLoS Biology</i> , 2016, 14, e1002581.	2.6	35
889	Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data. <i>PLoS ONE</i> , 2016, 11, e0152792.	1.1	59
890	Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis. <i>PLoS ONE</i> , 2016, 11, e0162809.	1.1	18
891	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 807.	0.9	10

#	ARTICLE	IF	CITATIONS
892	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. <i>Oncotarget</i> , 2016, 7, 18394-18402.	0.8	38
893	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215.	0.7	13
894	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393.	0.8	27
895	^{63}Ni induces the expression of FAT2 and Slug to promote tumor invasion. <i>Oncotarget</i> , 2016, 7, 28592-28611.	0.8	49
896	Genomic architecture of lung cancers. <i>Current Opinion in Oncology</i> , 2016, 28, 52-57.	1.1	9
897	Missing the mark in <i>FGFR1</i> -amplified squamous cell cancer of the lung. <i>Cancer</i> , 2016, 122, 2938-2940.	2.0	8
898	RES-529. <i>Anti-Cancer Drugs</i> , 2016, 27, 475-487.	0.7	30
899	Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 193-214.	1.5	52
900	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. <i>Head and Neck</i> , 2016, 38, E1646-52.	0.9	31
901	Across-Platform Imputation of DNA Methylation Levels Incorporating Nonlocal Information Using Penalized Functional Regression. <i>Genetic Epidemiology</i> , 2016, 40, 333-340.	0.6	10
902	Genetic variants in <i>ABCG1</i> are associated with survival of non-small cell lung cancer patients. <i>International Journal of Cancer</i> , 2016, 138, 2592-2601.	2.3	41
903	Detection of <i>PIK3CA</i> mutations, including a novel mutation of <i>V344G</i> in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 <i>FNA</i> cases. <i>Cancer Cytopathology</i> , 2016, 124, 485-492.	1.4	6
904	Biomarker development in the precision medicine era: lung cancer as a case study. <i>Nature Reviews Cancer</i> , 2016, 16, 525-537.	12.8	406
905	Composition and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Disease. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 53-60.	2.0	80
906	Community detection from genomic datasets across human cancers. , 2016, , .		3
907	Systems Pharmacology and Pharmacodynamics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , .	0.2	9
908	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. <i>Genome Biology</i> , 2016, 17, 140.	3.8	67
909	LNDriver: identifying driver genes by integrating mutation and expression data based on gene-gene interaction network. <i>BMC Bioinformatics</i> , 2016, 17, 467.	1.2	28

#	ARTICLE	IF	CITATIONS
910	Differentiation and Integration of Machine Learning Feature Vectors. , 2016, , .		0
911	CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Scientific Reports, 2016, 6, 24006.	1.6	37
912	A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. Scientific Reports, 2016, 6, 39259.	1.6	76
913	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 83.	6.9	45
914	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer, 2016, 2, 16007.	2.3	33
915	Insights into the role of NRF2 in cancer provided by cancer genomics. Current Opinion in Toxicology, 2016, 1, 111-117.	2.6	18
916	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Medicine, 2016, 8, 136.	3.6	64
918	Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nature Communications, 2016, 7, 12601.	5.8	123
919	Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. Carcinogenesis, 2017, 38, bgw128.	1.3	29
920	Emerging therapeutic agents for lung cancer. Journal of Hematology and Oncology, 2016, 9, 138.	6.9	77
921	Identification of cancer-driver genes in focal genomic alterations from whole genome sequencing data. Scientific Reports, 2016, 6, 25582.	1.6	4
922	Complex analysis of the p53 tumor suppressor in lung carcinoma. Oncology Reports, 2016, 35, 1859-1867.	1.2	7
923	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
924	<i>FGFR</i> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676.	1.7	31
926	Loss of Nrf2 abrogates the protective effect of Keap1 downregulation in a preclinical model of cutaneous squamous cell carcinoma. Scientific Reports, 2016, 6, 25804.	1.6	28
927	SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Scientific Reports, 2016, 6, 20113.	1.6	32
928	“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology. European Respiratory Journal, 2016, 47, 1842-1854.	3.1	25
929	Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-“small cell lung carcinomas using fine-needle aspiration cases. Human Pathology, 2016, 54, 8-16.	1.1	14

#	ARTICLE	IF	CITATIONS
930	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 681-691.	2.2	46
931	<i>Drosophila</i> Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic. <i>Cell Reports</i> , 2016, 14, 1477-1487.	2.9	88
933	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1153-1169.	0.5	9
934	Dysregulated FGF signalling in neoplastic disorders. <i>Seminars in Cell and Developmental Biology</i> , 2016, 53, 126-135.	2.3	69
935	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , 2016, 11, 946-963.	0.5	173
936	5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?. <i>Cancer Prevention Research</i> , 2016, 9, 616-623.	0.7	6
937	<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 481-486.	1.9	94
938	Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. <i>Cancer Research</i> , 2016, 76, 4850-4860.	0.4	33
939	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant <i>KRAS</i> Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5851-5863.	3.2	67
940	Kernelized Information-Theoretic Metric Learning for Cancer Diagnosis Using High-Dimensional Molecular Profiling Data. <i>ACM Transactions on Knowledge Discovery From Data</i> , 2016, 10, 1-23.	2.5	7
941	Amplification of <i>FGFR1</i> gene and expression of <i>FGFR1</i> protein is found in different histological types of lung carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 173-182.	1.4	17
942	Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. <i>Nature Reviews Molecular Cell Biology</i> , 2016, 17, 523-532.	16.1	16
943	Epigenetic Determinants of Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a019505.	2.3	834
944	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
945	Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e401-e404.	0.9	11
946	Deep Sequencing Analysis Reveals That <i>KRAS</i> Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1282-1292.	0.5	64
947	Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1220-1231.	2.5	83
948	New oncogenes drivers in lung cancer—new therapeutic targets. <i>Current Pulmonology Reports</i> , 2016, 5, 49-56.	0.5	0

#	ARTICLE	IF	CITATIONS
949	Identification of crucial regulatory relationships between long non-coding RNAs and protein-coding genes in lung squamous cell carcinoma. <i>Molecular and Cellular Probes</i> , 2016, 30, 146-152.	0.9	14
950	A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 838-849.	0.5	24
951	Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. <i>Genome Research</i> , 2016, 26, 732-744.	2.4	225
952	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. <i>Modern Pathology</i> , 2016, 29, 735-742.	2.9	58
953	Characterizing genomic alterations in cancer by complementary functional associations. <i>Nature Biotechnology</i> , 2016, 34, 539-546.	9.4	78
954	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , 2016, 48, 607-616.	9.4	933
955	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29
956	Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. <i>BMC Systems Biology</i> , 2016, 10, 16.	3.0	24
957	Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. <i>Cancer Cell</i> , 2016, 29, 622-637.	7.7	237
958	Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. <i>Oncogene</i> , 2016, 35, 5807-5816.	2.6	13
959	Clinical Implications of Genomic Discoveries in Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1864-1873.	13.9	235
960	Early Events in the Molecular Pathogenesis of Lung Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 518-527.	0.7	82
961	Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2247-2257.	0.8	102
962	Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1682-1690.	1.9	31
963	Elevated integrin $\alpha 6 \beta 4$ expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer. <i>Human Pathology</i> , 2016, 54, 174-183.	1.1	49
964	Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. <i>Cell Reports</i> , 2016, 16, 2605-2617.	2.9	155
965	Chemotherapy and Stem Cell Transplantation Increase p16 INK4a Expression, a Biomarker of T-cell Aging. <i>EBioMedicine</i> , 2016, 11, 227-238.	2.7	49
966	Therapeutic targeting of splicing in cancer. <i>Nature Medicine</i> , 2016, 22, 976-986.	15.2	484

#	ARTICLE	IF	CITATIONS
967	Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunological Investigations, 2016, 45, 619-640.	1.0	143
968	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports, 2016, 16, 2003-2016.	2.9	69
969	Gene regulatory effects of disease-associated variation in the NRF2 network. Current Opinion in Toxicology, 2016, 1, 71-79.	2.6	23
970	Intergenicallly Spliced Chimeric RNAs in Cancer. Trends in Cancer, 2016, 2, 475-484.	3.8	76
971	The complex role of NRF2 in cancer: A genomic view. Current Opinion in Toxicology, 2016, 1, 37-45.	2.6	10
973	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. Expert Review of Respiratory Medicine, 2016, 10, 1229-1241.	1.0	9
974	Notch signaling in oral squamous neoplasia. Pathology International, 2016, 66, 609-617.	0.6	23
975	Synthetic lethality in lung cancer and translation to clinical therapies. Molecular Cancer, 2016, 15, 61.	7.9	31
976	SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer Cell, 2016, 30, 519-532.	7.7	178
977	Regulation of the Keap1-Nrf2 pathway by p62/SQSTM1. Current Opinion in Toxicology, 2016, 1, 54-61.	2.6	124
978	Brain Metastasis: Clinical Implications of Branched Evolution. Trends in Cancer, 2016, 2, 332-337.	3.8	16
979	Metastatic Lung Cancer: Emerging Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 736-749.	0.8	1
980	Mechanistic study on lung cancer mortality after radon exposure in the Wismut cohort supports important role of clonal expansion in lung carcinogenesis. Radiation and Environmental Biophysics, 2016, 55, 299-315.	0.6	14
981	Identifying cancer type specific oncogenes and tumor suppressors using limited size data. Journal of Bioinformatics and Computational Biology, 2016, 14, 1650031.	0.3	9
982	SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the Mouse. Cancer Cell, 2016, 30, 505-507.	7.7	9
983	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	9.4	124
984	Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes. Neoplasia, 2016, 18, 577-583.	2.3	19
985	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65

#	ARTICLE	IF	CITATIONS
986	Overexpression of ZIC5 promotes proliferation in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 479, 502-509.	1.0	24
987	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 444-454.	1.0	26
988	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. <i>Cell Reports</i> , 2016, 16, 2032-2046.	2.9	36
989	Molecular biotechnology for diagnostics. , 2016, , 303-343.		3
990	The Molecular Pathology of Lung Cancer. <i>Surgical Pathology Clinics</i> , 2016, 9, 353-378.	0.7	23
991	Biomarkers of genome instability and cancer epigenetics. <i>Tumor Biology</i> , 2016, 37, 13029-13038.	0.8	26
992	Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?. <i>Cancer Medicine</i> , 2016, 5, 2048-2060.	1.3	41
993	A phase I, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 316-323.	1.0	4
994	Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 262-272.	0.6	11
995	Cell adhesion and polarity in squamous cell carcinoma of the lung. <i>Journal of Pathology</i> , 2016, 238, 606-616.	2.1	24
996	High-throughput Phenotyping of Lung Cancer Somatic Mutations. <i>Cancer Cell</i> , 2016, 30, 214-228.	7.7	171
997	PD-1 Pathway Inhibitors: Immunology Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
998	A network medicine approach to build a comprehensive atlas for the prognosis of human cancer. <i>Briefings in Bioinformatics</i> , 2016, 17, bbw076.	3.2	32
999	AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2586-2597.	1.9	69
1000	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
1001	The multi-omic landscape of transcription factor inactivation in cancer. <i>Genome Medicine</i> , 2016, 8, 89.	3.6	26
1002	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016, 388, 1002-1011.	6.3	132
1003	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016, 388, 1012-1024.	6.3	381

#	ARTICLE	IF	CITATIONS
1004	PRECISION MEDICINE: DATA AND DISCOVERY FOR IMPROVED HEALTH AND THERAPY. , 2016, , .		2
1005	Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chemical Biology, 2016, 11, 3214-3225.	1.6	364
1006	Hot spot mutations in Finnish non-small cell lung cancers. Lung Cancer, 2016, 99, 102-110.	0.9	21
1007	The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer, 2016, 16, 718-731.	12.8	447
1008	Molecular Cytopathology. Essentials in Cytopathology Series, 2016, , .	0.1	1
1009	An Evolutionary Genetic Perspective on Cancer Biology. Annual Review of Ecology, Evolution, and Systematics, 2016, 47, 25-49.	3.8	10
1010	Targeted Therapies for Lung Cancer. Cancer Treatment and Research, 2016, 170, 165-182.	0.2	10
1011	E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. Molecular Cancer Therapeutics, 2016, 15, 2630-2639.	1.9	26
1012	Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13768-13773.	3.3	50
1013	Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Targeted Oncology, 2016, 11, 825-835.	1.7	33
1014	Lung Cancer Stem Cells. , 2016, , 149-175.		1
1015	Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases. BMC Cancer, 2016, 16, 539.	1.1	30
1016	Nonâ€“Small Cell Lung Cancer. , 2016, , 809-842.e8.		0
1017	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. Journal of Clinical Oncology, 2016, 34, 3803-3815.	0.8	336
1018	The role of wild type RAS isoforms in cancer. Seminars in Cell and Developmental Biology, 2016, 58, 60-69.	2.3	104
1019	Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362.	5.1	156
1020	Small-molecule binding sites to explore proteinâ€“protein interactions in the cancer proteome. Molecular BioSystems, 2016, 12, 3067-3087.	2.9	15
1021	Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma. Orthopaedic Surgery, 2016, 8, 129-138.	0.7	2

#	ARTICLE	IF	CITATIONS
1022	p62<scp>SQSTM</scp>1â€™Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer. FEBS Letters, 2016, 590, 2375-2397.	1.3	104
1023	Increased global transcription activity as a mechanism of replication stress in cancer. Nature Communications, 2016, 7, 13087.	5.8	232
1025	Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. British Journal of Cancer, 2016, 115, 1530-1539.	2.9	31
1026	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. Scientific Reports, 2016, 6, 26483.	1.6	20
1027	Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. BMC Medical Genomics, 2016, 9, 64.	0.7	14
1028	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	3.3	145
1029	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. Scientific Reports, 2016, 6, 35249.	1.6	33
1031	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	5.8	136
1032	Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules. Scientific Reports, 2016, 6, 35939.	1.6	18
1033	Characterization of cytokinome landscape for clinical responses in human cancers. Oncolmmunology, 2016, 5, e1214789.	2.1	21
1034	Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. International Journal of Oncology, 2016, 49, 235-242.	1.4	9
1035	SURVIV for survival analysis of mRNA isoform variation. Nature Communications, 2016, 7, 11548.	5.8	85
1036	Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nature Communications, 2016, 7, 12474.	5.8	694
1037	Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer. Scientific Reports, 2016, 6, 27514.	1.6	8
1038	Whole-exome sequencing identifies recurrent <i>AKT1</i> mutations in sclerosing hemangioma of lung. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10672-10677.	3.3	42
1039	An empirical likelihood ratio test robust to individual heterogeneity for differential expression analysis of RNA-seq. Briefings in Bioinformatics, 2018, 19, bbw103.	3.2	3
1040	Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications, 2016, 7, 13200.	5.8	132
1041	Basic Principles of Carcinogenesis. , 2016, , 1-17.		1

#	ARTICLE	IF	CITATIONS
1042	Prediction of distant recurrence in resected stage I and II lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 101, 82-87.	0.9	22
1043	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
1044	Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. <i>Nature Biotechnology</i> , 2016, 34, 1279-1286.	9.4	380
1045	p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. <i>Nature Communications</i> , 2016, 7, 12030.	5.8	253
1046	Insights into cancer severity from biomolecular interaction mechanisms. <i>Scientific Reports</i> , 2016, 6, 34490.	1.6	21
1047	Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 993-1002.	1.1	33
1048	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. <i>Oncology</i> , 2016, 90, 280-288.	0.9	7
1049	Significance of duon mutations in cancer genomes. <i>Scientific Reports</i> , 2016, 6, 27437.	1.6	5
1050	Molecular profiles to biology and pathways: a systems biology approach. <i>Chinese Journal of Cancer</i> , 2016, 35, 53.	4.9	6
1051	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016, 16, 692.	1.1	27
1052	A matrix rank based concordance index for evaluating and detecting conditional specific co-expressed gene modules. <i>BMC Genomics</i> , 2016, 17, 519.	1.2	22
1053	XMRF: an R package to fit Markov Networks to high-throughput genetics data. <i>BMC Systems Biology</i> , 2016, 10, 69.	3.0	15
1054	The expression profile and clinic significance of the SIX family in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 119.	6.9	57
1055	In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. <i>Clinical Epigenetics</i> , 2016, 8, 120.	1.8	76
1056	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. <i>Medicine (United States)</i> , 2016, 95, e5447.	0.4	12
1057	Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. <i>GigaScience</i> , 2016, 5, 1.	3.3	96
1058	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. <i>American Journal of Roentgenology</i> , 2016, 207, 534-543.	1.0	121
1059	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. <i>Pharmacological Research</i> , 2016, 111, 290-302.	3.1	156

#	ARTICLE	IF	CITATIONS
1060	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , 2016, 14, 589-598.	1.5	29
1061	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw144.	3.0	271
1062	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	0.5	101
1063	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 474-482.	1.1	19
1064	Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. <i>European Urology</i> , 2016, 69, 1055-1061.	0.9	96
1065	RASopathy Gene Mutations in Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1755-1759.	0.3	26
1066	Medoidshift clustering applied to genomic bulk tumor data. <i>BMC Genomics</i> , 2016, 17, 6.	1.2	4
1067	Integrating mutation and gene expression cross-sectional data to infer cancer progression. <i>BMC Systems Biology</i> , 2016, 10, 12.	3.0	24
1068	Emerging roles of Nrf2 signal in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 14.	6.9	50
1069	ELF5 isoform expression is tissue-specific and significantly altered in cancer. <i>Breast Cancer Research</i> , 2016, 18, 4.	2.2	37
1070	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. <i>Breast Cancer Research</i> , 2016, 18, 27.	2.2	67
1071	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. <i>Oral Oncology</i> , 2016, 58, 52-58.	0.8	58
1072	Block-Constraint Robust Principal Component Analysis and its Application to Integrated Analysis of TCGA Data. <i>IEEE Transactions on Nanobioscience</i> , 2016, 15, 510-516.	2.2	17
1073	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016, 166, 755-765.	13.5	804
1074	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 691-701.	2.6	40
1075	The biology of circulating tumor cells. <i>Oncogene</i> , 2016, 35, 1216-1224.	2.6	421
1076	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048929.	0.3	31
1077	Activation of EGFR Bypass Signaling by TGF β Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 162-171.	1.9	54

#	ARTICLE	IF	CITATIONS
1078	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 504-515.	0.5	19
1079	Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 324-333.	0.5	28
1080	Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC. <i>Oncogene</i> , 2016, 35, 4345-4357.	2.6	27
1081	Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, 346-360.	0.5	11
1082	The INO80 Complex Requires the Arp5-les6 Subcomplex for Chromatin Remodeling and Metabolic Regulation. <i>Molecular and Cellular Biology</i> , 2016, 36, 979-991.	1.1	48
1083	MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer. <i>Nucleic Acids Research</i> , 2016, 44, D986-D991.	6.5	21
1084	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	3.2	51
1085	Targeting CDK4 and CDK6: From Discovery to Therapy. <i>Cancer Discovery</i> , 2016, 6, 353-367.	7.7	717
1086	Large-scale profiling of microRNAs for The Cancer Genome Atlas. <i>Nucleic Acids Research</i> , 2016, 44, e3-e3.	6.5	125
1087	Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. <i>Nature Genetics</i> , 2016, 48, 176-182.	9.4	283
1088	Systematic discovery of complex insertions and deletions in human cancers. <i>Nature Medicine</i> , 2016, 22, 97-104.	15.2	93
1089	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
1090	Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 51-67.	1.2	42
1091	Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a <i>BRAF</i> ^{V600E} Mutation-Prevalent Area. <i>Thyroid</i> , 2016, 26, 683-690.	2.4	66
1092	¹²⁵ I-Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma. <i>Nucleic Acids Research</i> , 2016, 44, 3204-3218.	6.5	21
1093	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. <i>Gastroenterology</i> , 2016, 150, 1171-1182.	0.6	265
1094	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. <i>Oncologist</i> , 2016, 21, 205-213.	1.9	22
1095	Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 416-424.	1.2	11

#	ARTICLE	IF	CITATIONS
1096	The importance of p53 pathway genetics in inherited and somatic cancer genomes. <i>Nature Reviews Cancer</i> , 2016, 16, 251-265.	12.8	131
1097	Thermodynamic measures of cancer: Gibbs free energy and entropy of protein-protein interactions. <i>Journal of Biological Physics</i> , 2016, 42, 339-350.	0.7	42
1098	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
1099	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
1100	Mutation of cancer driver <i>MLL2</i> results in transcription stress and genome instability. <i>Genes and Development</i> , 2016, 30, 408-420.	2.7	112
1101	Novel therapies for advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2016, 12, 659-667.	1.1	11
1102	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , 2016, 93, 9-16.	0.9	27
1103	Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 28.	1.1	14
1104	Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients. <i>Medical Oncology</i> , 2016, 33, 29.	1.2	32
1105	ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 661-669.	1.9	146
1106	A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. <i>Genome Research</i> , 2016, 26, 541-553.	2.4	45
1107	Clinical and Molecular Characteristics of <i>NF1</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3148-3156.	3.2	71
1108	Next-Generation Sequencing for the Analysis of Cancer Specimens. , 2016, , 911-931.		0
1110	Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K α and PI3K β , Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 877-889.	1.9	38
1111	Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 536-542.	1.2	4
1112	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of <i>DDR2</i> . <i>Clinical Cancer Research</i> , 2016, 22, 3663-3671.	3.2	14
1113	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	2.7	25
1114	Molecular Pathology of Solid Tumors. , 2016, , 557-594.		0

#	ARTICLE	IF	CITATIONS
1115	Recent advances in the pathology and molecular genetics of lung cancer: A practical review for cytopathologists. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 252-265.	0.2	0
1116	Overexpression of Tbx20 in Adult Cardiomyocytes Promotes Proliferation and Improves Cardiac Function After Myocardial Infarction. <i>Circulation</i> , 2016, 133, 1081-1092.	1.6	133
1117	On Predicting lung cancer subtypes using <i>omic</i> ™ data from tumor and tumor-adjacent histologically-normal tissue. <i>BMC Cancer</i> , 2016, 16, 184.	1.1	10
1118	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 1-23.	0.8	7
1119	Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression. <i>Cancer Research</i> , 2016, 76, 1245-1259.	0.4	21
1120	Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 203-222.	0.8	28
1121	Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer. <i>ACS Nano</i> , 2016, 10, 1640-1647.	7.3	67
1122	Bromodomains: Structure, function and pharmacology of inhibition. <i>Biochemical Pharmacology</i> , 2016, 106, 1-18.	2.0	186
1123	<i>FGFR1</i> Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status. <i>American Journal of Clinical Pathology</i> , 2016, 145, 55-61.	0.4	10
1124	A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 23-36.	1.9	6
1126	Next Generation Sequencing in Oncology. , 2016, , 63-74.		0
1127	KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 155-178.	0.8	23
1128	Highly multiplexed targeted DNA sequencing from single nuclei. <i>Nature Protocols</i> , 2016, 11, 214-235.	5.5	49
1129	Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. <i>Oncogene</i> , 2016, 35, 3587-3597.	2.6	30
1130	Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer. <i>European Urology</i> , 2016, 69, 823-830.	0.9	39
1132	Regulation of the ErbB network by the MIC6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 115-124.	2.3	20
1133	ccmGDB: a database for cancer cell metabolism genes. <i>Nucleic Acids Research</i> , 2016, 44, D959-D968.	6.5	41
1134	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	0.8	336

#	ARTICLE	IF	CITATIONS
1135	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016, 150, 48-63.	0.6	90
1136	Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. <i>Oncogene</i> , 2016, 35, 2413-2427.	2.6	426
1137	Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. <i>Oncogene</i> , 2016, 35, 577-586.	2.6	45
1138	Activating ERBB4 mutations in non-small cell lung cancer. <i>Oncogene</i> , 2016, 35, 1283-1291.	2.6	57
1139	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
1140	Epidemiology of Lung Cancer. , 2016, , 927-939.e5.		5
1141	Application of CRISPR-mediated genome engineering in cancer research. <i>Cancer Letters</i> , 2017, 387, 10-17.	3.2	16
1142	DDX59 promotes DNA replication in lung adenocarcinoma. <i>Cell Death Discovery</i> , 2017, 3, 16095.	2.0	12
1143	Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications. <i>Oncogene</i> , 2017, 36, 3375-3383.	2.6	14
1144	Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer. <i>Brain Tumor Pathology</i> , 2017, 34, 36-41.	1.1	8
1145	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017, 8, 14098.	5.8	80
1146	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , 2017, 543, 378-384.	13.7	1,158
1147	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017, 12, 704-713.	0.5	71
1148	Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 207-217.	1.9	17
1150	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-“Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. <i>Clinical Lung Cancer</i> , 2017, 18, 519-526.e1.	1.1	3
1151	Identifying gene-environment interactions for prognosis using a robust approach. <i>Econometrics and Statistics</i> , 2017, 4, 105-120.	0.4	6
1152	The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. <i>Oncogene</i> , 2017, 36, 3168-3177.	2.6	84
1153	The NF1 gene in tumor syndromes and melanoma. <i>Laboratory Investigation</i> , 2017, 97, 146-157.	1.7	144

#	ARTICLE	IF	CITATIONS
1154	Clinicopathologic characteristics and outcomes of Chinese patients with non-small cell lung cancer and <i>BRAF</i> mutation. <i>Cancer Medicine</i> , 2017, 6, 555-562.	1.3	46
1155	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017, 19, 4.	1.8	15
1156	Neutrophils dominate the immune cell composition in non-small cell lung cancer. <i>Nature Communications</i> , 2017, 8, 14381.	5.8	304
1157	Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions. <i>Journal of Translational Medicine</i> , 2017, 15, 22.	1.8	22
1158	Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. <i>Nature Communications</i> , 2017, 8, 14249.	5.8	52
1159	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 295-304.	0.9	12
1160	Epithelial cell migration as a potential therapeutic target in early lung cancer. <i>European Respiratory Review</i> , 2017, 26, 160069.	3.0	16
1161	Giving AXL the axe: targeting AXL in human malignancy. <i>British Journal of Cancer</i> , 2017, 116, 415-423.	2.9	245
1162	A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	119
1163	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. <i>Cell</i> , 2017, 168, 460-472.e14.	13.5	106
1164	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 791-803.	0.5	127
1165	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
1166	Co-expression network analysis of long noncoding RNAs (lncRNAs) and cancer genes reveals <i>SFTA1P</i> and <i>CASC2</i> abnormalities in lung squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 115-122.	1.5	32
1167	Therapeutic and pathological roles of fibroblast growth factors in pulmonary diseases. <i>Developmental Dynamics</i> , 2017, 246, 235-244.	0.8	22
1168	Loss of p16 INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. <i>Journal of Thoracic Oncology</i> , 2017, 12, 860-871.	0.5	28
1169	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017, 13, 914.	3.2	73
1170	SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1494-1508.	2.5	26
1171	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38

#	ARTICLE	IF	CITATIONS
1172	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 415-426.	1.9	5
1173	Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. <i>JAMA Oncology</i> , 2017, 3, 801.	3.4	78
1174	The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories. <i>Cancer Cytopathology</i> , 2017, 125, 153-154.	1.4	0
1175	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. <i>Gut</i> , 2017, 66, 215-225.	6.1	34
1176	Biological therapies in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601520.	3.1	37
1177	The Relationship Between DOT1L, Histone H3 Methylation, and Genome Stability in Cancer. <i>Current Molecular Biology Reports</i> , 2017, 3, 18-27.	0.8	4
1178	Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy. <i>Scientific Reports</i> , 2017, 7, 42060.	1.6	32
1179	Bone metastasis from lung cancer identified by genetic profiling. <i>Oncology Letters</i> , 2017, 13, 847-850.	0.8	4
1182	Integrative epigenetic and genetic pan-cancer somatic alteration portraits. <i>Epigenetics</i> , 2017, 12, 561-574.	1.3	18
1183	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017, 16, 1.	7.9	196
1184	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 271-280.	1.4	15
1185	Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features. <i>Clinical Cancer Research</i> , 2017, 23, 4855-4864.	3.2	39
1186	<i>KIF13B-NRG1</i> Gene Fusion and <i>KRAS</i> Amplification in a Case of Natural Progression of Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2017, 25, 238-240.	0.4	9
1187	Bioinformatics analysis to screen the key prognostic genes in ovarian cancer. <i>Journal of Ovarian Research</i> , 2017, 10, 27.	1.3	43
1188	Intrinsic Molecular Processes: Impact on Mutagenesis. <i>Trends in Cancer</i> , 2017, 3, 357-371.	3.8	4
1189	p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function. <i>Oncogenesis</i> , 2017, 6, e320-e320.	2.1	8
1190	Lung carcinogenesis and fibrosis taken together. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 290-297.	1.2	5
1191	Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. <i>Nucleic Acids Research</i> , 2017, 45, 2973-2985.	6.5	158

#	ARTICLE	IF	CITATIONS
1192	A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. <i>Oncogene</i> , 2017, 36, 5285-5295.	2.6	87
1193	EBT: a statistic test identifying moderate size of significant features with balanced power and precision for genome-wide rate comparisons. <i>Bioinformatics</i> , 2017, 33, 2631-2641.	1.8	23
1194	High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1040-1050.	1.5	34
1195	Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study. <i>Clinical Otolaryngology</i> , 2017, 42, 681-686.	0.6	1
1196	A three-caller pipeline for variant analysis of cancer whole-exome sequencing data. <i>Molecular Medicine Reports</i> , 2017, 15, 2489-2494.	1.1	16
1197	PI3K is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3964-E3973.	3.3	54
1198	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 469-479.	1.0	11
1199	Optimized expression-based microdissection of formalin-fixed lung cancer tissue. <i>Laboratory Investigation</i> , 2017, 97, 863-872.	1.7	3
1200	Tracking the Evolution of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	13.9	1,786
1201	Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3766-E3775.	3.3	27
1202	Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1098-1108.	0.5	21
1203	DNA methylation: an epigenetic mark of cellular memory. <i>Experimental and Molecular Medicine</i> , 2017, 49, e322-e322.	3.2	286
1204	Next-Generation Sequencing of Lung Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1-12.	0.9	12
1205	Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 1471-1480.	3.2	24
1206	Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer. <i>Cancer Medicine</i> , 2017, 6, 235-244.	1.3	4
1207	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <i>Respiration</i> , 2017, 93, 1-14.	1.2	7
1208	Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data. <i>Molecular Medicine Reports</i> , 2017, 16, 609-616.	1.1	19
1209	Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. <i>Microbes and Infection</i> , 2017, 19, 464-475.	1.0	49

#	ARTICLE	IF	CITATIONS
1210	Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. <i>Gastroenterology</i> , 2017, 153, 1082-1095.	0.6	55
1211	Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. <i>Human Molecular Genetics</i> , 2017, 26, 3014-3027.	1.4	97
1212	FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 72.	3.5	50
1213	Biomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects. <i>Biomarkers in Medicine</i> , 2017, 11, 405-407.	0.6	4
1214	Establishment of a Strong Link Between Smoking and Cancer Pathogenesis through DNA Methylation Analysis. <i>Scientific Reports</i> , 2017, 7, 1811.	1.6	59
1215	Immune Signatures of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 913-915.	0.5	4
1216	Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	3.2	44
1217	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. <i>Acta Neuropathologica</i> , 2017, 134, 691-703.	3.9	131
1218	Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 109, 28-35.	0.9	10
1219	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. <i>BMC Cancer</i> , 2017, 17, 281.	1.1	31
1220	Paper-based biosensor for noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients. <i>Sensors and Actuators B: Chemical</i> , 2017, 251, 440-445.	4.0	48
1221	CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 3703-3708.	0.8	22
1222	Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. <i>Nature Communications</i> , 2017, 8, 15290.	5.8	195
1223	The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. <i>Nature Communications</i> , 2017, 8, 15503.	5.8	116
1225	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.	0.9	25
1226	Seeing the Forest through the Phylogenetic Tree. <i>New England Journal of Medicine</i> , 2017, 376, 2190-2191.	13.9	1
1227	Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy. <i>Toxicology Reports</i> , 2017, 4, 306-318.	1.6	108
1228	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a000778.	0.5	20

#	ARTICLE	IF	CITATIONS
1229	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 5366-5373.	3.2	109
1230	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1610-1622.	1.9	22
1231	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	0.9	195
1233	Biologically-based mechanistic models of radiation-related carcinogenesis applied to epidemiological data. <i>International Journal of Radiation Biology</i> , 2017, 93, 1093-1117.	1.0	59
1234	PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data. <i>Bioinformatics</i> , 2017, 33, 2238-2240.	1.8	50
1235	Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 559-569.	1.5	56
1236	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42
1237	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. <i>Cell Reports</i> , 2017, 18, 673-684.	2.9	47
1238	PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4. <i>Scientific Reports</i> , 2017, 7, 45038.	1.6	15
1239	Molecular biomarkers for lung adenocarcinoma. <i>European Respiratory Journal</i> , 2017, 49, 1601734.	3.1	110
1240	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017, 8, 14922.	5.8	80
1241	Functional variants in DCAF4 associated with lung cancer risk in European populations. <i>Carcinogenesis</i> , 2017, 38, 541-551.	1.3	16
1242	Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. <i>Clinical Cancer Research</i> , 2017, 23, 4501-4510.	3.2	45
1243	Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges. <i>Tumor Biology</i> , 2017, 39, 101042831769757.	0.8	25
1244	Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 701-716.	0.9	35
1245	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	1.6	141
1246	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. <i>Scientific Reports</i> , 2017, 7, 738.	1.6	12
1247	Analysis of significantly mutated genes as a clinical tool for the diagnosis in a case of lung cancer. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 171-175.	0.2	4

#	ARTICLE	IF	CITATIONS
1248	Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer. <i>Scientific Reports</i> , 2017, 7, 44997.	1.6	92
1249	Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma. <i>American Journal of Pathology</i> , 2017, 187, 954-962.	1.9	44
1250	MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 4037-4046.	2.6	101
1251	The Mechanistic Role of the Calcium-Activated Chloride Channel ANO1 in Tumor Growth and Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2017, 966, 1-14.	0.8	28
1252	Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy. <i>Current Oncology Reports</i> , 2017, 19, 24.	1.8	32
1253	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. <i>Clinical Cancer Research</i> , 2017, 23, 3203-3213.	3.2	66
1254	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. <i>Journal of Thoracic Oncology</i> , 2017, 12, 943-953.	0.5	136
1255	IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS. , 2017, 22, 473-484.		7
1256	The Varied Roles of Notch in Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 245-275.	9.6	511
1257	Cornerstones of CRISPR-Cas in drug discovery and therapy. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 89-100.	21.5	370
1258	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. <i>Clinical Cancer Research</i> , 2017, 23, 3203-3213.	3.2	66
1259	Programmed cell death ligand 1 (<i>PD-L1</i>) expression and fibroblast growth factor receptor 1 (<i>FGFR1</i>) amplification in stage III/IV lung squamous cell carcinoma (<i>SQC</i>). <i>Thoracic Cancer</i> , 2017, 8, 73-79.	0.8	17
1261	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706
1262	A Histologic Basis for the Efficacy of SBRT to the lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, 510-519.	0.5	82
1263	Genomic Adequacy from Solid Tumor Core Needle Biopsies of ex Vivo Tissue and in Vivo Lung Masses: Prospective Study. <i>Radiology</i> , 2017, 282, 903-912.	3.6	31
1264	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 1-12.	2.0	67
1265	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <i>Journal of Clinical Oncology</i> , 2017, 35, 243-252.	0.8	19
1266	Integrated genomic characterization of oesophageal carcinoma. <i>Nature</i> , 2017, 541, 169-175.	13.7	1,448

#	ARTICLE	IF	CITATIONS
1267	Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2017, 18, 246-262.	16.1	444
1268	Autophagy in the liver: functions in health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 170-184.	8.2	384
1269	PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. <i>Lung Cancer</i> , 2017, 103, 52-57.	0.9	28
1270	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. <i>Nature Communications</i> , 2017, 8, 1081.	5.8	16
1271	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. <i>Nature Medicine</i> , 2017, 23, 1362-1368.	15.2	462
1272	Nuclear topology modulates the mutational landscapes of cancer genomes. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 1000-1006.	3.6	28
1273	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. <i>Clinical Cancer Research</i> , 2017, 23, 7633-7640.	3.2	27
1274	Sample Size Calculation for Differential Expression Analysis of RNA-Seq Data. , 2017, , 359-379.		0
1275	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
1277	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. <i>Cancer Research</i> , 2017, 77, 6415-6428.	0.4	206
1278	<i>EGFR</i>-Mutant Non-“Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline <i>EGFR</i> T790M Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1188-1192.	2.3	7
1279	Bimetallic nanoplasmonic gap-mode SERS substrate for lung normal and cancer-derived exosomes detection. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2017, 80, 149-155.	2.7	45
1280	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
1281	Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. <i>Cancer Science</i> , 2017, 108, 2487-2494.	1.7	57
1282	Lung squamous cell carcinoma exhibits a targetable glucose dependency unique among non-small cell lung cancers. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1364211.	0.3	8
1283	A novel approach for data integration and disease subtyping. <i>Genome Research</i> , 2017, 27, 2025-2039.	2.4	139
1284	Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2447-2453.	1.2	16
1285	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017, 60, 1-11.	3.4	29

#	ARTICLE	IF	CITATIONS
1286	Low tumour cell content in a lung tumour bank: implications for molecular characterisation. <i>Pathology</i> , 2017, 49, 611-617.	0.3	3
1287	Discovering potential driver genes through an integrated model of somatic mutation profiles and gene functional information. <i>Molecular BioSystems</i> , 2017, 13, 2135-2144.	2.9	20
1288	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. <i>Annals of Oncology</i> , 2017, 28, 2595-2605.	0.6	229
1289	Molecular Characteristics of Patient-Derived Tumor Xenografts: Similarities to Patient Tumors and Relevance for Biomarker Discovery. <i>Molecular and Translational Medicine</i> , 2017, , 227-243.	0.4	1
1290	A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA. <i>Clinical Cancer Research</i> , 2017, 23, 7141-7152.	3.2	116
1291	FGFR19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. <i>Thoracic Cancer</i> , 2017, 8, 655-665.	0.8	23
1292	YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation. <i>Cancer Research</i> , 2017, 77, 5769-5781.	0.4	70
1293	Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. <i>Cancer Cell</i> , 2017, 32, 360-376.e6.	7.7	162
1294	Network-based machine learning and graph theory algorithms for precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 25.	2.3	74
1295	Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. <i>Nature Communications</i> , 2017, 8, 524.	5.8	103
1296	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
1297	Techniques to Identify Novel Fusion Genes and to Detect Known Fusion Genes. , 2017, , 59-79.		0
1298	Molecular Signatures for Tumor Classification. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 881-891.	1.2	22
1299	A signal-based method for finding driver modules of breast cancer metastasis to the lung. <i>Scientific Reports</i> , 2017, 7, 10023.	1.6	5
1300	Forward and backward evolutionary processes and allele frequency spectrum in a cancer cell population. <i>Theoretical Population Biology</i> , 2017, 117, 43-50.	0.5	23
1301	geneSurv: An interactive web-based tool for survival analysis in genomics research. <i>Computers in Biology and Medicine</i> , 2017, 89, 487-496.	3.9	4
1302	IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. <i>Oncogene</i> , 2017, 36, 6315-6324.	2.6	46
1303	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , 2017, 19, 649-658.	2.3	4,166

#	ARTICLE	IF	CITATIONS
1304	<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2017, 123, 4099-4105.	2.0	132
1305	Squamous cell carcinomas and adenocarcinomas of the esophagus: One treatment does not rule them all. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1446-1447.	0.4	6
1306	Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. <i>Human Pathology</i> , 2017, 67, 69-77.	1.1	34
1307	Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. <i>Cancer Cell</i> , 2017, 32, 155-168.e6.	7.7	93
1308	Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. <i>Journal of Surgical Research</i> , 2017, 220, 125-132.	0.8	45
1309	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017, 23, 4441-4449.	3.2	342
1310	High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification. <i>Oncogene</i> , 2017, 36, 6383-6390.	2.6	13
1311	Whole-Genome Sequencing in Common Respiratory Diseases. Ready, Set, Go!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 121-122.	2.5	5
1312	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 2078-2089.	1.2	15
1313	Mutant p53 as a target for cancer treatment. <i>European Journal of Cancer</i> , 2017, 83, 258-265.	1.3	287
1314	<i>miR-432</i> Induces NRF2 Stabilization by Directly Targeting KEAP1. <i>Molecular Cancer Research</i> , 2017, 15, 1570-1578.	1.5	53
1315	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017, 32, 204-220.e15.	7.7	642
1316	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1864-1888.	2.5	32
1317	NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 17064.	1.6	67
1318	⁶³ Np Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. <i>Cell Reports</i> , 2017, 21, 2926-2939.	2.9	61
1319	<i>Kras</i> mutant genetically engineered mouse models of human cancers are genomically heterogeneous. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10947-E10955.	3.3	58
1320	Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 15511.	1.6	54
1321	Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance. <i>Scientific Reports</i> , 2017, 7, 15324.	1.6	49

#	ARTICLE	IF	CITATIONS
1322	Endoplasmic Reticulum Stress Promotes Autophagy and Apoptosis and Reduces Chemotherapy Resistance in Mutant p53 Lung Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 133-151.	1.1	38
1323	A seven-gene prognostic signature for rapid determination of head and neck squamous cell carcinoma survival. <i>Oncology Reports</i> , 2017, 38, 3403-3411.	1.2	29
1324	Very early response of circulating tumourâ€derived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonâ€small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 86, 349-357.	1.3	82
1325	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. <i>Lung Cancer</i> , 2017, 112, 96-101.	0.9	17
1326	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
1327	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	3.2	107
1328	Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. <i>Scientific Reports</i> , 2017, 7, 4059.	1.6	34
1329	Epigenetics during EMT in lung cancer: EZH2 as a potential therapeutic target. <i>Cancer Treatment and Research Communications</i> , 2017, 12, 40-48.	0.7	9
1330	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	0.9	160
1331	Targeting FGFR in Squamous Cell Carcinoma of the Lung. <i>Targeted Oncology</i> , 2017, 12, 741-755.	1.7	21
1332	Somatic mutations in ZFH4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. <i>Scientific Reports</i> , 2017, 7, 4951.	1.6	46
1333	Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. <i>Molecular Cancer Research</i> , 2017, 15, 1354-1365.	1.5	25
1334	Neutralizing Extracellular Histones in Acute Respiratory Distress Syndrome. A New Role for an Endogenous Pathway. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 122-124.	2.5	17
1335	ZNF692 promotes proliferation and cell mobility in lung adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 1189-1196.	1.0	14
1336	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Nonâ€Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1529.	3.4	412
1337	Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1512-1523.	0.5	6
1338	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 31-33.	0.2	6
1339	Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. <i>Clinical Lung Cancer</i> , 2017, 18, 667-674.e1.	1.1	13

#	ARTICLE	IF	CITATIONS
1340	GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 4448-4459.	0.4	24
1341	RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples. <i>BMC Genomics</i> , 2017, 18, 443.	1.2	74
1342	Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report. <i>BMC Cancer</i> , 2017, 17, 65.	1.1	25
1343	A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells. <i>BMC Cancer</i> , 2017, 17, 301.	1.1	4
1344	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. <i>Respiratory Research</i> , 2017, 18, 120.	1.4	41
1345	Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies. <i>Genome Biology</i> , 2017, 18, 17.	3.8	112
1346	The NF1 somatic mutational landscape in sporadic human cancers. <i>Human Genomics</i> , 2017, 11, 13.	1.4	203
1347	Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. <i>Briefings in Bioinformatics</i> , 2018, 19, 1370-1381.	3.2	185
1348	Shared epithelial pathways to lung repair and disease. <i>European Respiratory Review</i> , 2017, 26, 170048.	3.0	18
1349	KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2017, 140, 930-937.	2.3	28
1350	"Genotype/immunotype"™ correlations in resected NSCLC. <i>Annals of Oncology</i> , 2017, 28, 7-8.	0.6	7
1351	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. <i>International Journal of Cancer</i> , 2017, 140, 662-673.	2.3	67
1352	Multiplatform-based molecular subtypes of non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 1384-1393.	2.6	118
1353	Clustering of mRNA-Seq data based on alternative splicing patterns. <i>Biostatistics</i> , 2017, 18, 295-307.	0.9	7
1354	DMAK: A curated pan-cancer DNA methylation annotation knowledgebase. <i>Bioengineered</i> , 2017, 8, 182-190.	1.4	4
1355	Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2017, 23, 757-765.	3.2	144
1356	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	6.3	2,267
1357	Cancer heterogeneity determined by functional proteomics. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 132-142.	2.3	17

#	ARTICLE	IF	CITATIONS
1358	A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts. <i>Journal of Thoracic Oncology</i> , 2017, 12, 65-76.	0.5	26
1359	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. <i>Bioinformatics</i> , 2017, 33, 177-183.	1.8	5
1360	Role of <i>KEAP1</i> and <i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. <i>Cancer Discovery</i> , 2017, 7, 86-101.	7.7	239
1361	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. <i>Oncogene</i> , 2017, 36, 1339-1350.	2.6	39
1362	“Omic and Electronic Health Record Big Data Analytics for Precision Medicine. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 263-273.	2.5	198
1363	Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. <i>Progress in Retinal and Eye Research</i> , 2017, 56, 58-83.	7.3	103
1364	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. <i>Annals of Oncology</i> , 2017, 28, 83-89.	0.6	97
1365	Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. <i>Clinical Cancer Research</i> , 2017, 23, 1998-2005.	3.2	193
1366	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. <i>Journal of Human Genetics</i> , 2017, 62, 397-405.	1.1	55
1367	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1937-1944.	3.2	67
1368	Genome analyses identify the genetic modification of lung cancer subtypes. <i>Seminars in Cancer Biology</i> , 2017, 42, 20-30.	4.3	47
1369	Pan-cancer analysis of somatic copy-number alterations implicates <i>IRS4</i> and <i>IGF2</i> in enhancer hijacking. <i>Nature Genetics</i> , 2017, 49, 65-74.	9.4	326
1370	Chemical Carcinogenesis Models of Cancer: Back to the Future. <i>Annual Review of Cancer Biology</i> , 2017, 1, 295-312.	2.3	30
1371	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	3.2	92
1372	microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network. <i>Oncogene</i> , 2017, 36, 731-745.	2.6	19
1373	Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. <i>European Journal of Radiology</i> , 2017, 86, 297-307.	1.2	222
1374	QSEA modelling of genome-wide DNA methylation from sequencing enrichment experiments. <i>Nucleic Acids Research</i> , 2017, 45, e44-e44.	6.5	39
1375	Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1744-1745.	0.5	2

#	ARTICLE	IF	CITATIONS
1376	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
1377	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. <i>Nucleic Acids Research</i> , 2017, 45, 583-596.	6.5	18
1378	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. <i>Lung Cancer Management</i> , 2017, 6, 93-107.	1.5	5
1379	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. <i>Oncotarget</i> , 2017, 8, 41334-41347.	0.8	22
1380	Lung: Translocations in Squamous Cell Carcinoma. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	0
1381	Identification of potential prognostic ceRNA module biomarkers in patients with pancreatic adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 94493-94504.	0.8	15
1382	Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. <i>Oncotarget</i> , 2017, 8, 18885-18900.	0.8	21
1383	Germline and Somatic Smoothed Mutations in Non-“Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	3
1384	Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. <i>Oncotarget</i> , 2017, 8, 2681-2693.	0.8	22
1385	<i>GAB2</i> Amplification in Squamous Cell Lung Cancer of Non-Smokers. <i>Journal of Korean Medical Science</i> , 2017, 32, 1784.	1.1	14
1386	Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)“from morphology to molecular testing. <i>Journal of Thoracic Disease</i> , 2017, 9, S395-S404.	0.6	30
1387	Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging. <i>Theranostics</i> , 2017, 7, 1612-1632.	4.6	38
1388	Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 34.	1.3	6
1389	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1172.	1.8	73
1390	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
1391	A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 83.	1.8	59
1392	Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer. <i>BMC Genomics</i> , 2017, 18, 901.	1.2	63
1393	Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 49.	1.7	53

#	ARTICLE	IF	CITATIONS
1394	Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. <i>Cells</i> , 2017, 6, 12.	1.8	75
1395	MYC Deregulation in Primary Human Cancers. <i>Genes</i> , 2017, 8, 151.	1.0	281
1396	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. <i>International Journal of Molecular Sciences</i> , 2017, 18, 308.	1.8	353
1397	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
1398	Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. <i>Frontiers in Medicine</i> , 2017, 4, 9.	1.2	14
1399	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
1400	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 50.	1.3	30
1401	The KEAP1—NRF2 System in Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 85.	1.3	370
1402	Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. <i>Frontiers in Oncology</i> , 2017, 7, 193.	1.3	343
1403	Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 222.	1.3	5
1404	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2513-2526.	1.0	33
1405	Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. <i>International Journal of Biological Sciences</i> , 2017, 13, 1163-1171.	2.6	39
1406	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 147-157.	0.8	7
1407	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 34796-34810.	0.8	45
1408	Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. <i>Journal of Korean Medical Science</i> , 2017, 32, 415.	1.1	8
1409	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125.	1.3	49
1410	An integrated method for the identification of novel genes related to oral cancer. <i>PLoS ONE</i> , 2017, 12, e0175185.	1.1	23
1411	Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis. <i>PLoS ONE</i> , 2017, 12, e0187308.	1.1	7

#	ARTICLE	IF	CITATIONS
1412	Clinical Epigenetics of Lung Cancer. , 2017, , 97-133.		3
1413	Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics. Clinical Proteomics, 2017, 14, 31.	1.1	29
1414	Systems-epigenomics inference of transcription factor activity implicates aryl-hydrocarbon-receptor inactivation as a key event in lung cancer development. Genome Biology, 2017, 18, 236.	3.8	46
1415	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Medicine, 2017, 9, 89.	3.6	39
1416	Predicting cancer type from tumour DNA signatures. Genome Medicine, 2017, 9, 104.	3.6	40
1417	Tri-methylation of H3K79 is decreased in TGF- β 1-induced epithelial-to-mesenchymal transition in lung cancer. Clinical Epigenetics, 2017, 9, 80.	1.8	40
1418	A practical prognostic lncRNA signature for lung squamous cell carcinoma. Translational Medicine Communications, 2017, 2, .	0.5	1
1419	A step-by-step microRNA guide to cancer development and metastasis. Cellular Oncology (Dordrecht), 2017, 40, 303-339.	2.1	129
1420	Classifying cancer genome aberrations by their mutually exclusive effects on transcription. BMC Medical Genomics, 2017, 10, 66.	0.7	7
1421	Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. Oncotarget, 2017, 8, 87292-87306.	0.8	16
1422	Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer. Oncotarget, 2017, 8, 79404-79413.	0.8	15
1423	Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget, 2017, 8, 59113-59122.	0.8	52
1424	Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. Oncotarget, 2017, 8, 59268-59281.	0.8	19
1425	Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget, 2017, 8, 31133-31143.	0.8	57
1426	MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. Oncotarget, 2017, 8, 56143-56157.	0.8	28
1427	Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget, 2017, 8, 97476-97489.	0.8	33
1428	Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma. Lung Cancer: Targets and Therapy, 2017, Volume 8, 13-19.	1.3	18
1429	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget, 2017, 8, 11114-11126.	0.8	22

#	ARTICLE	IF	CITATIONS
1430	Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 2942-2951.	0.6	53
1431	Molecular Testing of Lung Cancers. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 242-254.	0.4	26
1432	Access to Oncology Drugs in Brazil: Juggling Innovation and Sustainability in Developing Countries. <i>Medicine Access Point of Care</i> , 2017, 1, maapoc.0000004.	1.0	2
1433	Future Genetic/Genomic Biomarker Testing in Non-“Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 12-17.	1.8	3
1434	Eight potential biomarkers for distinguishing between lung adenocarcinoma and squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 71759-71771.	0.8	56
1435	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	0.8	311
1436	Triptolide suppresses the <i>in vitro</i> and <i>in vivo</i> growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling. <i>Oncotarget</i> , 2017, 8, 26927-26940.	0.8	51
1437	Landscape of Microsatellite Instability Across 39 Cancer Types. <i>JCO Precision Oncology</i> , 2017, 2017, 1-15.	1.5	796
1438	Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non-“Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2018-2027.	0.8	91
1439	Genomics of lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E155-E157.	0.6	2
1440	Neutrophils dominate the immune landscape of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E468-E469.	0.6	7
1441	Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E598-E604.	0.6	6
1442	Tumor spread through air space (STAS) is an important predictor of clinical outcome in stage IA lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 2283-2285.	0.6	4
1443	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	0.6	51
1444	Uniportal video assisted thoracic surgery with 2 cm skin incision for right middle lobectomy with systematic lymphadenectomy. <i>Journal of Thoracic Disease</i> , 2017, 9, 4592-4596.	0.6	3
1445	Recon3D enables a three-dimensional view of gene variation in human metabolism. <i>Nature Biotechnology</i> , 2018, 36, 272-281.	9.4	520
1446	Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. <i>Scientific Reports</i> , 2018, 8, 3284.	1.6	20
1447	Proteomic biomarkers for lung cancer progression. <i>Biomarkers in Medicine</i> , 2018, 12, 205-215.	0.6	7

#	ARTICLE	IF	CITATIONS
1448	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA Journal, 2018, 9, 77-102.	3.3	184
1449	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Human Pathology, 2018, 75, 167-178.	1.1	13
1450	Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Molecular Cancer Therapeutics, 2018, 17, 795-805.	1.9	37
1451	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1011-1022.	2.0	36
1452	Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. Cancer Cell International, 2018, 18, 27.	1.8	26
1453	Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer. International Journal of Cancer, 2018, 143, 878-885.	2.3	13
1454	Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less. Archives of Pathology and Laboratory Medicine, 2018, 142, 291-298.	1.2	60
1455	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. Annals of Surgical Oncology, 2018, 25, 1564-1571.	0.7	23
1456	Nanomaterials for Cancer Precision Medicine. Advanced Materials, 2018, 30, e1705660.	11.1	136
1457	Identification of four plasma microRNA as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. Cancer Medicine, 2018, 7, 2370-2381.	1.3	32
1458	Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. Journal of Thoracic Oncology, 2018, 13, 1217-1221.	0.5	123
1459	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. Journal of the National Cancer Institute, 2018, 110, 1386-1392.	3.0	137
1460	RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Molecular Cancer Therapeutics, 2018, 17, 1526-1539.	1.9	39
1461	IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. Cancer Immunology Research, 2018, 6, 645-657.	1.6	31
1462	An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo. Oncogene, 2018, 37, 3894-3908.	2.6	17
1463	NIPS, a 3D network-integrated predictor of deleterious protein SAPs, and its application in cancer prognosis. Scientific Reports, 2018, 8, 6021.	1.6	1
1464	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
1465	A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics, 2018, 19, 71-86.	0.9	158

#	ARTICLE	IF	CITATIONS
1466	BRAF ^{wild} papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. <i>Head and Neck</i> , 2018, 40, 1707-1718.	0.9	3
1467	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	13.5	2,277
1468	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	13.5	2,111
1469	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	2.9	245
1470	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	7.2	398
1471	Clinical and Pathological Characteristics of <i>KEAP1</i> - and <i>NFE2L2</i> -Mutated Non-Small Cell Lung Carcinoma (NSCLC). <i>Clinical Cancer Research</i> , 2018, 24, 3087-3096.	3.2	116
1472	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3978-E3986.	3.3	78
1473	Evaluating tumor-suppressor gene combinations. <i>Nature Genetics</i> , 2018, 50, 480-482.	9.4	2
1474	Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode. <i>Biosensors and Bioelectronics</i> , 2018, 113, 108-115.	5.3	58
1475	Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. <i>Biomacromolecules</i> , 2018, 19, 803-815.	2.6	39
1476	Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. <i>Neoplasia</i> , 2018, 20, 256-262.	2.3	44
1477	The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2018, 23, 452-457.	1.0	10
1478	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
1479	Mouse models in squamous cell lung cancer: impact for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 347-358.	2.5	14
1480	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018, 31, 947-955.	2.9	56
1481	Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). <i>Oncology Reports</i> , 2018, 39, 901-911.	1.2	60
1482	Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and p63/p40. <i>Human Pathology</i> , 2018, 78, 177-181.	1.1	16
1483	Suppression of lung inflammation by the methanol extract of <i>Spilanthes acmella</i> Murray is related to differential regulation of NF- κ B and Nrf2. <i>Journal of Ethnopharmacology</i> , 2018, 217, 89-97.	2.0	17

#	ARTICLE	IF	CITATIONS
1484	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. <i>Clinical Cancer Research</i> , 2018, 24, 2182-2193.	3.2	68
1485	Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 267-275.	1.1	47
1486	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 335-345.	1.5	19
1487	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. <i>Carcinogenesis</i> , 2018, 39, 336-346.	1.3	29
1488	The OncoPPI Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. <i>Bioinformatics</i> , 2018, 34, 1183-1191.	1.8	41
1489	PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGF β . <i>Cancer Research</i> , 2018, 78, 1805-1819.	0.4	38
1490	Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. <i>Oncolmmunology</i> , 2018, 7, e1428156.	2.1	14
1491	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
1492	Mesenchymal stem cells over-expressing cxcl12 enhance the radioresistance of the small intestine. <i>Cell Death and Disease</i> , 2018, 9, 154.	2.7	13
1493	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270
1494	Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1691-1704.	3.2	53
1495	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2018, 25, 1160-1173.	5.0	51
1496	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
1497	FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 759-769.	1.4	10
1498	Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. <i>Pathology and Oncology Research</i> , 2018, 24, 723-731.	0.9	21
1499	CT Radiomics in Thoracic Oncology: Technique and Clinical Applications. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 91-98.	0.6	22
1500	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
1501	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 568-575.	0.5	17

#	ARTICLE	IF	CITATIONS
1502	Kernel machine methods for integrative analysis of genome-wide methylation and genotyping studies. <i>Genetic Epidemiology</i> , 2018, 42, 156-167.	0.6	8
1503	RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1473-1485.	3.2	49
1504	Dual role of autophagy in hallmarks of cancer. <i>Oncogene</i> , 2018, 37, 1142-1158.	2.6	403
1505	Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2). <i>Journal of Biological Chemistry</i> , 2018, 293, 2029-2040.	1.6	51
1506	Cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 237-247.	0.6	495
1507	IKK β inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E812-E821.	3.3	44
1508	Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images. <i>EBioMedicine</i> , 2018, 27, 317-328.	2.7	240
1509	Induction of non-apoptotic programmed cell death by oncogenic RAS in human epithelial cells and its suppression by MYC overexpression. <i>Carcinogenesis</i> , 2018, 39, 202-213.	1.3	13
1510	DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 53.	6.9	72
1511	Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC. <i>Clinical Epigenetics</i> , 2018, 10, 41.	1.8	12
1512	Targeted therapy according to next generation sequencing-based panel sequencing. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 9-14.	0.1	17
1513	Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. <i>Nature Communications</i> , 2018, 9, 1677.	5.8	96
1514	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. <i>Cancer Treatment Reviews</i> , 2018, 66, 82-94.	3.4	112
1515	INO80 Chromatin Remodeling Coordinates Metabolic Homeostasis with Cell Division. <i>Cell Reports</i> , 2018, 22, 611-623.	2.9	28
1516	MVisAGe Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors. <i>Cancer Research</i> , 2018, 78, 3375-3385.	0.4	5
1517	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. <i>Annals of Oncology</i> , 2018, 29, 200-208.	0.6	25
1518	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1621-1626.	0.7	5
1519	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	2.9	605

#	ARTICLE	IF	CITATIONS
1520	Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876761.	1.0	64
1521	Somatic DNA Copy-Number Alterations Detection for Esophageal Adenocarcinoma Using Digital Polymerase Chain Reaction. <i>Methods in Molecular Biology</i> , 2018, 1756, 195-212.	0.4	1
1522	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. <i>Nature Biomedical Engineering</i> , 2018, 2, 239-253.	11.6	18
1523	Integrative Analysis of Omics Big Data. <i>Methods in Molecular Biology</i> , 2018, 1754, 109-135.	0.4	54
1524	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018, 9, 1048.	5.8	254
1525	Cetuximab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 483-493.	1.4	44
1526	Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1535-1552.	2.5	31
1527	Exosomal lipids for classifying early and late stage non-small cell lung cancer. <i>Analytica Chimica Acta</i> , 2018, 1037, 256-264.	2.6	72
1528	The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma. <i>Cancer Research</i> , 2018, 78, 2839-2851.	0.4	211
1529	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
1530	FAT1 inhibits cell migration and invasion by affecting cellular mechanical properties in esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2018, 39, 2136-2146.	1.2	19
1531	Afatinib in advanced NSCLC: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 89-98.	0.3	14
1532	Screening for gene mutations in central nervous system metastases of non-small cell lung cancer. <i>Brain Pathology</i> , 2018, 28, 295-297.	2.1	4
1533	Biological function and histone recognition of family IV bromodomain-containing proteins. <i>Journal of Cellular Physiology</i> , 2018, 233, 1877-1886.	2.0	62
1534	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. <i>PET Clinics</i> , 2018, 13, 33-42.	1.5	2
1535	Novel genetic variants in the P38MAPK pathway gene <i>ZAK</i> and susceptibility to lung cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 216-224.	1.3	9
1536	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
1537	TDP-43 regulates cancer-associated microRNAs. <i>Protein and Cell</i> , 2018, 9, 848-866.	4.8	35

#	ARTICLE	IF	CITATIONS
1538	Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. <i>Cancer Discovery</i> , 2018, 8, 108-125.	7.7	99
1539	The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 182-192.	1.3	89
1540	Knockdown of translationally controlled tumor protein inhibits growth, migration and invasion of lung cancer cells. <i>Life Sciences</i> , 2018, 193, 292-299.	2.0	8
1541	Semivarying coefficient least-squares support vector regression for analyzing high-dimensional gene-environmental data. <i>Journal of Applied Statistics</i> , 2018, 45, 1370-1381.	0.6	2
1542	Genetic Susceptibility to Lung Cancer. , 2018, , 46-51.e2.		5
1543	Copy Number Abnormalities and Gene Fusions in Lung Cancer. , 2018, , 82-94.e4.		0
1544	Mutational Events in Lung Cancer. , 2018, , 95-103.e2.		5
1545	Epigenetic Events in Lung Cancer. , 2018, , 104-116.e5.		1
1546	Radiobiology of Lung Cancer. , 2018, , 330-336.e2.		0
1547	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. , 2018, , 418-433.e6.		0
1548	Diagnostic Algorithms. , 2018, , 651-658.e1.		0
1549	A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 1207-1214.	1.9	30
1550	HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. <i>Molecular Cancer Research</i> , 2018, 16, 90-102.	1.5	151
1551	Lung cancer epigenetics: From knowledge to applications. <i>Seminars in Cancer Biology</i> , 2018, 51, 116-128.	4.3	202
1552	The Regulation of NRF2 by Nutrient-Responsive Signaling and Its Role in Anabolic Cancer Metabolism. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1774-1791.	2.5	54
1553	Classic Anatomic Pathology and Lung Cancer. , 2018, , 143-163.e4.		5
1554	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
1555	Prognosis and "œgranularity" Building on staging foundations?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 354-355.	0.4	0

#	ARTICLE	IF	CITATIONS
1556	Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. <i>Journal of Thoracic Oncology</i> , 2018, 13, 112-123.	0.5	104
1557	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 2-11.	1.0	23
1558	Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 2307-2313.	7.2	36
1559	Lektion gelernt? Die molekularen Grundlagen von Kinase-gerichteten Therapien und Wirkstoffresistenz im nicht-kleinzelligen Lungenkrebs. <i>Angewandte Chemie</i> , 2018, 130, 2329-2335.	1.6	1
1560	Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. <i>Cancer Research</i> , 2018, 78, 451-462.	0.4	22
1561	Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 103-109.	4.3	534
1562	Genomic variations in the counterpart normal controls of lung squamous cell carcinomas. <i>Frontiers of Medicine</i> , 2018, 12, 280-288.	1.5	13
1563	Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 237-245.	0.5	47
1564	Ubiquitin ligases in oncogenic transformation and cancer therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 69-88.	12.8	340
1565	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	7.7	255
1566	TGF β 2 pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130.		85
1567	The <i>NOTCH4</i> Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 619-633.	3.2	63
1568	<i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1436-1447.	3.2	56
1569	Mutational Landscape of <i>DDR2</i> Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing. <i>Clinical Lung Cancer</i> , 2018, 19, 163-169.e4.	1.1	11
1570	Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients. <i>Gastroenterology</i> , 2018, 154, 374-389.	0.6	188
1571	Aligning digital CD8 ⁺ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. <i>Histopathology</i> , 2018, 72, 270-284.	1.6	17
1572	Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 5904-5912.	0.6	17
1573	Pathway-Centric Analysis of the TCGA - NSCLC Transcriptome Data Pertaining to Deceased Patients. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
1574	Oncogene-addicted non-small cell lung cancer and immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1547-S1555.	0.6	25
1575	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. <i>Translational Lung Cancer Research</i> , 2018, 7, 464-486.	1.3	11
1576	Exploring DNA Methylation Data of Lung Cancer Samples with Variational Autoencoders. , 2018, , .		15
1577	Using the SVM Method for Lung Adenocarcinoma Prognosis Based on Expression Level. , 2018, , .		0
1578	Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. <i>Translational Lung Cancer Research</i> , 2018, 7, S265-S269.	1.3	1
1579	STAT3 cyclic oligonucleotide decoy" a new therapeutic avenue for NSCLC?. <i>Translational Lung Cancer Research</i> , 2018, 7, S381-S384.	1.3	3
1580	SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients. <i>Respiratory Research</i> , 2018, 19, 241.	1.4	16
1581	Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGF1R-driven lung cancer. <i>PLoS ONE</i> , 2018, 13, e0206948.	1.1	5
1582	A radiogenomic dataset of non-small cell lung cancer. <i>Scientific Data</i> , 2018, 5, 180202.	2.4	167
1583	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	3
1584	What is the best drug as a front-line treatment for EGFR activating mutation?. <i>Precision Cancer Medicine</i> , 2018, 1, 16-16.	1.8	0
1585	The Role of TGF- β 2 Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3611.	1.8	66
1586	A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7691-7697.	1.0	6
1587	MicroRNA induction by copy number gain is associated with poor outcome in squamous cell carcinoma of the lung. <i>Scientific Reports</i> , 2018, 8, 15363.	1.6	12
1588	Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0207204.	1.1	42
1589	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	0.9	27
1590	FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 1108-1116.	1.5	6
1591	Deletion of C9orf53 promotes the growth of head and neck squamous cell carcinoma and is associated with poor prognosis of patients with head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 17, 1223-1228.	0.8	1

#	ARTICLE	IF	CITATIONS
1592	Noninvasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG-PET/CT and CT. <i>Oncology Reports</i> , 2018, 41, 447-454.	1.2	2
1593	circRNA meets gene amplification. <i>Non-coding RNA Investigation</i> , 2018, 2, 38-38.	0.6	2
1594	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. <i>Oncotarget</i> , 2018, 9, 10635-10649.	0.8	41
1595	MicroRNA dysregulatory synergistic network: discovering microRNA dysregulatory modules across subtypes in non-small cell lung cancers. <i>BMC Bioinformatics</i> , 2018, 19, 504.	1.2	9
1596	MeDEStrand: an improved method to infer genome-wide absolute methylation levels from DNA enrichment data. <i>BMC Bioinformatics</i> , 2018, 19, 540.	1.2	7
1597	Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 6897-6904.	0.9	5
1599	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8565-8573.	1.0	8
1600	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. <i>Cancers</i> , 2018, 10, 518.	1.7	10
1601	BayCount: A Bayesian decomposition method for inferring tumor heterogeneity using RNA-Seq counts. <i>Annals of Applied Statistics</i> , 2018, 12, .	0.5	4
1602	Construction of a transcription factor-long non-coding RNA-microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2018, 19, 1101-1109.	1.1	1
1603	Classification histomoléculaire des cancers pulmonaires. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 236-247.	0.0	0
1604	Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 433-439.	1.0	6
1605	Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. <i>Cancers</i> , 2018, 10, 478.	1.7	30
1606	Sensing Oxidative Stress: The NRF2 Signaling Pathway. , 2018, , 337-351.		0
1607	Identification of differentially methylated cell types in epigenome-wide association studies. <i>Nature Methods</i> , 2018, 15, 1059-1066.	9.0	166
1608	Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11671-E11680.	3.3	51
1609	Identification and Characterization of MicroRNAs Associated with Somatic Copy Number Alterations in Cancer. <i>Cancers</i> , 2018, 10, 475.	1.7	6
1610	Molecular Lesions of Insulator CTCF and Its Parologue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies. <i>High-Throughput</i> , 2018, 7, 30.	4.4	8

#	ARTICLE	IF	CITATIONS
1611	Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? (Review). <i>Biomedical Reports</i> , 2018, 9, 375-382.	0.9	26
1612	Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 105, 1-12.	1.2	8
1613	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2018, 104, 1-8.	1.3	10
1614	Identification of key genes and long non-coding RNAs in celecoxib-treated lung squamous cell carcinoma cell line by RNA-sequencing. <i>Molecular Medicine Reports</i> , 2018, 17, 6456-6464.	1.1	6
1615	Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880180.	0.8	18
1616	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1676-1691.	0.5	21
1617	A case of solitary paraaortic lymph node recurrence of lung squamous cell carcinoma after resection. <i>Journal of Medical Investigation</i> , 2018, 65, 283-285.	0.2	1
1618	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.	2.4	15
1619	Validation of a next-generation sequencing oncology panel optimized for low input DNA. <i>Cancer Genetics</i> , 2018, 228-229, 55-63.	0.2	6
1620	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. <i>PLoS Computational Biology</i> , 2018, 14, e1006520.	1.5	13
1621	Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. <i>Cell Reports</i> , 2018, 25, 1066-1080.e8.	2.9	239
1623	Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. <i>Cancer Management and Research</i> , 2018, Volume 10, 4039-4050.	0.9	12
1624	Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. <i>Nature Medicine</i> , 2018, 24, 1559-1567.	15.2	1,768
1625	Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 663-675.	2.1	22
1626	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
1627	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung – A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1743-1749.	0.5	13
1628	Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 958.	1.6	19
1629	Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. <i>Nature Communications</i> , 2018, 9, 3619.	5.8	179

#	ARTICLE	IF	CITATIONS
1630	Î ²⁶² Np63Î± Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. <i>Cell Reports</i> , 2018, 24, 3224-3236.	2.9	32
1631	A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. <i>Cell Reports</i> , 2018, 24, 3353-3366.e5.	2.9	80
1632	Identification of a functional antioxidant response element at the HIF1A locus. <i>Redox Biology</i> , 2018, 19, 401-411.	3.9	77
1633	Preventing central nervous system metastases in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1077-1083.	1.1	3
1634	Somatic genome alterations in relation to age in lung squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 32161-32172.	0.8	3
1635	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	1.3	11
1636	Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes. <i>Carcinogenesis</i> , 2018, 39, 1447-1454.	1.3	4
1637	Genetic Alterations of TRAF Proteins in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2111.	2.2	67
1639	Profiling DNA Methylation Patterns of Non-coding RNAs (ncRNAs) in Human Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1094, 49-64.	0.8	4
1640	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. <i>Translational Oncology</i> , 2018, 11, 1343-1349.	1.7	25
1641	Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without <i>EGFR</i> Mutations or <i>ALK</i> Fusion. <i>Journal of Cancer</i> , 2018, 9, 1096-1105.	1.2	6
1642	A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations. <i>Redox Biology</i> , 2018, 19, 235-249.	3.9	37
1643	The Cancer Genome Atlas Project in Bladder Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 259-271.	0.2	16
1644	VAMP8, a vesicle-SNARE required for RAB37-mediated exocytosis, possesses a tumor metastasis suppressor function. <i>Cancer Letters</i> , 2018, 437, 79-88.	3.2	17
1645	Non-small cell lung carcinoma: molecular genetics with consideration of cytologic samples. <i>Diagnostic Histopathology</i> , 2018, 24, 388-396.	0.2	2
1646	Multidomain architecture of estrogen receptor reveals interfacial cross-talk between its DNA-binding and ligand-binding domains. <i>Nature Communications</i> , 2018, 9, 3520.	5.8	38
1647	Detecting repeated cancer evolution from multi-region tumor sequencing data. <i>Nature Methods</i> , 2018, 15, 707-714.	9.0	124
1648	Assessment of tumor-induced pain and C-reactive protein levels in dogs with canine transmissible venereal tumors. <i>Turkish Journal of Veterinary and Animal Sciences</i> , 2018, 42, 429-434.	0.2	0

#	ARTICLE	IF	CITATIONS
1649	Precursors of Malignancy. , 2018, , 598-616.		2
1650	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances, 2018, 2, 2052-2062.	2.5	24
1651	Head and Neck Tumors. , 2018, , 1-136.		1
1652	Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. Nature Communications, 2018, 9, 2054.	5.8	68
1653	Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. Oncology Letters, 2018, 15, 6925-6930.	0.8	14
1654	PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Molecular Cancer Research, 2018, 16, 1241-1254.	1.5	20
1655	Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood, 2018, 132, 435-447.	0.6	31
1656	TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. Oncology Reports, 2018, 40, 206-216.	1.2	37
1657	Hepatocellular Carcinoma Outcome Is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1091-1100.	1.1	11
1658	Factor XIIIa-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nature Communications, 2018, 9, 1988.	5.8	69
1659	Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Tumori, 2018, 104, 338-343.	0.6	15
1660	Deciphering the cells of origin of squamous cell carcinomas. Nature Reviews Cancer, 2018, 18, 549-561.	12.8	171
1661	FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene, 2018, 37, 5340-5354.	2.6	123
1662	The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell, 2018, 33, 905-921.e5.	7.7	135
1663	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Japanese Journal of Clinical Oncology, 2018, 48, 603-608.	0.6	24
1664	Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors. Cancer Drug Discovery and Development, 2018, , 63-97.	0.2	0
1665	Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition. Cancer Drug Discovery and Development, 2018, , 155-183.	0.2	0
1666	The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochemical and Biophysical Research Communications, 2018, 503, 1123-1129.	1.0	14

#	ARTICLE	IF	CITATIONS
1667	Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. <i>Cell Metabolism</i> , 2018, 28, 383-399.e9.	7.2	62
1668	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. <i>Current Treatment Options in Oncology</i> , 2018, 19, 43.	1.3	10
1669	p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. <i>Journal of Cell Biology</i> , 2018, 217, 3183-3201.	2.3	21
1670	Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-21.	1.9	41
1671	Exploration of drug-response mechanism by integrating genetics and epigenetics across cancers. <i>Epigenomics</i> , 2018, 10, 993-1010.	1.0	6
1672	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , 2018, 39, 971-980.	1.3	48
1673	Copy Number Variation. , 2018, , 43-54.		1
1674	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1496-1507.	0.5	22
1675	Identification of DNA methylation prognostic signature of acute myelocytic leukemia. <i>PLoS ONE</i> , 2018, 13, e0199689.	1.1	8
1676	The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding. <i>Biochimie</i> , 2018, 154, 35-44.	1.3	54
1677	KRAS-Mutant non-small cell lung cancer: From biology to therapy. <i>Lung Cancer</i> , 2018, 124, 53-64.	0.9	232
1678	RECK isoforms have opposing effects on cell migration. <i>Molecular Biology of the Cell</i> , 2018, 29, 1825-1838.	0.9	20
1679	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. <i>Cancers</i> , 2018, 10, 248.	1.7	258
1680	RDM1 plays an oncogenic role in human lung adenocarcinoma cells. <i>Scientific Reports</i> , 2018, 8, 11525.	1.6	18
1681	Genome-wide analysis of DNA methylation in bronchial washings. <i>Clinical Epigenetics</i> , 2018, 10, 65.	1.8	19
1682	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 937-945.	1.4	13
1683	MicroRNA–mRNA expression profiles associated with medulloblastoma subgroup 4. <i>Cancer Management and Research</i> , 2018, Volume 10, 339-352.	0.9	11
1684	Curcumin Inhibits Growth of Human NCI-H292 Lung Squamous Cell Carcinoma Cells by Increasing FOXA2 Expression. <i>Frontiers in Pharmacology</i> , 2018, 9, 60.	1.6	24

#	ARTICLE	IF	CITATIONS
1685	Long non-coding RNAs RP5-821D11.7, APCDD1L-AS1 and RP11-277P12.9 were associated with the prognosis of lung squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2018, 17, 7238-7248.	1.1	16
1686	Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. <i>Oncology Letters</i> , 2018, 16, 3992-4000.	0.8	6
1687	The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. <i>Physiological Reviews</i> , 2018, 98, 1169-1203.	13.1	1,067
1688	Inference of Crosstalk Effects between DNA Methylation and lncRNA Regulation in NSCLC. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	13
1689	Transcription Factors Contribute to Differential Expression in Cellular Pathways in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2018, 10, 836-847.	2.2	19
1690	Activation of p62/SQSTM1â€œKeap1â€œNuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 210.	1.3	82
1691	Emerging targets in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 61-72.	1.1	21
1692	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
1693	A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes. <i>Genes</i> , 2018, 9, 314.	1.0	15
1694	Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations. <i>High-Throughput</i> , 2018, 7, 6.	4.4	3
1695	Pulmonary Malignancies (1): Lung Cancerâ€œWhat Are the Roles of Genetic Factors in Lung Cancer Pathogenesis?. <i>Respiratory Disease Series</i> , 2018, , 193-206.	0.1	0
1696	Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. <i>Lung Cancer</i> , 2018, 123, 99-106.	0.9	20
1697	â€œKeapingâ€œa lid on lung cancer: the Keap1-Nrf2 pathway. <i>Cell Cycle</i> , 2018, 17, 1696-1707.	1.3	39
1698	Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. <i>Genome Biology</i> , 2018, 19, 67.	3.8	81
1699	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. <i>Oncogene</i> , 2018, 37, 6096-6104.	2.6	10
1700	Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior. <i>ELife</i> , 2018, 7, .	2.8	29
1701	Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. <i>Cancer Letters</i> , 2018, 434, 132-143.	3.2	54
1702	Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. <i>Genome Medicine</i> , 2018, 10, 55.	3.6	37

#	ARTICLE	IF	CITATIONS
1703	Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. <i>Clinical Oncology</i> , 2018, 30, 605-608.	0.6	6
1704	Necitumumab: a new option for first-line treatment of squamous cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 765-772.	1.5	4
1705	Weak sharing of genetic association signals in three lung cancer subtypes: evidence at the SNP, gene, regulation, and pathway levels. <i>Genome Medicine</i> , 2018, 10, 16.	3.6	32
1706	Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1509-1521.	1.2	25
1707	ARID1A loss in cancer: Towards a mechanistic understanding. , 2018, 190, 15-23.		97
1708	Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 164-172.	1.8	33
1709	Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. <i>Journal of Translational Medicine</i> , 2018, 16, 15.	1.8	29
1710	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study. <i>BMC Cancer</i> , 2018, 18, 333.	1.1	10
1711	Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers. <i>Scientific Reports</i> , 2018, 8, 7326.	1.6	16
1712	Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform. <i>BMC Bioinformatics</i> , 2018, 19, 5.	1.2	24
1714	MethCNA: a database for integrating genomic and epigenomic data in human cancer. <i>BMC Genomics</i> , 2018, 19, 138.	1.2	12
1715	Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. <i>Oncogene</i> , 2018, 37, 4475-4488.	2.6	75
1716	Insights from multidimensional analyses of the pan-cancer DNA methylome heterogeneity and the uncanonical CpG-gene associations. <i>International Journal of Cancer</i> , 2018, 143, 2814-2827.	2.3	12
1717	iMapSplice: Alleviating reference bias through personalized RNA-seq alignment. <i>PLoS ONE</i> , 2018, 13, e0201554.	1.1	9
1718	Synthetic Lethality: From Research to Precision Cancer Nanomedicine. <i>Current Cancer Drug Targets</i> , 2018, 18, 337-346.	0.8	17
1719	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5990-6000.	3.2	17
1720	Integrated Genomic Analysis of HNSCC Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	7.7	195
1721	Comparative proteomics reveals a diagnostic signature for pulmonary head&neck cancer metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	41

#	ARTICLE	IF	CITATIONS
1722	Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview. <i>Current Oncology</i> , 2018, 25, 77-85.	0.9	9
1723	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. <i>Oral Oncology</i> , 2018, 85, 44-51.	0.8	11
1724	STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. <i>Genes and Development</i> , 2018, 32, 1175-1187.	2.7	55
1725	Interaction between the microbiome and TP53 in human lung cancer. <i>Genome Biology</i> , 2018, 19, 123.	3.8	247
1726	Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities. <i>Biomolecules and Therapeutics</i> , 2018, 26, 57-68.	1.1	67
1727	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
1728	Silencing non-SMC chromosome-associated polypeptide G inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 1246-1254.	0.7	29
1729	Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?. <i>Frontiers in Oncology</i> , 2018, 8, 267.	1.3	135
1730	BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. <i>Nature Communications</i> , 2018, 9, 3327.	5.8	54
1731	p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	51
1732	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1918-1925.	0.6	26
1733	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	91
1734	Patient Similarity Networks for Precision Medicine. <i>Journal of Molecular Biology</i> , 2018, 430, 2924-2938.	2.0	93
1735	Molecular Basis of Pulmonary Disease. , 2018, , 347-386.		0
1736	Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. <i>Nucleic Acids Research</i> , 2018, 46, 7022-7039.	6.5	33
1737	Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis. <i>Blood</i> , 2018, 132, 1413-1425.	0.6	25
1738	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
1739	Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas. <i>PLoS ONE</i> , 2018, 13, e0192742.	1.1	16

#	ARTICLE	IF	CITATIONS
1740	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1701-1709.	0.6	24
1741	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. <i>Precision Clinical Medicine</i> , 2018, 1, 29-48.	1.3	79
1742	Roles of Thyroid Transcription Factor 1 in Lung Cancer Biology. <i>Vitamins and Hormones</i> , 2018, 106, 517-544.	0.7	16
1743	Toward A variable RBE for proton beam therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 68-75.	0.3	71
1744	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 180-188.	3.0	74
1745	Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors. , 2019, , 101-121.		0
1746	A novel immunodeficient rat model supports human lung cancer xenografts. <i>FASEB Journal</i> , 2019, 33, 140-150.	0.2	25
1747	TP53 gain-of-function mutation promotes inflammation in glioblastoma. <i>Cell Death and Differentiation</i> , 2019, 26, 409-425.	5.0	123
1748	Personalized prediction of genes with tumor-causing somatic mutations based on multi-modal deep Boltzmann machine. <i>Neurocomputing</i> , 2019, 324, 51-62.	3.5	10
1749	Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 7-12.e1.	1.1	5
1750	CI-SNF: Exploiting contextual information to improve SNF based information retrieval. <i>Information Fusion</i> , 2019, 52, 175-186.	11.7	6
1751	Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases. <i>Pathology and Oncology Research</i> , 2019, 25, 1401-1409.	0.9	25
1752	A comparison of mechanistic signaling pathway activity analysis methods. <i>Briefings in Bioinformatics</i> , 2019, 20, 1655-1668.	3.2	33
1753	Integrated systemsâ€genetic analyses reveal a network target for delaying glioma progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1616-1638.	1.7	8
1754	Proteogenomic landscape of squamous cell lung cancer. <i>Nature Communications</i> , 2019, 10, 3578.	5.8	84
1755	Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). <i>PLoS ONE</i> , 2019, 14, e0220567.	1.1	21
1756	Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. <i>Nature Communications</i> , 2019, 10, 3574.	5.8	111
1757	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , 2019, 11, 1141.	1.7	71

#	ARTICLE	IF	CITATIONS
1758	KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. <i>Cancers</i> , 2019, 11, 1145.	1.7	33
1759	p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. <i>Cell Reports</i> , 2019, 28, 1860-1878.e9.	2.9	68
1760	Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. <i>Lancet Respiratory Medicine</i> , 2019, 7, 881-891.	5.2	167
1761	Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact. <i>Biomarkers in Medicine</i> , 2019, 13, 761-771.	0.6	19
1762	Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling. <i>FEBS Letters</i> , 2019, 593, 2289-2305.	1.3	69
1763	Novel Genes Associated with the Development of Carotid Paragangliomas. <i>Molecular Biology</i> , 2019, 53, 547-559.	0.4	9
1764	Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response. <i>BMC Cancer</i> , 2019, 19, 824.	1.1	34
1765	Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data. <i>Oncology Letters</i> , 2019, 18, 2125-2131.	0.8	27
1766	Emergence of <i>ERBB2</i> Mutation as a Biomarker and an Actionable Target in Solid Cancers. <i>Oncologist</i> , 2019, 24, e1303-e1314.	1.9	64
1767	Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2019, 461, 56-64.	3.2	16
1768	circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. <i>Nature Communications</i> , 2019, 10, 3200.	5.8	262
1769	Metabolic Regulation of Redox Balance in Cancer. <i>Cancers</i> , 2019, 11, 955.	1.7	80
1770	Oral keratosis of unknown significance shares genomic overlap with oral dysplasia. <i>Oral Diseases</i> , 2019, 25, 1707-1714.	1.5	34
1771	Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 680.	1.1	31
1772	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 75.	6.9	84
1773	The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. <i>Nature Communications</i> , 2019, 10, 3108.	5.8	69
1774	Cancer driver gene discovery in transcriptional regulatory networks using influence maximization approach. <i>Computers in Biology and Medicine</i> , 2019, 114, 103362.	3.9	13
1775	Building a Hybrid Physical-Statistical Classifier for Predicting the Effect of Variants Related to Protein-Drug Interactions. <i>Structure</i> , 2019, 27, 1469-1481.e3.	1.6	6

#	ARTICLE	IF	CITATIONS
1776	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. <i>Journal of Thoracic Disease</i> , 2019, 11, 2383-2391.	0.6	3
1777	Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer. <i>In Vivo</i> , 2019, 33, 1027-1037.	0.6	80
1778	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1009.	1.7	2
1779	Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. <i>International Journal of Medical Sciences</i> , 2019, 16, 981-989.	1.1	104
1780	Systematic analysis of the intersection of disease mutations with protein modifications. <i>BMC Medical Genomics</i> , 2019, 12, 109.	0.7	16
1781	Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 3246-3258.	1.9	20
1782	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1457-1471.	1.6	105
1783	What makes cells move: Requirements and obstacles for leader cells in collective invasion. <i>Experimental Cell Research</i> , 2019, 382, 111481.	1.2	10
1784	Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 122-137.	3.3	5
1785	ERBB2 Regulates MED24 during Cancer Progression in Mice with Pten and Smad4 Deletion in the Pulmonary Epithelium. <i>Cells</i> , 2019, 8, 615.	1.8	5
1786	ClickGene: an open cloud-based platform for big pan-cancer data genome-wide association study, visualization and exploration. <i>BioData Mining</i> , 2019, 12, 12.	2.2	13
1787	Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. <i>BMC Medical Genomics</i> , 2019, 12, 92.	0.7	29
1788	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.	1.7	124
1789	<i>SALL2</i> Is a Novel Prognostic Methylation Marker in Patients with Oral Squamous Carcinomas: Associations with <i>SALL1</i> and <i>SALL3</i> Methylation Status. <i>DNA and Cell Biology</i> , 2019, 38, 678-687.	0.9	9
1790	SWOG S1400C (NCT02154490) A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1853-1859.	0.5	58
1791	Angiotensin II-induced micro RNA-21 culprit for non-small cell lung adenocarcinoma. <i>Drug Development Research</i> , 2019, 80, 1031-1039.	1.4	6
1792	Population-Based Outcomes in NSCLC. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz022.	1.4	0
1793	MicroRNA and mRNA Interaction Network Regulates the Malignant Transformation of Human Bronchial Epithelial Cells Induced by Cigarette Smoke. <i>Frontiers in Oncology</i> , 2019, 9, 1029.	1.3	27

#	ARTICLE	IF	CITATIONS
1794	Machine Learning in Biology and Medicine. <i>Advances in Molecular Pathology</i> , 2019, 2, 143-152.	0.2	13
1795	Somatic substitution signature as an innovative tool in lung cancer diagnosis. <i>Scientific Reports</i> , 2019, 9, 14561.	1.6	2
1796	A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2019, 26, 239-247.	0.8	3
1797	A hierarchical integration deep flexible neural forest framework for cancer subtype classification by integrating multi-omics data. <i>BMC Bioinformatics</i> , 2019, 20, 527.	1.2	69
1798	Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine. <i>Frontiers in Genetics</i> , 2019, 10, 930.	1.1	22
1800	Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC). <i>Journal of Clinical Medicine</i> , 2019, 8, 1896.	1.0	49
1801	A Breath of Fresh Air: Opening up the Lung Cancer Genome. <i>Cancer Research</i> , 2019, 79, 4808-4810.	0.4	0
1802	Integrated Network Analysis Reveals FOXM1 and MYBL2 as Key Regulators of Cell Proliferation in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1011.	1.3	54
1803	Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. <i>Cancer Medicine</i> , 2019, 8, 7669-7678.	1.3	27
1804	Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations. <i>Cancer Management and Research</i> , 2019, Volume 11, 9017-9024.	0.9	2
1805	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1924-1934.	0.5	60
1806	Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1881-1883.	0.5	17
1807	Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC. <i>Molecular Oncology</i> , 2019, 13, 2604-2615.	2.1	11
1808	Docking-based approach for identification of mutations that disrupt binding between Bcl2 and Bax proteins: Inducing apoptosis in cancer cells. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e910.	0.6	30
1809	Non-canonical Raf/p70S6K signalling in non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7632-7640.	1.6	8
1810	Integrative analysis of genetic and epigenetic profiling of lung squamous cell carcinoma (LSCC) patients to identify smoking level relevant biomarkers. <i>BioData Mining</i> , 2019, 12, 18.	2.2	4
1811	Identification of seven-gene signature for prediction of lung squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5979-5988.	1.0	36
1812	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6535-6548.	1.0	26

#	ARTICLE	IF	CITATIONS
1813	A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. <i>Cell</i> , 2019, 178, 1465-1477.e17.	13.5	144
1814	Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2495-2506.	1.2	5
1815	Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. <i>Oncogenesis</i> , 2019, 8, 50.	2.1	41
1816	Best practices for bioinformatic characterization of neoantigens for clinical utility. <i>Genome Medicine</i> , 2019, 11, 56.	3.6	146
1817	The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. <i>Journal of Translational Medicine</i> , 2019, 17, 298.	1.8	33
1818	Transcriptome analyses of tumor-adjacent somatic tissues reveal genes co-expressed with transposable elements. <i>Mobile DNA</i> , 2019, 10, 39.	1.3	21
1819	Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	100
1820	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , 2019, 11, 1318.	1.7	61
1821	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1847-1852.	0.5	62
1822	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.4	69
1823	Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis. <i>Cancer Cell International</i> , 2019, 19, 239.	1.8	35
1824	Cross-disease analysis identified novel common genes for both lung adenocarcinoma and lung squamous cell carcinoma. <i>Oncology Letters</i> , 2019, 18, 3463-3470.	0.8	3
1825	Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. <i>Cell Death and Disease</i> , 2019, 10, 660.	2.7	68
1826	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918
1827	LOTUS: A single- and multitask machine learning algorithm for the prediction of cancer driver genes. <i>PLoS Computational Biology</i> , 2019, 15, e1007381.	1.5	28
1828	Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells. <i>Scientific Reports</i> , 2019, 9, 13753.	1.6	24
1829	miR-214-3p addiction in lung cancer cells and its impact on cancer therapy. <i>Cancer Letters</i> , 2019, 467, 40-49.	3.2	55
1830	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019, 25, 1540-1548.	15.2	75

#	ARTICLE	IF	CITATIONS
1831	Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung. PLoS ONE, 2019, 14, e0223298.	1.1	9
1832	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€‘Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 2019, 3, 1-12.	1.5	21
1833	Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nature Medicine, 2019, 25, 517-525.	15.2	178
1834	Head and Neck Tumors. , 2019, , 627-762.		0
1835	Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene, 2019, 38, 4125-4141.	2.6	34
1836	The lysineâ€‘specific methyltransferase <sc>KMT</sc> 2C/ <sc>MLL</sc> 3 regulates <sc>DNA</sc> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93
1837	Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. Journal of Cancer Research and Clinical Oncology, 2019, 145, 747-757.	1.2	8
1838	The inherited variations of a p53-responsive enhancer in 13q12.12 confer lung cancer risk by attenuating TNFRSF19 expression. Genome Biology, 2019, 20, 103.	3.8	27
1839	The Open Chromatin Landscape of Nonâ€‘Small Cell Lung Carcinoma. Cancer Research, 2019, 79, 4840-4854.	0.4	24
1840	Dysregulated Tgfbr2/ERK-Smad4/SOX2 Signaling Promotes Lung Squamous Cell Carcinoma Formation. Cancer Research, 2019, 79, 4466-4479.	0.4	29
1841	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer, 2019, 134, 167-173.	0.9	9
1842	Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nature Communications, 2019, 10, 2764.	5.8	166
1843	MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets. Journal of Cellular Biochemistry, 2019, 120, 18956-18966.	1.2	33
1844	Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell, 2019, 178, 316-329.e18.	13.5	385
1845	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. Lung Cancer, 2019, 134, 7-15.	0.9	38
1846	A mutation analysis of the EGFR pathway genes, <i>RAS</i>, <i>EGFR</i>, <i>PIK3CA</i>, <i>AKT1</i> and <i>BRAF</i>, and <i>TP53</i> gene in thymic carcinoma and thymoma type A/B3. Histopathology, 2019, 75, 755-766.	1.6	28
1848	Identifying Epistasis in Cancer Genomes: A Delicate Affair. Cell, 2019, 177, 1375-1383.	13.5	81
1849	Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. Lung Cancer, 2019, 134, 108-116.	0.9	22

#	ARTICLE	IF	CITATIONS
1850	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 619-636.	1.7	71
1851	Gene regulation and prognostic indicators of lung squamous cell carcinoma: TCGA-derived miRNA/mRNA sequencing and DNA methylation data. <i>Journal of Cellular Physiology</i> , 2019, 234, 22896-22910.	2.0	6
1852	A pan-cancer analysis of synonymous mutations. <i>Nature Communications</i> , 2019, 10, 2569.	5.8	147
1853	Somatic Mutations in miRNA Genes in Lung Cancer—Potential Functional Consequences of Non-Coding Sequence Variants. <i>Cancers</i> , 2019, 11, 793.	1.7	37
1854	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019, 133, 144-150.	0.9	90
1855	Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. <i>British Journal of Cancer</i> , 2019, 121, 51-64.	2.9	33
1856	Inhibition of the Hedgehog pathway in lung cancer. <i>Lung Cancer</i> , 2019, 133, 56-61.	0.9	13
1857	New Treatment Options in Advanced Squamous Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e198-e206.	1.8	27
1858	Deregulation of lncRNA AC078883.3 and microRNA 19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. <i>Journal of Cellular Physiology</i> , 2019, 234, 22657-22665.	2.0	26
1859	The Generalized Ridge Estimator of the Inverse Covariance Matrix. <i>Journal of Computational and Graphical Statistics</i> , 2019, 28, 932-942.	0.9	11
1860	JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. <i>Nature Communications</i> , 2019, 10, 2148.	5.8	20
1861	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. <i>Oncotarget</i> , 2019, 10, 1760-1774.	0.8	25
1862	TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11408-11417.	3.3	54
1864	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019, 166, 128-138.	2.0	12
1865	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5015-5026.	3.2	143
1866	Clinical Implications of Noncoding Indels in the Surfactant-Encoding Genes in Lung Cancer. <i>Cancers</i> , 2019, 11, 552.	1.7	11
1867	Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. <i>Nature Communications</i> , 2019, 10, 1856.	5.8	70
1868	Modulating autophagy as a therapeutic strategy for the treatment of paediatric high-grade glioma. <i>Brain Pathology</i> , 2019, 29, 707-725.	2.1	12

#	ARTICLE	IF	CITATIONS
1869	A Pathway-Based Strategy to Identify Biomarkers for Lung Cancer Diagnosis and Prognosis. <i>Evolutionary Bioinformatics</i> , 2019, 15, 117693431983849.	0.6	6
1870	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. <i>Cell</i> , 2019, 177, 1035-1049.e19.	13.5	498
1871	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	9.4	2,396
1872	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
1873	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019, 10, 2031.	5.8	87
1874	Precision oncology of lung cancer: genetic and genomic differences in Chinese population. <i>Npj Precision Oncology</i> , 2019, 3, 14.	2.3	31
1875	DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells. <i>DNA Repair</i> , 2019, 79, 1-9.	1.3	6
1876	Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. <i>Cancers</i> , 2019, 11, 599.	1.7	41
1877	RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. <i>Nature</i> , 2019, 569, 423-427.	13.7	62
1878	Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. <i>Nature Communications</i> , 2019, 10, 1772.	5.8	149
1879	Engineering Multidimensional Evolutionary Forces to Combat Cancer. <i>Cancer Discovery</i> , 2019, 9, 587-604.	7.7	13
1880	Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 165.	3.5	15
1881	Cancer overdiagnosis: a biological challenge and clinical dilemma. <i>Nature Reviews Cancer</i> , 2019, 19, 349-358.	12.8	220
1882	Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 742-750.	2.5	20
1883	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019, 9, 166.	1.3	61
1885	Dependency of the Cancer-Specific Transcriptional Regulation Circuitry on the Promoter DNA Methylome. <i>Cell Reports</i> , 2019, 26, 3461-3474.e5.	2.9	22
1886	Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1096-1104.	1.7	16
1887	CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 449-458.	2.1	13

#	ARTICLE	IF	CITATIONS
1888	I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. <i>Genome Biology</i> , 2019, 20, 52.	3.8	7
1889	^{137}Np 63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment. <i>Molecular Oncology</i> , 2019, 13, 981-1001.	2.1	56
1890	Enhancing the prediction of disease-gene associations with multimodal deep learning. <i>Bioinformatics</i> , 2019, 35, 3735-3742.	1.8	52
1891	Clinical significance and biological role of cancer-derived Type I collagen in lung and esophageal cancers. <i>Thoracic Cancer</i> , 2019, 10, 277-288.	0.8	78
1892	Brain Metastases from Lung Cancer: Is MET an Actionable Target?. <i>Cancers</i> , 2019, 11, 271.	1.7	12
1893	Robust network-based regularization and variable selection for high-dimensional genomic data in cancer prognosis. <i>Genetic Epidemiology</i> , 2019, 43, 276-291.	0.6	42
1894	Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 3235.	1.6	60
1895	The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery. <i>Molecular Oncology</i> , 2019, 13, 1166-1179.	2.1	57
1896	Somatic genome alterations in relation to age in lung adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2091-2099.	2.3	1
1897	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538.	1.0	3
1898	netDx: interpretable patient classification using integrated patient similarity networks. <i>Molecular Systems Biology</i> , 2019, 15, e8497.	3.2	65
1899	Synthetic Lethality in Lung Cancer—From the Perspective of Cancer Genomics. <i>Medicines (Basel)</i> , 2019, 8, 1414.	0.7	0
1900	Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0214610.	1.1	16
1901	An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. <i>Translational Oncology</i> , 2019, 12, 836-845.	1.7	19
1902	Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 4300-4308.	3.2	20
1903	MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. <i>Journal of Pathology</i> , 2019, 249, 52-64.	2.1	117
1904	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. <i>EClinicalMedicine</i> , 2019, 9, 19-25.	3.2	6
1905	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019, 19, 289-297.	12.8	692

#	ARTICLE	IF	CITATIONS
1906	ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1427-1436.	1.2	10
1907	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. <i>Cancers</i> , 2019, 11, 414.	1.7	19
1908	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
1909	Measuring DNA Copy Number Variation Using High-Density Methylation Microarrays. <i>Journal of Computational Biology</i> , 2019, 26, 295-304.	0.8	12
1910	<i>LINC00261</i> Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response. <i>Cancer Research</i> , 2019, 79, 3050-3062.	0.4	75
1911	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019, 130, 135-142.	0.9	10
1912	FBXW7 is a biologically validated cancer driver gene for CLL. <i>Blood</i> , 2019, 133, 774-776.	0.6	5
1913	PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. <i>Lung Cancer</i> , 2019, 129, 41-47.	0.9	24
1914	Role of Nrf2 and Its Activators in Respiratory Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-17.	1.9	130
1915	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
1916	Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. , 2019, 7, 38.		121
1917	Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. <i>Cancers</i> , 2019, 11, 204.	1.7	48
1918	The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis. <i>Postgraduate Medicine</i> , 2019, 131, 199-206.	0.9	21
1919	Polymeric Micelles in Management of Lung Cancer. , 2019, , 193-216.		2
1920	Nanotechnology in the diagnosis and treatment of lung cancer. , 2019, 198, 189-205.		106
1921	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	169
1922	NRF2 Activation in Cancer: From DNA to Protein. <i>Cancer Research</i> , 2019, 79, 889-898.	0.4	140
1923	Artificial intelligence and big data facilitated targeted drug discovery. <i>Stroke and Vascular Neurology</i> , 2019, 4, 206-213.	1.5	42

#	ARTICLE	IF	CITATIONS
1924	Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2019, 79, 6084-6100.	0.4	24
1925	ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer. <i>Cancer Research</i> , 2019, 79, 4828-4839.	0.4	15
1926	Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy. <i>Translational Lung Cancer Research</i> , 2019, 8, 614-635.	1.3	29
1927	Importance of Feature Weighing in Cervical Cancer Subtypes Identification. , 2019, , .		0
1928	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 477-479.	1.2	5
1929	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. <i>Anti-Cancer Drugs</i> , 2019, 30, 873-878.	0.7	6
1930	SMaSH: Sample matching using SNPs in humans. <i>BMC Genomics</i> , 2019, 20, 1001.	1.2	12
1931	Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 1228.	1.1	6
1932	Tumor diversity and the trade-off between universal cancer tasks. <i>Nature Communications</i> , 2019, 10, 5423.	5.8	53
1933	Extracting a biologically latent space of lung cancer epigenetics with variational autoencoders. <i>BMC Bioinformatics</i> , 2019, 20, 568.	1.2	23
1934	NF-YA Overexpression in Lung Cancer: LUSC. <i>Genes</i> , 2019, 10, 937.	1.0	28
1935	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. <i>Cell</i> , 2019, 179, 1330-1341.e13.	13.5	206
1936	Genomic and immune profiling of pre-invasive lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5472.	5.8	127
1937	Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	5
1938	Aberrant expression of embryonic mesendoderm factor MESP1 promotes tumorigenesis. <i>EBioMedicine</i> , 2019, 50, 55-66.	2.7	5
1939	Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases. <i>Frontiers in Genetics</i> , 2019, 10, 1260.	1.1	9
1940	Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer. <i>BMC Cancer</i> , 2019, 19, 1230.	1.1	28
1941	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. <i>Nature Communications</i> , 2019, 10, 5712.	5.8	27

#	ARTICLE	IF	CITATIONS
1942	Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans. <i>Nature Communications</i> , 2019, 10, 5735.	5.8	22
1943	Genetic determinants of the molecular portraits of epithelial cancers. <i>Nature Communications</i> , 2019, 10, 5666.	5.8	21
1944	Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.	13.7	722
1945	Mining and validating the expression pattern and prognostic value of acetylcholine receptors in non-small cell lung cancer. <i>Medicine (United States)</i> , 2019, 98, e15555.	0.4	11
1946	Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. <i>Clinical Cancer Research</i> , 2019, 25, 7396-7404.	3.2	33
1947	Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	1
1948	Frequency and clinical significance of <i>NF1</i> mutation in lung adenocarcinomas from East Asian patients. <i>International Journal of Cancer</i> , 2019, 144, 290-296.	2.3	13
1949	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e39-e51.	1.1	11
1950	Pharmacogenomics: Success and Challenges. , 2019, , 595-606.		0
1951	Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. <i>Oncogene</i> , 2019, 38, 2953-2966.	2.6	38
1952	Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e123-e132.	1.1	53
1953	Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 788-801.	2.3	16
1954	Knockdown of FOXP1 promotes the development of lung adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 537-545.	1.5	25
1955	Tumor clonality and resistance mechanisms in <i>EGFR</i> mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. <i>Future Oncology</i> , 2019, 15, 637-652.	1.1	80
1956	Detection of Known and Novel FGFR Fusions in Non-small Cell Lung Cancer by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2019, 14, 54-62.	0.5	64
1957	Identification of cancer omics commonality and difference via community fusion. <i>Statistics in Medicine</i> , 2019, 38, 1200-1212.	0.8	10
1958	Genetic variants in <i>RUNX3</i> , <i>AMD1</i> and <i>MSRA</i> in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 621-631.	2.3	21
1959	Analysis of Acrolein-Derived 1, <i>N</i> ² -Propanodeoxyguanosine Adducts in Human Lung DNA from Smokers and Nonsmokers. <i>Chemical Research in Toxicology</i> , 2019, 32, 318-325.	1.7	33

#	ARTICLE	IF	CITATIONS
1960	Structure of BAI1/ELMO2 complex reveals an action mechanism of adhesion GPCRs via ELMO family scaffolds. <i>Nature Communications</i> , 2019, 10, 51.	5.8	24
1961	Histo-genomics: digital pathology at the forefront of precision medicine. <i>Diagnosis</i> , 2019, 6, 203-212.	1.2	23
1962	Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. <i>Clinical Cancer Research</i> , 2019, 25, 2254-2263.	3.2	62
1963	Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. <i>Lung Cancer</i> , 2019, 130, 50-58.	0.9	127
1964	LUBAC determines chemotherapy resistance in squamous cell lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 450-465.	4.2	57
1965	Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 828-832.	1.0	5
1966	Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melanogenic microenvironment across 14 solid cancer types. <i>Journal of Pineal Research</i> , 2019, 66, e12557.	3.4	26
1967	Necitumumab for the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 705-716.	1.1	28
1968	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. <i>Oncogene</i> , 2019, 38, 1661-1675.	2.6	26
1969	Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 348-356.	1.1	5
1970	A Computational Protocol for Detecting Somatic Mutations by Integrating DNA and RNA Sequencing. <i>Methods in Molecular Biology</i> , 2019, 1878, 109-124.	0.4	0
1971	Integrative cancer patient stratification via subspace merging. <i>Bioinformatics</i> , 2019, 35, 1653-1659.	1.8	20
1972	TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 625-636.	1.2	68
1973	Establishment and characterization of CRISPR/Cas9-mediated <i>NF2</i> human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. <i>Cancer Science</i> , 2019, 110, 180-193.	1.7	13
1974	Next generation sequencing-based gene panel tests for the management of solid tumors. <i>Cancer Science</i> , 2019, 110, 6-15.	1.7	107
1975	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. <i>Lung Cancer</i> , 2019, 127, 12-18.	0.9	40
1976	Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. <i>Human Pathology</i> , 2019, 84, 18-25.	1.1	5
1977	Modulating NRF2 in Disease: Timing Is Everything. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 555-575.	4.2	289

#	ARTICLE	IF	CITATIONS
1978	Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression. <i>Cell Death and Differentiation</i> , 2019, 26, 1283-1298.	5.0	18
1979	GOLPH3: a Golgi phosphatidylinositol(4)phosphate effector that directs vesicle trafficking and drives cancer. <i>Journal of Lipid Research</i> , 2019, 60, 269-275.	2.0	51
1980	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019, 20, 30-36.e3.	1.1	37
1981	Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability. <i>Briefings in Bioinformatics</i> , 2019, 20, 254-266.	3.2	46
1982	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28.	4.3	51
1983	Bayesian Hierarchical Varying-Sparsity Regression Models with Application to Cancer Proteogenomics. <i>Journal of the American Statistical Association</i> , 2019, 114, 48-60.	1.8	15
1984	Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. <i>Cellular and Molecular Immunology</i> , 2019, 16, 6-18.	4.8	322
1985	A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis. <i>International Journal of Cancer</i> , 2020, 146, 388-399.	2.3	21
1986	An advanced c-MET-amplified NSCLC patient that was treated with crizotinib. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 474-477.	0.5	1
1987	An Efficient Algorithm for Identifying Mutated Subnetworks Associated with Survival in Cancer. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2020, 17, 1582-1594.	1.9	0
1988	NExUS: Bayesian simultaneous network estimation across unequal sample sizes. <i>Bioinformatics</i> , 2020, 36, 798-804.	1.8	2
1989	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 180-198.	4.3	28
1990	Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival. <i>International Journal of Cancer</i> , 2020, 147, 392-403.	2.3	6
1991	Identification of distinctive long noncoding RNA competitive interactions and a six-methylated gene prognostic signature in acute myeloid leukemia with $\sim 5/\text{del}(5q)$ or $\sim 7/\text{del}(7q)$. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 1563-1574.	1.2	5
1992	Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. <i>Oncogene</i> , 2020, 39, 1302-1317.	2.6	26
1993	PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. <i>Epigenetics</i> , 2020, 15, 604-617.	1.3	15
1994	Exploiting metabolic vulnerabilities of Non small cell lung carcinoma. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 54-62.	2.3	36
1995	Cancer of the Lung. , 2020, , 1108-1158.e16.		11

#	ARTICLE	IF	CITATIONS
1996	Defining the “Metastosome”: Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences. <i>Seminars in Cancer Biology</i> , 2020, 60, 1-13.	4.3	20
1997	SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond. <i>Oncogene</i> , 2020, 39, 278-292.	2.6	116
1998	Organoid Cultures as Preclinical Models of Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1162-1174.	3.2	148
1999	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. <i>Modern Pathology</i> , 2020, 33, 626-638.	2.9	38
2000	Epithelial cell plasticity defines heterogeneity in lung cancer. <i>Cellular Signalling</i> , 2020, 65, 109463.	1.7	17
2001	Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research. <i>Seminars in Cancer Biology</i> , 2020, 61, 158-166.	4.3	44
2002	Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 103-112.	0.8	23
2003	MLL2 promotes cancer cell lymph node metastasis by interacting with RelA and facilitating STC1 transcription. <i>Cellular Signalling</i> , 2020, 65, 109457.	1.7	8
2004	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	3.2	75
2005	Genome-wide association study of INDELS identified four novel susceptibility loci associated with lung cancer risk. <i>International Journal of Cancer</i> , 2020, 146, 2855-2864.	2.3	7
2006	Novel <i>SS18-NEDD4</i> gene fusion in a primary renal synovial sarcoma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 203-208.	1.5	16
2007	Feasibility of fully automated classification of whole slide images based on deep learning. <i>Korean Journal of Physiology and Pharmacology</i> , 2020, 24, 89.	0.6	14
2008	Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 153-167.	1.2	24
2009	Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas. <i>EPMA Journal</i> , 2020, 11, 73-94.	3.3	17
2010	Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model. <i>Cancer Genetics</i> , 2020, 241, 51-56.	0.2	7
2011	Causal network perturbations for instance-specific analysis of single cell and disease samples. <i>Bioinformatics</i> , 2020, 36, 2515-2521.	1.8	14
2012	Sample Tracking Using Unique Sequence Controls. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 141-146.	1.2	10
2013	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020, 140, 35-41.	0.9	22

#	ARTICLE	IF	CITATIONS
2014	Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e151-e163.	1.1	9
2015	The genomic landscape of nonsmall cell lung carcinoma in never smokers. <i>International Journal of Cancer</i> , 2020, 146, 3207-3218.	2.3	28
2016	TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. <i>Cell Reports</i> , 2020, 30, 98-111.e5.	2.9	35
2017	Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC). <i>Experimental and Molecular Pathology</i> , 2020, 112, 104354.	0.9	17
2018	Unraveling cancer lineage drivers in squamous cell carcinomas. , 2020, 206, 107448.		20
2019	Counterpoint: Distributed Model for Molecular Diagnostics. <i>Clinical Chemistry</i> , 2020, 66, 140-142.	1.5	3
2020	Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. <i>Cell Metabolism</i> , 2020, 31, 339-350.e4.	7.2	103
2021	Structured analysis of the high-dimensional FMR model. <i>Computational Statistics and Data Analysis</i> , 2020, 144, 106883.	0.7	3
2022	Inhibition of IL1 β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. <i>Cancer Research</i> , 2020, 80, 5597-5605.	0.4	58
2023	Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet. <i>PLoS Computational Biology</i> , 2020, 16, e1008234.	1.5	12
2024	8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3079.	1.0	16
2025	Improved detection of tumor suppressor events in single-cell RNA-Seq data. <i>Npj Genomic Medicine</i> , 2020, 5, 43.	1.7	15
2026	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. <i>Biomolecules</i> , 2020, 10, 1365.	1.8	22
2027	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. <i>Nature Communications</i> , 2020, 11, 5156.	5.8	12
2028	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
2029	Epigenetic Scanning of KEAP1 CpG Sites Uncovers New Molecular-Driven Patterns in Lung Adeno and Squamous Cell Carcinomas. <i>Antioxidants</i> , 2020, 9, 904.	2.2	7
2030	Molecular Pathology of Primary Non-small Cell Lung Cancer. <i>Archives of Medical Research</i> , 2020, 51, 784-798.	1.5	55
2031	A Cellular Mechanism to Detect and Alleviate Reductive Stress. <i>Cell</i> , 2020, 183, 46-61.e21.	13.5	85

#	ARTICLE	IF	CITATIONS
2032	A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. <i>Cancer Research</i> , 2020, 80, 4972-4985.	0.4	23
2033	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. <i>Nature Communications</i> , 2020, 11, 4878.	5.8	27
2034	SOX2 and squamous cancers. <i>Seminars in Cancer Biology</i> , 2020, 67, 154-167.	4.3	16
2035	DNA helicases and their roles in cancer. <i>DNA Repair</i> , 2020, 96, 102994.	1.3	20
2036	Revealing the subtyping of non-small cell lung cancer based on genomic evolutionary patterns by multi-region sequencing. <i>Cancer Medicine</i> , 2020, 9, 9485-9498.	1.3	1
2037	Modeling and analysis of site-specific mutations in cancer identifies known plus putative novel hotspots and bias due to contextual sequences. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1664-1675.	1.9	5
2038	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020, 61, 103030.	2.7	67
2039	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2020, 9, 811-815.	1.3	3
2040	A Systematic Analysis of Dysregulated Long Non-Coding RNAs/microRNAs/mRNAs in Lung Squamous Cell Carcinoma. <i>American Journal of the Medical Sciences</i> , 2020, 360, 701-710.	0.4	2
2041	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
2042	Everolimus in the treatment of metastatic thymic epithelial tumors. <i>Lung Cancer</i> , 2020, 149, 97-102.	0.9	12
2043	Comprehensive Molecular Characterization of Squamous Cell Carcinomas. , 2020, , .		1
2044	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	13.7	96
2045	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100013.	0.6	4
2046	Integrated analysis of optical mapping and whole-genome sequencing reveals intratumoral genetic heterogeneity in metastatic lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 670-681.	1.3	11
2047	Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes. <i>Translational Lung Cancer Research</i> , 2020, 9, 659-669.	1.3	5
2048	Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1398.	0.6	10
2049	Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2743-2752.	1.2	9

#	ARTICLE	IF	CITATIONS
2050	How should molecular findings be integrated in the classification for lung cancer?. Translational Lung Cancer Research, 2020, 9, 2245-2254.	1.3	5
2051	The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes. Cancers, 2020, 12, 3369.	1.7	15
2052	Selected updates in molecular and genomic pathology of esophageal cancer. Annals of the New York Academy of Sciences, 2020, 1482, 225-235.	1.8	2
2053	Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers. Nature Communications, 2020, 11, 5911.	5.8	60
2054	Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. Scientific Reports, 2020, 10, 20243.	1.6	21
2055	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Translational Lung Cancer Research, 2020, 9, 2214-2232.	1.3	51
2056	The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies. Antioxidants, 2020, 9, 1151.	2.2	74
2057	BRAF: A Two-Faced Janus. Cells, 2020, 9, 2549.	1.8	23
2058	<p><p>Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma</p><p>Cancer Management and Research, 2020, Volume 12, 11973-11988.	0.9	2
2059	Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma. Annals of Translational Medicine, 2020, 8, 1176-1176.	0.7	8
2060	A novel circular RNA, circXPO1, promotes lung adenocarcinoma progression by interacting with IGF2BP1. Cell Death and Disease, 2020, 11, 1031.	2.7	68
2061	Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers, 2020, 12, 3605.	1.7	92
2062	NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. Cancers, 2020, 12, 3609.	1.7	44
2063	Lung squamous cell carcinoma and lung adenocarcinoma differential gene expression regulation through pathways of Notch, Hedgehog, Wnt, and ErbB signalling. Scientific Reports, 2020, 10, 21128.	1.6	40
2064	Weighted dimensionality reduction and robust Gaussian mixture model based cancer patient subtyping from gene expression data. Journal of Biomedical Informatics, 2020, 112, 103620.	2.5	6
2065	Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy. Epigenetics Insights, 2020, 13, 251686572096480.	0.6	9
2066	Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis. International Journal of Molecular Sciences, 2020, 21, 5378.	1.8	22
2067	Molecular basis of pulmonary disease. , 2020, , 285-321.		0

#	ARTICLE	IF	CITATIONS
2068	Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients. <i>Cancer Science</i> , 2020, 111, 3893-3901.	1.7	15
2069	Nrf2 promotes esophageal squamous cell carcinoma (ESCC) resistance to radiotherapy through the CaMKII β -associated activation of autophagy. <i>Cell and Bioscience</i> , 2020, 10, 90.	2.1	22
2070	Molecular profiling of non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236580.	1.1	17
2071	A compendium of mutational cancer driver genes. <i>Nature Reviews Cancer</i> , 2020, 20, 555-572.	12.8	605
2072	Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer. , 2020, 8, e000336.		9
2073	Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies. <i>Cancer Reports</i> , 2020, 3, e1267.	0.6	2
2074	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2020, 10, 1489-1499.	7.7	60
2075	Pyruvate Kinase M2 is a marker of poor prognosis in lung adenocarcinoma but not lung squamous cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 3293-3302.	0.4	3
2076	Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 57, 102846.	2.7	23
2077	Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. <i>Lung Cancer</i> , 2020, 146, 341-349.	0.9	3
2078	M1 ^{hot} tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. , 2020, 8, e000778.		99
2079	Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies. <i>BMC Clinical Pathology</i> , 2020, 13, 2632010X2092187.	0.7	0
2080	Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 652.	1.8	10
2081	Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL). <i>Frontiers in Oncology</i> , 2020, 10, 1072.	1.3	4
2082	The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1256.	1.3	33
2083	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. <i>Cancers</i> , 2020, 12, 2003.	1.7	5
2084	Pan-cancer image-based detection of clinically actionable genetic alterations. <i>Nature Cancer</i> , 2020, 1, 789-799.	5.7	343
2085	Tipifarnib as a Precision Therapy for <i>HRAS</i> -Mutant Head and Neck Squamous Cell Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1784-1796.	1.9	72

#	ARTICLE	IF	CITATIONS
2086	Targeting p53 for the treatment of cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 58-67.	4.3	177
2087	PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas. <i>Experimental Cell Research</i> , 2020, 395, 112187.	1.2	3
2088	Cell-specific expression of lung disease risk-related genes in the human small airway epithelium. <i>Respiratory Research</i> , 2020, 21, 200.	1.4	27
2089	Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing. <i>Cancers</i> , 2020, 12, 2065.	1.7	25
2090	Cells of origin of lung cancers: lessons from mouse studies. <i>Genes and Development</i> , 2020, 34, 1017-1032.	2.7	108
2091	Next-Generation Sequencing at High Sequencing Depth as a Tool to Study the Evolution of Metastasis Driven by Genetic Change Events of Lung Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1215.	1.3	7
2092	Antioxidants with two faces toward cancer. <i>Life Sciences</i> , 2020, 258, 118186.	2.0	31
2093	Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients. <i>Thoracic Cancer</i> , 2020, 11, 2542-2551.	0.8	5
2094	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	0.9	31
2095	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. <i>Annals of Translational Medicine</i> , 2020, 8, 860-860.	0.7	9
2096	The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 516850.	1.3	23
2097	Predicting Deep Learning Based Multi-Omics Parallel Integration Survival Subtypes in Lung Cancer Using Reverse Phase Protein Array Data. <i>Biomolecules</i> , 2020, 10, 1460.	1.8	41
2098	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	5.1	68
2099	Best practices for variant calling in clinical sequencing. <i>Genome Medicine</i> , 2020, 12, 91.	3.6	178
2100	Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3081.	1.7	8
2101	Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. <i>Lung Cancer</i> , 2020, 150, 132-138.	0.9	15
2102	3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. <i>Molecular Cell</i> , 2020, 80, 828-844.e6.	4.5	110
2103	High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 1032.	1.1	31

#	ARTICLE	IF	CITATIONS
2104	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18605.	1.6	16
2105	Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2. <i>Molecular and Cellular Biology</i> , 2020, 40, .	1.1	24
2106	EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data. <i>Genome Biology</i> , 2020, 21, 221.	3.8	58
2107	Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1187-1201.	1.3	10
2108	Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 1457.	1.3	21
2109	VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4788.	5.8	27
2110	Deregulated microRNAs Are Associated with Patient Survival and Predicted to Target Genes That Modulate Lung Cancer Signaling Pathways. <i>Cancers</i> , 2020, 12, 2711.	1.7	5
2111	Whole-Exome Profiling of NSCLC Among African Americans. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1880-1892.	0.5	19
2112	Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan. <i>BMJ Open</i> , 2020, 10, e035615.	0.8	4
2113	Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. <i>Molecular Cancer Research</i> , 2020, 18, 1777-1788.	1.5	24
2114	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patients' Suitability for Immune Checkpoint Inhibition. <i>Cancer Management and Research</i> , 2020, Volume 12, 7881-7890.	0.9	6
2115	Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 103-133.	0.9	9
2116	World Lung Day: what, why, and where to?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L527-L533.	1.3	6
2117	Human transcription factor and protein kinase gene fusions in human cancer. <i>Scientific Reports</i> , 2020, 10, 14169.	1.6	9
2118	ReactomeGSA - Efficient Multi-Omics Comparative Pathway Analysis. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 2115-2125.	2.5	145
2119	PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications. <i>Journal of Translational Medicine</i> , 2020, 18, 307.	1.8	9
2120	Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian). <i>Journal of Thoracic Disease</i> , 2020, 12, 3776-3784.	0.6	24
2122	Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients. <i>Molecular Oncology</i> , 2020, 14, 2759-2774.	2.1	13

#	ARTICLE	IF	CITATIONS
2124	Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d. <i>Cancers</i> , 2020, 12, 3805.	1.7	8
2125	NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. <i>Cells</i> , 2020, 9, 2677.	1.8	37
2126	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932.	1.3	4
2127	Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 607130.	1.3	6
2128	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020, 13, 173.	6.9	91
2129	Copy Number Analysis Reveal Genetic Risks of Penile Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 596261.	1.3	3
2130	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. <i>Therapie</i> , 2020, 75, 183-193.	0.6	0
2131	Human pluripotent stem cell-derived lung organoids: Potential applications in development and disease modeling. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2021, 10, e399.	5.9	32
2132	Frequent Germline and Somatic Single Nucleotide Variants in the Promoter Region of the Ribosomal RNA Gene in Japanese Lung Adenocarcinoma Patients. <i>Cells</i> , 2020, 9, 2409.	1.8	4
2133	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1781-1789.	1.2	13
2134	Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 757-769.	2.2	69
2135	Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa021.	1.5	5
2136	Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 995.	1.3	18
2137	Dynamical network analysis reveals key microRNAs in progressive stages of lung cancer. <i>PLoS Computational Biology</i> , 2020, 16, e1007793.	1.5	4
2138	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
2139	Oviz-Bio: a web-based platform for interactive cancer genomics data visualization. <i>Nucleic Acids Research</i> , 2020, 48, W415-W426.	6.5	17
2140	FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1255-1265.	1.9	15
2141	PenDA, a rank-based method for personalized differential analysis: Application to lung cancer. <i>PLoS Computational Biology</i> , 2020, 16, e1007869.	1.5	10

#	ARTICLE	IF	CITATIONS
2142	Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling. <i>Translational Lung Cancer Research</i> , 2020, 9, 373-378.	1.3	6
2143	Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	6
2144	Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers. <i>Trends in Cancer</i> , 2020, 6, 462-477.	3.8	43
2145	The role of natural products in revealing NRF2 function. <i>Natural Product Reports</i> , 2020, 37, 797-826.	5.2	71
2146	Applying Tobacco, Environmental, and Dietary-Related Biomarkers to Understand Cancer Etiology and Evaluate Prevention Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1904-1919.	1.1	4
2147	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	2.9	18
2148	Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to wholeâ€slide images. <i>Cancer Medicine</i> , 2020, 9, 4864-4875.	1.3	14
2149	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. <i>Nature Medicine</i> , 2020, 26, 1054-1062.	15.2	181
2150	Distinct immune evasion in <sc>APOBEC</sc>-enriched, <sc>HPV</sc>-negative <sc>HNSCC</sc>. <i>International Journal of Cancer</i> , 2020, 147, 2293-2302.	2.3	10
2151	Identification of common and dissimilar biomarkers for different cancer types from gene expressions of RNA-sequencing data. <i>Gene Reports</i> , 2020, 19, 100654.	0.4	2
2152	Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 332-345.	0.2	21
2153	The Impact of the Ubiquitin System in the Pathogenesis of Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1595.	1.7	11
2154	NRF2-Driven <i>KEAP1</i> Transcription in Human Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1465-1476.	1.5	9
2155	Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine. <i>Cancers</i> , 2020, 12, 1381.	1.7	14
2156	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
2157	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	0.8	3
2158	A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment. <i>IEEE Access</i> , 2020, 8, 89031-89040.	2.6	7
2159	Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 480-494.	21.5	396

#	ARTICLE	IF	CITATIONS
2160	Immune microenvironment composition in non-small cell lung cancer and its association with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1142.	1.7	119
2161	Lung cancer histology-driven strategic therapeutic approaches. <i>Shanghai Chest</i> , 0, 4, 29-29.	0.3	4
2162	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1870.	1.0	16
2163	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. <i>Nature Cancer</i> , 2020, 1, 589-602.	5.7	44
2164	The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7
2165	Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 748.	1.3	20
2166	G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer. <i>Clinical Epigenetics</i> , 2020, 12, 88.	1.8	28
2167	Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 206.	1.6	29
2168	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1658.	1.8	22
2169	An Effective Graph Clustering Method to Identify Cancer Driver Modules. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 271.	2.0	2
2170	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 111-138.	1.3	27
2171	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
2172	The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer. <i>Annual Review of Cancer Biology</i> , 2020, 4, 413-435.	2.3	45
2173	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	3.2	41
2174	Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. <i>ACS Chemical Biology</i> , 2020, 15, 1424-1444.	1.6	4
2175	The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. <i>Cancer Research</i> , 2020, 80, 3062-3069.	0.4	8
2176	Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 118.	1.8	21
2177	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119

#	ARTICLE	IF	CITATIONS
2178	EGFR mutation exists in squamous cell lung carcinoma. <i>Pathology</i> , 2020, 52, 323-328.	0.3	20
2179	Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients. <i>Frontiers in Oncology</i> , 2020, 10, 963.	1.3	6
2180	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. <i>Oncolimmunology</i> , 2020, 9, 1773205.	2.1	3
2181	Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3704.	1.3	1
2182	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2896-2909.	0.6	5
2183	High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets. <i>Purinergic Signalling</i> , 2020, 16, 347-366.	1.1	41
2184	Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. <i>Cell Communication and Signaling</i> , 2020, 18, 98.	2.7	38
2185	Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. <i>Current Treatment Options in Oncology</i> , 2020, 21, 60.	1.3	6
2186	Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. <i>Thoracic Cancer</i> , 2020, 11, 2262-2269.	0.8	5
2187	The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4507.	1.8	289
2188	MET receptor in oncology: From biomarker to therapeutic target. <i>Advances in Cancer Research</i> , 2020, 147, 259-301.	1.9	20
2189	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. <i>Journal of Thoracic Disease</i> , 2020, 12, 1952-1959.	0.6	6
2190	A prognostic 11-DNA methylation signature for lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 2569-2582.	0.6	9
2191	Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2279-2284.	3.3	7
2192	<p>The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 1-11.	1.3	17
2193	Identification of Clonality through Genomic Profile Analysis in Multiple Lung Cancers. <i>Journal of Clinical Medicine</i> , 2020, 9, 573.	1.0	19
2194	Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 525, 483-490.	1.0	4
2195	XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. <i>Oncogene</i> , 2020, 39, 3541-3554.	2.6	26

#	ARTICLE	IF	CITATIONS
2196	Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 52.	1.3	11
2197	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. <i>Science Immunology</i> , 2020, 5, .	5.6	39
2198	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	0.8	52
2199	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
2200	5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. <i>British Journal of Cancer</i> , 2020, 122, 1194-1204.	2.9	12
2201	M3C: Monte Carlo reference-based consensus clustering. <i>Scientific Reports</i> , 2020, 10, 1816.	1.6	71
2202	Metabolic features of cancer cells in NRF2 addiction status. <i>Biophysical Reviews</i> , 2020, 12, 435-441.	1.5	34
2203	Non-coding RNA profile in lung cancer. <i>Experimental and Molecular Pathology</i> , 2020, 114, 104411.	0.9	47
2204	Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. <i>Clinical Lung Cancer</i> , 2020, 21, e355-e362.	1.1	6
2205	NRF2 negatively regulates primary ciliogenesis and hedgehog signaling. <i>PLoS Biology</i> , 2020, 18, e3000620.	2.6	19
2206	Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites. <i>Cancer Science</i> , 2020, 111, 667-678.	1.7	29
2207	Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. <i>Cell Reports</i> , 2020, 30, 771-782.e6.	2.9	23
2208	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802.	3.2	8
2209	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
2210	The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. <i>Cell Research</i> , 2020, 30, 146-162.	5.7	616
2211	Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer. <i>Life Sciences</i> , 2020, 254, 117325.	2.0	11
2212	Precision Management of Advanced Non-small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136.	5.0	101
2213	Guidelines for cell-type heterogeneity quantification based on a comparative analysis of reference-free DNA methylation deconvolution software. <i>BMC Bioinformatics</i> , 2020, 21, 16.	1.2	34

#	ARTICLE	IF	CITATIONS
2214	Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. <i>Surgical Pathology Clinics</i> , 2020, 13, 17-33.	0.7	248
2215	Tobacco smoking and somatic mutations in human bronchial epithelium. <i>Nature</i> , 2020, 578, 266-272.	13.7	336
2216	Virus expression detection reveals RNA-sequencing contamination in TCGA. <i>BMC Genomics</i> , 2020, 21, 79.	1.2	21
2217	Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer. <i>Cancer</i> , 2020, 126, 1804-1809.	2.0	14
2218	Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report. <i>BMC Medical Genomics</i> , 2020, 13, 15.	0.7	9
2219	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
2220	Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. <i>Nature Genetics</i> , 2020, 52, 306-319.	9.4	275
2221	Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study. <i>Cancer Medicine</i> , 2020, 9, 2343-2351.	1.3	10
2222	Applications of probability and statistics in cancer genomics. <i>Quantitative Biology</i> , 2020, 8, 95-108.	0.3	1
2223	Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. <i>Nature Communications</i> , 2020, 11, 2086.	5.8	20
2224	Mutational signatures are jointly shaped by DNA damage and repair. <i>Nature Communications</i> , 2020, 11, 2169.	5.8	137
2225	OSLuca: An Interactive Web Server to Evaluate Prognostic Biomarkers for Lung Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 420.	1.1	25
2226	Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165822.	1.8	43
2227	Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer. <i>Biochemical Pharmacology</i> , 2020, 177, 114002.	2.0	20
2228	KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 599-617.e7.	7.7	137
2229	Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC. <i>Medicine in Drug Discovery</i> , 2020, 6, 100035.	2.3	7
2230	OTU deubiquitinase 5 inhibits the progression of non-small cell lung cancer via regulating p53 and PDCD5. <i>Chemical Biology and Drug Design</i> , 2020, 96, 790-800.	1.5	8
2231	Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 268.	2.0	21

#	ARTICLE	IF	CITATIONS
2232	The Landscape of Somatic Copy Number Alterations in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 321.	1.3	17
2233	Clinical data analysis reveals the role of OGR1 (GPR68) in head and neck squamous cancer. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 55-61.	1.3	10
2234	Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin- α 5 β 1-AKT Signaling Pathway in Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 943-954.	1.5	65
2235	Spatiotemporal Regulation of p53 by TGF β -Regulated miRNAs Is Essential for Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 2833-2847.	0.4	19
2236	Maintaining protein stability of p53 via USP28 is required by squamous cancer cells. <i>EMBO Molecular Medicine</i> , 2020, 12, e11101.	3.3	42
2237	Pan-cancer analysis and applications. , 2020, , 307-316.		0
2238	TP53-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. <i>Cancer Research</i> , 2020, 80, 2484-2497.	0.4	16
2239	Metabolic Biomarkers of Squamous Cell Carcinoma of the Aerodigestive Tract: A Systematic Review and Quality Assessment. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-13.	1.9	3
2240	Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1423-1429.	1.1	6
2241	Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
2242	Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. <i>PLoS ONE</i> , 2020, 15, e0231227.	1.1	43
2243	NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. <i>Oncologist</i> , 2020, 25, e955-e963.	1.9	39
2244	Identifying prognostic biomarkers of non-small cell lung cancer by transcriptome analysis. <i>Cancer Biomarkers</i> , 2020, 27, 243-250.	0.8	9
2245	The Road Not Taken with Pyrrole-Imidazole Polyamides: Off-Target Effects and Genomic Binding. <i>Biomolecules</i> , 2020, 10, 544.	1.8	7
2246	Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. <i>Annals of Oncology</i> , 2020, 31, 873-883.	0.6	35
2247	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 221-229.	0.4	2
2248	Restoration of miR-30 expression suppresses lung cancer cell viability, proliferation, and migration. <i>Journal of Cellular Physiology</i> , 2021, 236, 273-283.	2.0	15
2249	Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	9

#	ARTICLE	IF	CITATIONS
2251	Drugging "undruggable" genes for cancer treatment: Are we making progress?. <i>International Journal of Cancer</i> , 2021, 148, 8-17.	2.3	63
2252	NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer. <i>Molecular and Cellular Biology</i> , 2021, 41, .	1.1	21
2253	Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 831-842.	3.2	8
2254	A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis. <i>International Journal of Cancer</i> , 2021, 148, 238-251.	2.3	10
2255	Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 90-101.	2.5	22
2256	Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 685-694.	0.7	9
2257	Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. <i>Journal of Hepatology</i> , 2021, 74, 613-626.	1.8	34
2258	NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 877-888.	3.2	84
2259	Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer. <i>Pathology</i> , 2021, 53, 239-246.	0.3	10
2260	AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 485-497.	1.5	32
2261	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
2262	Clinical applications of nanomedicines in lung cancer treatment. <i>Acta Biomaterialia</i> , 2021, 121, 134-142.	4.1	42
2263	NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. <i>Oncogene</i> , 2021, 40, 909-921.	2.6	34
2264	Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, 32-41.e1.	1.1	6
2265	Amplification of 8p11.23 in cancers and the role of amplicon genes. <i>Life Sciences</i> , 2021, 264, 118729.	2.0	12
2266	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
2267	MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations. <i>Bioinformatics</i> , 2021, 37, 1189-1197.	1.8	7
2268	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 395-403.	0.5	33

#	ARTICLE	IF	CITATIONS
2269	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, 67-70.	1.1	33
2270	TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas. <i>Modern Pathology</i> , 2021, 34, 1133-1142.	2.9	24
2271	Diseases related to Notch glycosylation. <i>Molecular Aspects of Medicine</i> , 2021, 79, 100938.	2.7	22
2272	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100615.	0.6	6
2273	The role of Hippo-YAP signaling in squamous cell carcinomas. <i>Cancer Science</i> , 2021, 112, 51-60.	1.7	38
2274	The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis. <i>Redox Biology</i> , 2021, 38, 101766.	3.9	22
2275	SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	2.1	29
2276	Bayesian approach to interpreting somatic cancer sequencing data: a case in point. <i>Journal of Clinical Pathology</i> , 2021, 74, 403-404.	1.0	0
2277	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 73-102.	2.4	13
2278	Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. <i>Frontiers of Medicine</i> , 2021, 15, 275-291.	1.5	21
2279	Interplay between HMGA and TP53 in cell cycle control along tumor progression. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 817-831.	2.4	10
2280	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. <i>Seminars in Cancer Biology</i> , 2021, 68, 59-74.	4.3	64
2281	Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. <i>Cancer Cell International</i> , 2021, 21, 49.	1.8	5
2282	Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. <i>Seminars in Cancer Biology</i> , 2022, 83, 335-352.	4.3	28
2283	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 36.	0.1	0
2284	New potential anticancer drug-like compounds for squamous cell lung cancer using transcriptome network analysis. <i>Informatics in Medicine Unlocked</i> , 2021, 24, 100599.	1.9	0
2285	Therapeutics Intervention of Skin Cancer in the OMICS Era. , 2021, , 131-141.		0
2286	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. <i>Acta Neuropathologica</i> , 2021, 141, 303-321.	3.9	30

#	ARTICLE	IF	CITATIONS
2287	Multiple microarray analyses identify key genes associated with the development of Non-Small Cell Lung Cancer from Chronic Obstructive Pulmonary Disease. <i>Journal of Cancer</i> , 2021, 12, 996-1010.	1.2	11
2288	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 847-859.	0.4	7
2291	Gene expression profiles of the original tumors influence the generation of PDX models of lung squamous cell carcinoma. <i>Laboratory Investigation</i> , 2021, 101, 543-553.	1.7	2
2292	Bioinformatics Analyses Reveals a Comprehensive Landscape of CXC Chemokine Family Functions in Non-Small Cell Lung Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-34.	0.9	4
2293	HEDGEHOG/GLI Modulates the PRR11-SKA2 Bidirectional Transcription Unit in Lung Squamous Cell Carcinomas. <i>Genes</i> , 2021, 12, 120.	1.0	6
2294	TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. <i>Cancer Discovery</i> , 2021, 11, 1411-1423.	7.7	26
2295	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	9.4	118
2296	Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 576855.	1.3	7
2297	Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma. <i>Aging</i> , 2021, 13, 4024-4044.	1.4	3
2300	Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 261-278.	1.9	10
2301	Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. <i>Science Advances</i> , 2021, 7, .	4.7	40
2302	The Keap1-Nrf2 Signaling Pathway in Lung Cancer. , 2021, , 661-682.		0
2304	Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis. <i>Cancers</i> , 2021, 13, 255.	1.7	1
2305	miR-31 Displays Subtype Specificity in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 1942-1953.	0.4	11
2306	DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. <i>Clinical Epigenetics</i> , 2021, 13, 38.	1.8	8
2307	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 737-752.	1.3	28
2309	A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis. <i>BMC Cancer</i> , 2021, 21, 128.	1.1	7
2310	Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?. <i>Frontiers in Genetics</i> , 2021, 12, 606537.	1.1	2

#	ARTICLE	IF	CITATIONS
2311	Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2021, 10, 766-775.	1.3	3
2312	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
2313	Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma. <i>Scientific Reports</i> , 2021, 11, 3932.	1.6	14
2314	Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?. <i>JCO Precision Oncology</i> , 2021, 5, 408-414.	1.5	7
2315	Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). <i>Thoracic Cancer</i> , 2021, 12, 1264-1268.	0.8	1
2316	Distinct epithelial-to-mesenchymal transitions induced by <i>PIK3CA</i> H1047R and <i>PIK3CB</i> . <i>Journal of Cell Science</i> , 2021, 134, .	1.2	2
2317	Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. <i>International Journal of Cancer</i> , 2021, 148, 3008-3018.	2.3	7
2318	Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma. <i>Aging</i> , 2021, 13, 5312-5331.	1.4	8
2319	Fusion Genes and RNAs in Cancer Development. <i>Non-coding RNA</i> , 2021, 7, 10.	1.3	24
2321	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. <i>Nature</i> , 2021, 590, 504-508.	13.7	79
2322	Differentially methylated regions within lung cancer risk loci are enriched in deregulated enhancers. <i>Epigenetics</i> , 2022, 17, 117-132.	1.3	2
2323	Integrative clustering methods for multi-omics data. <i>Wiley Interdisciplinary Reviews: Computational Statistics</i> , 2022, 14, e1553.	2.1	7
2324	<i>TRIM58</i> is a prognostic biomarker remodeling the tumor microenvironment in <i>KRAS</i> -driven lung adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 565-579.	1.1	9
2325	Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma. <i>Cell Reports</i> , 2021, 34, 108769.	2.9	42
2326	Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 154.	1.1	23
2327	Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. <i>BMC Genomics</i> , 2021, 22, 214.	1.2	39
2328	TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells. <i>Scientific Reports</i> , 2021, 11, 7119.	1.6	11
2329	Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641618.	1.8	25

#	ARTICLE	IF	CITATIONS
2330	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. <i>Lung Cancer</i> , 2021, 153, 90-98.	0.9	6
2331	The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. <i>Molecules</i> , 2021, 26, 1392.	1.7	21
2332	Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 682-690.	2.3	45
2333	Discriminating Spontaneous From Cigarette Smoke and THS 2.2 Aerosol Exposure-Related Proliferative Lung Lesions in A/J Mice by Using Gene Expression and Mutation Spectrum Data. <i>Frontiers in Toxicology</i> , 2021, 3, 634035.	1.6	0
2334	The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. <i>Archives of Pharmacal Research</i> , 2021, 44, 263-280.	2.7	23
2335	Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. <i>Oncotarget</i> , 2021, 12, 578-588.	0.8	13
2336	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	2.6	26
2337	Oxidative Stress and the Intersection of Oncogenic Signaling and Metabolism in Squamous Cell Carcinomas. <i>Cells</i> , 2021, 10, 606.	1.8	3
2338	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for <i>FGFR1</i> -Amplified Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3121-3133.	0.4	12
2339	Assessing the contribution of tumor mutational phenotypes to cancer progression risk. <i>PLoS Computational Biology</i> , 2021, 17, e1008777.	1.5	2
2340	Oxidative stress-mediated induction of pulmonary oncogenes, inflammatory, and apoptotic markers following time-course exposure to ethylene glycol monomethyl ether in rats. <i>Metabolism Open</i> , 2021, 9, 100075.	1.4	13
2342	E47 upregulates β -tubulin to promote growth of squamous cell carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 381.	2.7	6
2343	Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2021, 10, 1792-1803.	1.3	3
2345	Role of Annexin A1 in Squamous Cell Lung Cancer Progression. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	3
2346	Clinical application of a lung cancer organoid (tumoroid) culture system. <i>Npj Precision Oncology</i> , 2021, 5, 29.	2.3	34
2347	Frontiers of CRISPR-Cas9 for Cancer Research and Therapy. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000.	0.2	1
2348	Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma. <i>Proteomics</i> , 2021, 21, e2000283.	1.3	1
2349	SIPA1 Is a Modulator of HGF/MET Induced Tumour Metastasis via the Regulation of Tight Junction-Based Cell to Cell Barrier Function. <i>Cancers</i> , 2021, 13, 1747.	1.7	4

#	ARTICLE	IF	CITATIONS
2350	Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2839-2845.	1.0	2
2351	Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration. <i>Frontiers in Immunology</i> , 2021, 12, 612144.	2.2	38
2352	SH3BP4 promotes neuropilin-1 and β 5-integrin endocytosis and is inhibited by Akt. <i>Developmental Cell</i> , 2021, 56, 1164-1181.e12.	3.1	7
2353	Clinicopathological and prognostic significance of circRNAs in lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25415.	0.4	3
2354	Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous Kras ^{LSL-G12V} Driven Lung Cancer Mouse Model. <i>Pathology and Oncology Research</i> , 2021, 27, 596522.	0.9	1
2355	Analysis of TERT Isoforms across TCGA, GTEx and CCLE Datasets. <i>Cancers</i> , 2021, 13, 1853.	1.7	5
2356	Transcriptome Based Estrogen Related Genes Biomarkers for Diagnosis and Prognosis in Non-small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 666396.	1.1	6
2357	Identification of transcriptional subtypes in lung adenocarcinoma and squamous cell carcinoma through integrative analysis of microarray and RNA sequencing data. <i>Scientific Reports</i> , 2021, 11, 8709.	1.6	8
2358	Tracking Cancer Evolution through the Disease Course. <i>Cancer Discovery</i> , 2021, 11, 916-932.	7.7	77
2359	The foggy world(s) of p63 isoform regulation in normal cells and cancer. <i>Journal of Pathology</i> , 2021, 254, 454-473.	2.1	15
2360	Whole-exome Sequencing of Epstein-Barr Virus-associated Pulmonary Carcinoma With Low Lymphocytic Infiltration Shows Molecular Features Similar to Those of Classic Pulmonary Lymphoepithelioma-like Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1476-1486.	2.1	4
2362	Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN. <i>Frontiers in Oncology</i> , 2021, 11, 633579.	1.3	3
2363	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021, 11, 8551.	1.6	13
2364	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300.	2.0	6
2365	Aberrant epithelial polarity cues drive the development of precancerous airway lesions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
2366	High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. <i>Oncotarget</i> , 2021, 12, 859-872.	0.8	4
2367	Updates in Pharmacogenetics of Non-Small Cell Lung Cancer. , 0, , .		2
2368	Virus-Driven Carcinogenesis. <i>Cancers</i> , 2021, 13, 2625.	1.7	31

#	ARTICLE	IF	CITATIONS
2369	Prediction of prognosis of patients with lung cancer in combination with the immune score. <i>Bioscience Reports</i> , 2021, 41, .	1.1	5
2370	Molecular basis for the disruption of Keap1&Nrf2 interaction via Hinge & Latch mechanism. <i>Communications Biology</i> , 2021, 4, 576.	2.0	84
2371	NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. <i>Cell Reports Medicine</i> , 2021, 2, 100279.	3.3	7
2372	Systematic analysis of migration factors by MigExpress identifies essential cell migration control genes in non&small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 1797-1817.	2.1	9
2373	Decreased expression of Dlg5 is associated with a poor prognosis and epithelial&mesenchymal transition in squamous cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 3115-3125.	0.6	5
2374	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	3.2	44
2375	Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non&Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 350-355.	0.6	3
2377	A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 626.	1.1	6
2378	Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	5
2379	Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis. <i>Nature Communications</i> , 2021, 12, 2592.	5.8	42
2380	Elastic Net Models Based on DNA Copy Number Variations Predicts Clinical Features, Expression Signatures, and Mutations in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 668040.	1.1	1
2381	Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis. <i>Aging</i> , 2021, 13, 12691-12709.	1.4	1
2382	Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 2236.	1.0	4
2383	Identification of KIF4A as a pan-cancer diagnostic and prognostic biomarker via bioinformatics analysis and validation in osteosarcoma cell lines. <i>PeerJ</i> , 2021, 9, e11455.	0.9	4
2384	Penalized estimation of the Gaussian graphical model from data with replicates. <i>Statistics in Medicine</i> , 2021, 40, 4279-4293.	0.8	5
2385	Toward comprehensive functional analysis of gene lists weighted by gene essentiality scores. <i>Bioinformatics</i> , 2021, 37, 4399-4404.	1.8	9
2386	Genome-Wide Transcriptomic Analysis of Non-Tumorigenic Tissues Reveals Aging-Related Prognostic Markers and Drug Targets in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3045.	1.7	10
2387	CircPVT1 promotes proliferation of lung squamous cell carcinoma by binding to miR-30d/e. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 193.	3.5	24

#	ARTICLE	IF	CITATIONS
2388	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1167-1180.	2.0	4
2389	Targeting cytoskeletal phosphorylation in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
2390	Diagnostic and Prognostic Significance of Keap1 mRNA Expression for Lung Cancer Based on Microarray and Clinical Information from Oncomine Database. <i>Current Medical Science</i> , 2021, 41, 597-609.	0.7	0
2391	Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation. <i>ELife</i> , 2021, 10, .	2.8	7
2392	Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. <i>ESMO Open</i> , 2021, 6, 100106.	2.0	9
2393	DNA Methylation Markers in Lung Cancer. <i>Current Genomics</i> , 2021, 22, 79-87.	0.7	19
2394	Single-cell RNA sequencing identify SDCBP in ACE2-positive bronchial epithelial cells negatively correlates with COVID-19 severity. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7001-7012.	1.6	18
2395	Targeting NRF2 to treat cancer. <i>Seminars in Cancer Biology</i> , 2021, 76, 61-73.	4.3	32
2396	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. <i>Nature Communications</i> , 2021, 12, 3785.	5.8	16
2397	The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape. <i>Biochemical Society Transactions</i> , 2021, 49, 1041-1054.	1.6	29
2398	NF-Y Subunits Overexpression in HNSCC. <i>Cancers</i> , 2021, 13, 3019.	1.7	8
2399	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. <i>Frontiers in Oncology</i> , 2021, 11, 645159.	1.3	10
2401	The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7039-7051.	1.6	7
2402	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51
2403	Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2021, 274, 500-507.	2.1	8
2404	TMEM229A suppresses non-small cell lung cancer progression via inactivating the ERK pathway. <i>Oncology Reports</i> , 2021, 46, .	1.2	10
2405	Molecular Landscape of Vulvar Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7069.	1.8	14
2406	Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037838.	2.9	2

#	ARTICLE	IF	CITATIONS
2407	KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition. <i>IScience</i> , 2021, 24, 102649.	1.9	26
2408	DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma. <i>Scientific Reports</i> , 2021, 11, 12753.	1.6	6
2409	Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1428-1483.	2.5	13
2410	Cross-talk between next generation sequencing methodologies to identify genomic signatures of esophageal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103348.	2.0	1
2411	A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1692-1701.	1.9	18
2412	EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 680804.	1.3	19
2413	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	0.8	100
2415	miR-223-5p Suppresses OTX1 to Mediate Malignant Progression of Lung Squamous Cell Carcinoma Cells. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	5
2417	Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 705869.	1.3	4
2418	Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA. <i>Clinical Lung Cancer</i> , 2021, 22, 292-300.e1.	1.1	4
2419	Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges. <i>Cancers</i> , 2021, 13, 3759.	1.7	14
2420	Role of NRF2 in Lung Cancer. <i>Cells</i> , 2021, 10, 1879.	1.8	35
2421	3q26 Amplifications in Cervical Squamous Carcinomas. <i>Current Oncology</i> , 2021, 28, 2868-2880.	0.9	4
2422	Machine learning analysis of TCGA cancer data. <i>PeerJ Computer Science</i> , 2021, 7, e584.	2.7	13
2424	Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. <i>JCI Insight</i> , 2021, 6, .	2.3	6
2425	Chemopreventive effects of pterostilbene through p53 and cell cycle in mouse lung of squamous cell carcinoma model. <i>Scientific Reports</i> , 2021, 11, 14862.	1.6	10
2426	A pan-cancer organoid platform for precision medicine. <i>Cell Reports</i> , 2021, 36, 109429.	2.9	45
2427	Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. <i>Nature Communications</i> , 2021, 12, 4362.	5.8	50

#	ARTICLE	IF	CITATIONS
2428	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 5939-5950.	3.2	21
2429	Clinical Characteristics and Molecular Profiles of Lung Cancer in Ethiopia. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100196.	0.6	1
2430	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	3.2	11
2431	Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2021, 22, 646.	0.8	12
2432	Nrf2, the Major Regulator of the Cellular Oxidative Stress Response, is Partially Disordered. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7434.	1.8	19
2433	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. <i>Nature Communications</i> , 2021, 12, 4423.	5.8	111
2434	New Insights on Old Biomarkers Involved in Tumor Microenvironment Changes and Their Diagnostic Relevance in Non-Small Cell Lung Carcinoma. <i>Biomolecules</i> , 2021, 11, 1208.	1.8	7
2435	Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9451.	1.8	67
2436	Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 860.	0.8	2
2437	ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2129-2139.	1.9	21
2438	Skin Cancers and the Contribution of Rho GTPase Signaling Networks to Their Progression. <i>Cancers</i> , 2021, 13, 4362.	1.7	4
2439	Cancer biology deciphered by single-cell transcriptomic sequencing. <i>Protein and Cell</i> , 2022, 13, 167-179.	4.8	17
2440	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3633-3644.	0.8	27
2441	Role of novel cancer gene SLITRK3 to activate NTRK3 in squamous cell lung cancer. <i>Molecular Biomedicine</i> , 2021, 2, 26.	1.7	6
2442	GPCR Partners as Cancer Driver Genes: Association with PH-Signal Proteins in a Distinctive Signaling Network. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8985.	1.8	1
2443	Inhibition of Kelch-like epichlorohydrin-related protein 1 promotes the progression and drug resistance of lung adenocarcinoma. <i>PeerJ</i> , 2021, 9, e11908.	0.9	0
2444	Targeting AXL in NSCLC. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 67-79.	1.3	8
2445	Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models. <i>Communications Biology</i> , 2021, 4, 937.	2.0	6

#	ARTICLE	IF	CITATIONS
2446	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , 2021, 184, 4348-4371.e40.	13.5	170
2447	Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts. <i>Science Advances</i> , 2021, 7, .	4.7	12
2448	Insights Into Systemic Sclerosis from Gene Expression Profiling. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 208-221.	0.6	0
2449	Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. <i>Nature Communications</i> , 2021, 12, 4853.	5.8	27
2450	Next-generation sequencing of cancer genomes: lessons learned. <i>Future Oncology</i> , 2021, 17, 4041-4044.	1.1	1
2451	Clinical Implications of Inter- and Intratumor Heterogeneity of Immune Cell Markers in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 280-289.	3.0	8
2452	TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes. <i>Annals of Translational Medicine</i> , 2021, 9, 1330-1330.	0.7	8
2453	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	5.8	58
2454	Detection and characterization of lung cancer using cell-free DNA fragmentomes. <i>Nature Communications</i> , 2021, 12, 5060.	5.8	161
2456	Integrative Metabolomic and Lipidomic Profiling of Lung Squamous Cell Carcinoma for Characterization of Metabolites and Intact Lipid Species Related to the Metastatic Potential. <i>Cancers</i> , 2021, 13, 4179.	1.7	5
2457	Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma. <i>Nucleic Acids Research</i> , 2021, 49, 9246-9263.	6.5	13
2458	mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy. <i>DNA Repair</i> , 2021, 104, 103142.	1.3	14
2459	Proteogenomic characterization of pancreatic ductal adenocarcinoma. <i>Cell</i> , 2021, 184, 5031-5052.e26.	13.5	236
2461	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca ²⁺ flux to mitochondria. <i>Nature Communications</i> , 2021, 12, 5404.	5.8	20
2462	Convergent evolution of a genomic rearrangement may explain cancer resistance in hystrico- and sciuromorpha rodents. <i>Npj Aging and Mechanisms of Disease</i> , 2021, 7, 20.	4.5	2
2463	Triptolide Downregulates the Expression of NRF2 Target Genes by Increasing Cytoplasmic Localization of NRF2 in A549 Cells. <i>Frontiers in Pharmacology</i> , 2021, 12, 680167.	1.6	3
2464	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	1.9	66
2465	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. <i>Cancers</i> , 2021, 13, 4705.	1.7	86

#	ARTICLE	IF	CITATIONS
2466	A Step Towards NRF2-DNA Interaction Inhibitors by Fragment-Based NMR Methods. <i>ChemMedChem</i> , 2021, 16, 3576-3587.	1.6	3
2467	Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4734.	1.7	13
2468	Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100471.	0.7	1
2470	A Comprehensive Review of the Use of Antioxidants and Natural Products in Cancer Patients Receiving Anticancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	0
2471	Multiplatform discovery and regulatory function analysis of structural variations in non-small cell lung carcinoma. <i>Cell Reports</i> , 2021, 36, 109660.	2.9	3
2472	Deep learning-based prediction of the T cell receptor-antigen binding specificity. <i>Nature Machine Intelligence</i> , 2021, 3, 864-875.	8.3	99
2473	Genetic and immune characteristics of multiple primary lung cancers and lung metastases. <i>Thoracic Cancer</i> , 2021, 12, 2544-2550.	0.8	5
2474	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037820.	2.9	9
2475	Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5431.	5.8	23
2476	In silico assessment of EpCAM transcriptional expression and determination of the prognostic biomarker for human lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). <i>Biochemistry and Biophysics Reports</i> , 2021, 27, 101074.	0.7	3
2477	Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. <i>Journal of Clinical Oncology</i> , 2021, 39, 3747-3758.	0.8	38
2478	PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1040-1049.e8.	0.3	1
2479	USP52 inhibits cell proliferation by stabilizing PTEN protein in non-small cell lung cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	5
2480	Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 279-300.	4.2	74
2481	KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?. <i>Lung Cancer</i> , 2021, 159, 10-17.	0.9	18
2482	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	0.9	12
2483	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	13.7	36
2484	Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4805-4808.	1.0	2

#	ARTICLE	IF	CITATIONS
2485	A semiparametric isotonic regression model for skewed distributions with application to DNAâ€‘RNAâ€‘protein analysis. <i>Biometrics</i> , 2022, 78, 1464-1474.	0.8	0
2486	Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing. <i>Lung Cancer</i> , 2021, 160, 1-7.	0.9	11
2487	New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations. <i>Life Sciences</i> , 2021, 282, 119791.	2.0	1
2488	Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas. <i>Phytomedicine Plus</i> , 2021, 1, 100133.	0.9	0
2489	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.	0.9	14
2490	Preinvasive Airway Lesions. , 2022, , 697-704.		0
2491	Immunoediting and cancer priming. , 2022, , 111-136.		1
2492	Overview of Lung Cancer. , 2022, , 621-633.		0
2494	Risk of lung cancer due to external environmental factor and epidemiological data analysis. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 6079-6094.	1.0	6
2495	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. <i>Open Biology</i> , 2021, 11, 200247.	1.5	28
2496	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2
2497	Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	27
2498	Mutation profile of non-small cell lung cancer revealed by next generation sequencing. <i>Respiratory Research</i> , 2021, 22, 3.	1.4	35
2499	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
2500	Circulating Tumor Cells in the context Non-small Cell Lung Cancer. , 2021, , 65-92.		0
2501	Innovation and Advances in Precision Medicine in Head and Neck Cancer. , 2021, , 355-373.		2
2502	Pattern Recognition Algorithms for Multi-Omics Data Analysis. , 2021, , 141-158.		3
2503	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthaseâ€‘Low Squamous Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 87-92.	1.3	0

#	ARTICLE	IF	CITATIONS
2504	Prognostic Value of Diverse TP53 Mutations in Metastatic Cancers: An Analysis of the Cbioportal Database. SSRN Electronic Journal, 0, , .	0.4	0
2505	High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC. Cancer Treatment and Research Communications, 2021, 27, 100317.	0.7	9
2507	Exome sequencing identifies new somatic alterations and mutation patterns of tongue squamous cell carcinoma in a Chinese population. Journal of Pathology, 2020, 251, 353-364.	2.1	13
2508	Computational Deconvolution of Tumor-Infiltrating Immune Components with Bulk Tumor Gene Expression Data. Methods in Molecular Biology, 2020, 2120, 249-262.	0.4	18
2509	Omic Data, Information Derivable and Computational Needs. , 2014, , 41-63.		1
2510	Phosphoproteomics Profiling to Identify Altered Signaling Pathways and Kinase-Targeted Cancer Therapies. Methods in Molecular Biology, 2020, 2051, 241-264.	0.4	3
2511	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
2512	Mechanisms of Environmental and Occupational Carcinogenesis. , 2020, , 39-55.		1
2513	Bootstrap Bias Corrected Cross Validation Applied to Super Learning. Lecture Notes in Computer Science, 2020, , 550-563.	1.0	4
2515	A Short History of Chromosome Rearrangements and Gene Fusions in Cancer. , 2015, , 3-11.		75
2516	The Molecular Pathology of Lung Cancer: Pre-analytic Considerations. Molecular Pathology Library, 2018, , 79-92.	0.1	1
2517	Pulmonary Cytology. , 2018, , 103-131.		1
2518	MYC Regulation of Metabolism and Cancer. , 2015, , 101-122.		1
2519	CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases. Advances in Experimental Medicine and Biology, 2020, 1217, 211-223.	0.8	32
2520	Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein and Cell, 2021, 12, 599-620.	4.8	837
2521	The Genomics, Epigenomics, and Transcriptomics of HPV-Associated Oropharyngeal Cancer—Understanding the Basis of a Rapidly Evolving Disease. Advances in Genetics, 2016, 93, 1-56.	0.8	27
2522	Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer. Lung Cancer, 2017, 110, 35-41.	0.9	10
2523	NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. Molecular Cell, 2017, 68, 224-232.e4.	4.5	219

#	ARTICLE	IF	CITATIONS
2524	Prevalence of the EGFR T790M and other resistance mutations in the Australian population and histopathological correlation in a small subset of cases. <i>Pathology</i> , 2020, 52, 410-420.	0.3	4
2525	Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to \hat{I}^2 -lapachone. <i>Redox Biology</i> , 2020, 30, 101440.	3.9	31
2526	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. <i>Communications Biology</i> , 2020, 3, 784.	2.0	21
2527	SUMO E3 ligase CBX4 regulates hTERT-mediated transcription of <i>CDH1</i> and promotes breast cancer cell migration and invasion. <i>Biochemical Journal</i> , 2020, 477, 3803-3818.	1.7	27
2528	Prognostic Significance of the Preoperative Controlled Nutritional Status Score in Lung Cancer Patients Undergoing Surgical Resection. <i>Nutrition and Cancer</i> , 2021, 73, 2211-2218.	0.9	8
2529	Applying graph database technology for analyzing perturbed co-expression networks in cancer. <i>Database: the Journal of Biological Databases and Curation</i> , 2020, 2020, .	1.4	2
2530	AKT1 Mutations in Peripheral Bronchiolar Papilloma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 119-126.	2.1	21
2531	Aligner optimization increases accuracy and decreases compute times in multi-species sequence data. <i>Microbial Genomics</i> , 2017, 3, e000122.	1.0	13
2565	Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005785.	0.5	8
2566	A Feature Weighting-Assisted Approach for Cancer Subtypes Identification From Paired Expression Profiles. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2022, 19, 1403-1414.	1.9	1
2568	An Improved Murine Premalignant Squamous Cell Model: Tobacco Smoke Exposure Augments NTCU-Induced Murine Airway Dysplasia. <i>Cancer Prevention Research</i> , 2021, 14, 307-312.	0.7	5
2569	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. <i>JCI Insight</i> , 2016, 1, e85902.	2.3	179
2570	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. <i>Journal of Clinical Investigation</i> , 2013, 123, 2921-2934.	3.9	283
2571	Oncometabolites: linking altered metabolism with cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3652-3658.	3.9	334
2572	SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2014, 124, 1636-1645.	3.9	151
2573	Multifactorial ER \hat{I}^2 and NOTCH1 control of squamous differentiation and cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 2260-2276.	3.9	44
2574	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 3219-3235.	3.9	256
2575	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81

#	ARTICLE	IF	CITATIONS
2576	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	3.9	126
2578	An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. <i>Molecular Medicine</i> , 2020, 26, 48.	1.9	10
2579	Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters. <i>BMC Cancer</i> , 2020, 20, 56.	1.1	6
2580	Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine. <i>BMC Cancer</i> , 2020, 20, 935.	1.1	10
2581	Genomic Landscape of Squamous Cell Carcinoma of the Lung. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 348-353.	1.8	4
2582	Protective Effects of Astragaloside IV Combined with Budesonide in Bronchitis in Rats by Regulation of Nrf2/Keap1 Pathway. <i>Medical Science Monitor</i> , 2018, 24, 8481-8488.	0.5	10
2583	TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. <i>F1000Research</i> , 2016, 5, 1542.	0.8	140
2584	Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway. <i>PLoS Biology</i> , 2017, 15, e2000731.	2.6	37
2585	Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. <i>PLoS Genetics</i> , 2016, 12, e1005895.	1.5	144
2586	Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes. <i>PLoS ONE</i> , 2013, 8, e56823.	1.1	263
2587	Transcriptome Sequencing of Tumor Subpopulations Reveals a Spectrum of Therapeutic Options for Squamous Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e58714.	1.1	9
2588	Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. <i>PLoS ONE</i> , 2013, 8, e73484.	1.1	41
2589	Experimental Design-Based Functional Mining and Characterization of High-Throughput Sequencing Data in the Sequence Read Archive. <i>PLoS ONE</i> , 2013, 8, e77910.	1.1	32
2590	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. <i>PLoS ONE</i> , 2013, 8, e77945.	1.1	104
2591	Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e82241.	1.1	1,502
2592	On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles. <i>PLoS ONE</i> , 2014, 9, e87782.	1.1	26
2593	deltaNp63 Has a Role in Maintaining Epithelial Integrity in Airway Epithelium. <i>PLoS ONE</i> , 2014, 9, e88683.	1.1	51
2594	Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e107276.	1.1	20

#	ARTICLE	IF	CITATIONS
2595	Inferring Protein Modulation from Gene Expression Data Using Conditional Mutual Information. PLoS ONE, 2014, 9, e109569.	1.1	21
2596	Modulation of NF- κ B/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin. PLoS ONE, 2015, 10, e0121547.	1.1	75
2597	A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS ONE, 2015, 10, e0125482.	1.1	99
2598	Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. PLoS ONE, 2015, 10, e0126270.	1.1	12
2599	Increasing Nucleosome Occupancy Is Correlated with an Increasing Mutation Rate so Long as DNA Repair Machinery Is Intact. PLoS ONE, 2015, 10, e0136574.	1.1	29
2600	A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0142162.	1.1	31
2601	Genome Wide Methylome Alterations in Lung Cancer. PLoS ONE, 2015, 10, e0143826.	1.1	30
2602	Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. PLoS ONE, 2016, 11, e0161012.	1.1	39
2603	Quantitative Proteomic Profiling the Molecular Signatures of Annexin A5 in Lung Squamous Carcinoma Cells. PLoS ONE, 2016, 11, e0163622.	1.1	8
2604	An integrative study on the impact of highly differentially methylated genes on expression and cancer etiology. PLoS ONE, 2017, 12, e0171694.	1.1	1
2605	Electronic cigarette aerosols suppress cellular antioxidant defenses and induce significant oxidative DNA damage. PLoS ONE, 2017, 12, e0177780.	1.1	125
2606	Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS ONE, 2017, 12, e0187246.	1.1	51
2607	The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histology and Histopathology, 2015, 30, 503-21.	0.5	26
2608	Genomic Landscape of Squamous Cell Carcinoma of the Lung. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 348-353.	1.8	6
2609	<sc>CEN</sc> tools: an integrative platform to identify the contexts of essential genes. Molecular Systems Biology, 2020, 16, e9698.	3.2	14
2610	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Critical Reviews in Oncogenesis, 2015, 20, 339-347.	0.2	6
2611	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	1.9	5
2612	Corrupting the DNA damage response: a critical role for Rad52 in tumor cell survival. Aging, 2017, 9, 1647-1659.	1.4	12

#	ARTICLE	IF	CITATIONS
2613	Exome sequencing identifies somatic mutations in novel driver genes in non-small cell lung cancer. <i>Aging</i> , 2020, 12, 13701-13715.	1.4	9
2614	ALK-rearrangements and testing methods in non-small cell lung cancer: a review. <i>Genes and Cancer</i> , 2014, 5, 1-14.	0.6	54
2615	The combinatorial complexity of cancer precision medicine. <i>Oncoscience</i> , 2014, 1, 504-509.	0.9	48
2616	Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. <i>Oncotarget</i> , 2016, 7, 59314-59321.	0.8	54
2617	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. <i>Oncotarget</i> , 2016, 7, 57651-57670.	0.8	29
2618	Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 59664-59675.	0.8	45
2619	High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers. <i>Oncotarget</i> , 2016, 7, 75279-75292.	0.8	29
2620	G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. <i>Oncotarget</i> , 2016, 7, 70898-70911.	0.8	88
2621	<i>PITX2</i> and <i>PANCR</i> DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 75827-75838.	0.8	18
2622	Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 82254-82265.	0.8	6
2623	Multiple mutations of lung squamous cell carcinoma shared common mechanisms. <i>Oncotarget</i> , 2016, 7, 79629-79636.	0.8	14
2624	Targeted depletion of <i>PIK3R2</i> induces regression of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 85063-85078.	0.8	16
2625	Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers. <i>Oncotarget</i> , 2017, 8, 133-144.	0.8	54
2626	Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. <i>Oncotarget</i> , 2016, 7, 87124-87135.	0.8	9
2627	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. <i>Oncotarget</i> , 2017, 8, 5160-5178.	0.8	66
2628	Integrative computational analysis of transcriptional and epigenetic alterations implicates <i>DTX1</i> as a putative tumor suppressor gene in HNSCC. <i>Oncotarget</i> , 2017, 8, 15349-15363.	0.8	16
2629	KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents. <i>Oncotarget</i> , 2017, 8, 17995-18009.	0.8	11
2630	Alterations of immune response of non-small cell lung cancer with Azacytidine. <i>Oncotarget</i> , 2013, 4, 2067-2079.	0.8	336

#	ARTICLE	IF	CITATIONS
2631	KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. <i>Oncotarget</i> , 2013, 4, 2144-2153.	0.8	112
2632	Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. <i>Oncotarget</i> , 2017, 8, 28725-28735.	0.8	50
2633	Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. <i>Oncotarget</i> , 2017, 8, 53675-53683.	0.8	9
2634	Low-density lipoprotein receptor-related protein 6 is a novel coreceptor of protease-activated receptor-2 in the dynamics of cancer-associated β -catenin stabilization. <i>Oncotarget</i> , 2017, 8, 38650-38667.	0.8	12
2635	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 43555-43570.	0.8	10
2636	Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017, 8, 59889-59900.	0.8	33
2637	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15
2638	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	0.8	17
2639	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017, 8, 53068-53083.	0.8	19
2640	A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer. <i>Oncotarget</i> , 2017, 8, 65469-65480.	0.8	19
2641	A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients. <i>Oncotarget</i> , 2017, 8, 86897-86907.	0.8	30
2642	Candidate tumor suppressor ZNF154 suppresses invasion and metastasis in NPC by inhibiting the EMT via Wnt/ β -catenin signalling. <i>Oncotarget</i> , 2017, 8, 85749-85758.	0.8	23
2643	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017, 8, 73419-73432.	0.8	74
2644	Deletion of <i>Ptprd</i> and <i>Cdkn2a</i> cooperate to accelerate tumorigenesis. <i>Oncotarget</i> , 2014, 5, 6976-6982.	0.8	22
2645	Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 90706-90718.	0.8	10
2646	Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 103063-103076.	0.8	11
2647	Potential of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. <i>Oncotarget</i> , 2014, 5, 5674-5685.	0.8	159
2648	The <i>NF1</i> gene revisited - from bench to bedside. <i>Oncotarget</i> , 2014, 5, 5873-5892.	0.8	139

#	ARTICLE	IF	CITATIONS
2649	Clinicopathological significance of <i>CHFR</i> methylation in non-small cell lung cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 109732-109739.	0.8	7
2650	Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 101808-101831.	0.8	16
2651	Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. <i>Oncotarget</i> , 2017, 8, 108936-108945.	0.8	9
2652	Novel mutational landscapes and expression signatures of lung squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 7424-7441.	0.8	16
2653	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	0.8	12
2654	Potential therapeutic targets of <i>TP53</i> gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <i>Oncotarget</i> , 2018, 9, 16234-16247.	0.8	24
2655	Identification of copy number alterations in colon cancer from analysis of amplicon-based next generation sequencing data. <i>Oncotarget</i> , 2018, 9, 20409-20425.	0.8	11
2656	LSCC SNP variant regulates SOX2 modulation of VDAC3. <i>Oncotarget</i> , 2018, 9, 22340-22352.	0.8	2
2657	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. <i>Oncotarget</i> , 2018, 9, 23960-23974.	0.8	13
2658	Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 29379-29391.	0.8	12
2659	Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33258-33270.	0.8	9
2660	Anticancer activity of 2-hydroxyflavanone towards lung cancer. <i>Oncotarget</i> , 2018, 9, 36202-36219.	0.8	22
2661	CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. <i>Oncotarget</i> , 2018, 9, 37352-37366.	0.8	33
2662	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. <i>Oncotarget</i> , 2015, 6, 394-408.	0.8	27
2663	Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures. <i>Oncotarget</i> , 2019, 10, 6168-6183.	0.8	18
2664	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of <i>EGFR</i> mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 12783-12795.	0.8	58
2665	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 16746-16756.	0.8	13
2666	p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling. <i>Oncotarget</i> , 2017, 8, 16202-16219.	0.8	26

#	ARTICLE	IF	CITATIONS
2667	TQ inhibits hepatocellular carcinoma growth <i>in vitro</i> and <i>in vivo</i> via repression of Notch signaling. <i>Oncotarget</i> , 2015, 6, 32610-32621.	0.8	39
2668	Mutant HRAS as novel target for MEK and mTOR inhibitors. <i>Oncotarget</i> , 2015, 6, 42183-42196.	0.8	40
2669	Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 2496-2507.	0.8	31
2670	Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome. <i>Oncotarget</i> , 2016, 7, 11165-11193.	0.8	76
2671	Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 12582-12597.	0.8	58
2672	The essential role of methylthioadenosine phosphorylase in prostate cancer. <i>Oncotarget</i> , 2016, 7, 14380-14393.	0.8	29
2673	Mapping of deletion breakpoints at the <i>CDKN2A</i> locus in melanoma: detection of <i>MTAP-ANRIL</i> fusion transcripts. <i>Oncotarget</i> , 2016, 7, 16490-16504.	0.8	22
2674	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	0.8	6
2675	Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 28935-28946.	0.8	44
2676	Inactivation of <i>RASA1</i> promotes melanoma tumorigenesis via R-Ras activation. <i>Oncotarget</i> , 2016, 7, 23885-23896.	0.8	23
2677	Genetic changes of non-small cell lung cancer under neoadjuvant therapy. <i>Oncotarget</i> , 2016, 7, 29761-29769.	0.8	16
2678	<i>S100A4</i> drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. <i>Oncotarget</i> , 2016, 7, 34630-34642.	0.8	44
2679	Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. <i>Oncotarget</i> , 2016, 7, 39957-39969.	0.8	49
2680	Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 700-713.	1.4	33
2681	Identification of a potential tumor suppressor gene, <i>UBL3</i> , in non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 76-87.	1.4	9
2682	<i>MET</i> in human cancer: germline and somatic mutations. <i>Annals of Translational Medicine</i> , 2017, 5, 205-205.	0.7	55
2683	Relevance of genetic alterations in squamous and small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 373-373.	0.7	9
2684	Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 372-372.	0.7	3

#	ARTICLE	IF	CITATIONS
2685	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	0.7	13
2686	Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 2356-2366.	1.3	7
2687	Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2367-2367.	1.3	20
2688	<p>Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9305-9321.	1.0	16
2689	Therapeutic Targeting of Cancers with Loss of PTEN Function. <i>Current Drug Targets</i> , 2014, 15, 65-79.	1.0	194
2690	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
2691	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2128-2142.	1.0	9
2692	Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1535-1563.	1.0	22
2693	The Positive Relationship Between γ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. <i>In Vivo</i> , 2018, 32, 171-177.	0.6	10
2694	Mediator kinase module and human tumorigenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 393-426.	2.3	88
2695	Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?. <i>Cancers</i> , 2015, 7, 1925-1958.	1.7	51
2696	Immunotherapy and Complexity: Overcoming Barriers to Control of Advanced Cancer. <i>MEDICC Review</i> , 2014, 16, 65.	0.5	7
2698	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. <i>Endocrinology and Metabolism</i> , 2020, 35, 44.	1.3	21
2699	Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 45-49.	0.1	13
2700	CCL25 promotes the migration and invasion of non-small cell lung cancer cells by regulating VEGF and MMPs in a CCR9-dependent manner. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3571-3580.	0.8	10
2701	Comprehensive identification and characterization of somatic copy number alterations in triple-negative breast cancer. <i>International Journal of Oncology</i> , 2020, 56, 522-530.	1.4	12
2702	Cathepsin A knockdown decreases the proliferation and invasion of A549 lung adenocarcinoma cells. <i>Molecular Medicine Reports</i> , 2020, 21, 2553-2559.	1.1	8
2703	Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis. <i>Oncology Letters</i> , 2019, 18, 5185-5196.	0.8	10

#	ARTICLE	IF	CITATIONS
2704	Radioimmunoimaging of 125I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 6413-6422.	0.8	4
2705	Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients. <i>Oncology Letters</i> , 2020, 19, 3495-3505.	0.8	9
2706	Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
2707	Molecular biology of lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S479-90.	0.6	173
2708	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S579-92.	0.6	37
2709	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. <i>Journal of Thoracic Disease</i> , 2013, 5, 585-92.	0.6	23
2710	An emerging place for lung cancer genomics in 2013. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S491-7.	0.6	22
2711	Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. <i>Translational Lung Cancer Research</i> , 2015, 4, 242-52.	1.3	22
2712	Treatment of advanced squamous cell carcinoma of the lung: a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 524-32.	1.3	74
2713	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <i>Translational Lung Cancer Research</i> , 2016, 5, 110-4.	1.3	9
2714	Biology of MET: a double life between normal tissue repair and tumor progression. <i>Annals of Translational Medicine</i> , 2015, 3, 82.	0.7	38
2715	Transthoracic fine-needle aspiration diagnosis of solid, subsolid, and partially calcified lung nodules: A retrospective study from a single academic center. <i>CytoJournal</i> , 2019, 16, 16.	0.8	5
2716	Detection of clinically relevant epidermal growth factor receptor pathway mutations in circulating cell-free tumor DNA using next generation sequencing in squamous cell carcinoma lung. <i>South Asian Journal of Cancer</i> , 2019, 08, 247-249.	0.2	1
2717	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
2718	Promise and challenges on the horizon of MET-targeted cancer therapeutics. <i>World Journal of Biological Chemistry</i> , 2015, 6, 16.	1.7	6
2719	Holistic cancer genome profiling for every patient. <i>Swiss Medical Weekly</i> , 2020, 150, w20158.	0.8	5
2720	Dysregulation of mTOR activity through LKB1 inactivation. <i>Chinese Journal of Cancer</i> , 2013, 32, 427-433.	4.9	27
2721	Abnormal Ubiquitination of Ubiquitin-Proteasome System in Lung Squamous Cell Carcinomas. , 0, , .		1

#	ARTICLE	IF	CITATIONS
2722	Genomic Profiling of Liver Cancer. <i>Genomics and Informatics</i> , 2013, 11, 180.	0.4	8
2723	Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin. <i>ELife</i> , 2013, 2, e01279.	2.8	66
2724	Agents to treat BRAF-mutant lung cancer. <i>Drugs in Context</i> , 2019, 8, 1-5.	1.0	37
2725	A pan-cancer analysis of prognostic genes. <i>PeerJ</i> , 2015, 3, e1499.	0.9	32
2726	Variance component testing for identifying differentially expressed genes in RNA-seq data. <i>PeerJ</i> , 2017, 5, e3797.	0.9	4
2727	BALSA: integrated secondary analysis for whole-genome and whole-exome sequencing, accelerated by GPU. <i>PeerJ</i> , 2014, 2, e421.	0.9	16
2728	Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. <i>PeerJ</i> , 2018, 6, e4254.	0.9	47
2729	Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset. <i>PeerJ</i> , 2019, 7, e7107.	0.9	8
2730	Identification of lncRNAs associated with lung squamous cell carcinoma prognosis in the competitive endogenous RNA network. <i>PeerJ</i> , 2019, 7, e7727.	0.9	17
2732	Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas. <i>Cancer Medicine</i> , 2021, 10, 8673-8692.	1.3	9
2733	Low-density-lipoprotein-receptor-related protein 1 mediates Notch pathway activation. <i>Developmental Cell</i> , 2021, 56, 2902-2919.e8.	3.1	22
2734	Identification of Novel Biomarkers Related to Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-18.	0.7	4
2735	Protein co-expression network-based profiles revealed from laser-microdissected cancerous cells of lung squamous-cell carcinomas. <i>Scientific Reports</i> , 2021, 11, 20209.	1.6	5
2736	Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 757323.	1.3	9
2737	USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. <i>ELife</i> , 2021, 10, .	2.8	25
2738	Regulation of 5-Hydroxymethylcytosine by TET2 Contributes to Squamous Cell Carcinoma Tumorigenesis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1270-1279.e2.	0.3	8
2739	Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway. <i>Cell Death and Differentiation</i> , 2022, 29, 568-584.	5.0	16
2740	Transcriptional Control of Metastasis by Integrated Stress Response Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 770843.	1.3	4

#	ARTICLE	IF	CITATIONS
2741	USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma. Cells, 2021, 10, 2652.	1.8	18
2742	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188636.	3.3	27
2743	Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free Radical Biology and Medicine, 2021, 177, 58-71.	1.3	21
2744	Computational Tools and Resources for Integrative Modeling in Systems Biology. , 2013, , 399-428.		0
2747	Role of Next-Generation Sequencing Technologies. , 2013, , 1-16.		0
2749	EXTRACTING SIGNIFICANT SAMPLE-SPECIFIC CANCER MUTATIONS USING THEIR PROTEIN INTERACTIONS. , 2013, , .		0
2750	The Use of Mouse Models for Lung Cancer Chemoprevention Studies. Methods in Pharmacology and Toxicology, 2014, , 135-153.	0.1	0
2751	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
2752	Pathology, Biomarkers, and Molecular Diagnostics. , 2014, , 226-252.e6.		1
2753	Abstract IA09: Squamous cell carcinoma pathology, etiology, and molecular drivers.. Clinical Cancer Research, 2014, 20, IA09-IA09.	3.2	0
2754	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. , 2014, , 309-321.e3.		0
2755	Next Generation Sequencing in Cancer Research and Clinical Application. , 2014, , 71-94.		1
2756	Strategies in Patients with Other Molecular Alterations. , 2015, , 187-202.		0
2758	DNA Methylation as a Biomarker in Cancer. Biomarkers in Disease, 2015, , 107-133.	0.0	0
2759	Gene Therapy for the Treatment of Lung Cancer. , 2015, , 1065-1072.		0
2760	Dosing â€“ When Less is More. RSC Drug Discovery Series, 2015, , 249-266.	0.2	0
2767	Understanding Hidden Perspectives in Biology of Cancer - Approach to its Prevention and Management. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	0
2768	Gene Expression Analysis: Current Methods. , 2016, , 107-136.		2

#	ARTICLE	IF	CITATIONS
2769	Squamous Cell Carcinoma, Lung. , 2016, , 8-62-8-65.		0
2770	Molecular Biomarkers in Pulmonary Cytology. Essentials in Cytopathology Series, 2016, , 121-138.	0.1	0
2771	Gene Expression Analysis: Applications. , 2016, , 137-149.		0
2772	Applications of Non-coding RNA in the Molecular Pathology of Cancer. , 2016, , 177-217.		1
2777	The Molecular Pathology of Head and Neck Squamous Cell Carcinoma. , 2017, , 589-601.		0
2778	Grundprinzipien der Tumorstehung. , 2017, , 1-16.		0
2780	Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. , 2017, , 273-289.		0
2781	Minor-Driver Mutant. , 2017, , 199-212.		0
2782	Next-Generation Sequencing and Bioinformatics. , 2017, , 97-115.		0
2786	The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	0
2791	Targeted Therapies for Lung Cancer. Molecular Pathology Library, 2018, , 239-255.	0.1	0
2793	Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy. Molecular Pathology Library, 2018, , 257-273.	0.1	0
2795	Lung and Mediastinum. , 2018, , 243-301.		0
2803	MSH2 is Inactivated by Multiple Mechanisms in Prostate Tumors, Leading to a Distinct Immune Response and Clinical Outcome Compared to MSH2 Deficient Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
2804	Notch in Lung Cancer. , 2018, , 241-276.		0
2805	Annexin A1 is upregulated in p53-positive gastric cancer. Annals of Cancer Research and Therapy, 2018, 26, 26-30.	0.1	1
2806	INO80 Chromatin Remodelling Coordinates Metabolic Homeostasis with Cell Division. SSRN Electronic Journal, 0, , .	0.4	0
2807	Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. Anticancer Research, 2018, 38, 1317-1325.	0.5	5

#	ARTICLE	IF	CITATIONS
2808	Cross-Sectional Study of Gene Expression Analysis Identifies Critical Biological Pathways and Key Genes Implicated in Non-Small Cell Lung Cancer. Iranian Red Crescent Medical Journal, 2018, 20, .	0.5	0
2814	Current treatment options for squamous cell carcinoma of the lung. Onkologie (Czech Republic), 2018, 12, 161-167.	0.0	0
2817	Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. , 2019, , 57-89.		3
2818	Lung Cancer Prevention. , 2019, , 511-542.		0
2819	Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy. Heat Shock Proteins, 2019, , 359-395.	0.2	1
2820	MOLECULAR FEATURES OF LUNG CANCERS AND MODERN CONCEPTS OF THEIR MOLECULOBIOLOGICAL TESTING. Bulletin of Problems Biology and Medicine, 2019, 3, 41.	0.0	0
2821	Neoantigen Clonal Balance Predicts Immunotherapy Outcomes and Prognosis. SSRN Electronic Journal, 0, , .	0.4	0
2822	Experiencia Con Erlotinib Y Gefitinib En Pacientes Con Cáncer De Pulmón Avanzado Con Mutación Positiva En El Receptor De Factor De Crecimiento Epidérmico.. Revista Medica De Panama, 2019, 38, .	0.0	0
2829	Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer. Translational Cancer Research, 2019, 8, 736-751.	0.4	0
2832	Tumor Sequencing: Enabling Personalized Targeted Treatments with Informatics. Computers in Health Care, 2020, , 161-174.	0.2	0
2834	Reactive Oxygen Species (ROS): Modulator of Response to Cancer Therapy in Non-Small-Cell Lung Carcinoma (NSCLC). , 2020, , 363-383.		1
2837	Lung Cancer: Old Story, New Modalities!. , 2020, , 385-409.		0
2851	FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis. Cancer Science, 2020, 111, 2718-2725.	1.7	10
2855	BHLHE41/DEC2 Expression Induces Autophagic Cell Death in Lung Cancer Cells and Is Associated with Favorable Prognosis for Patients with Lung Adenocarcinoma. International Journal of Molecular Sciences, 2021, 22, 11509.	1.8	3
2856	EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Communications Biology, 2021, 4, 1237.	2.0	20
2857	Malignant Epithelial Tumors of the Lung. , 2020, , 317-400.		0
2858	Introduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges. Cancer Drug Discovery and Development, 2020, , 1-16.	0.2	2
2859	Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns. Medical Science Monitor, 2021, 27, e929524.	0.5	5

#	ARTICLE	IF	CITATIONS
2860	Next generation mouse models of squamous cell lung cancer for translational immuno-oncology. <i>Oncotarget</i> , 2020, 11, 4463-4464.	0.8	0
2861	FKBP51 induces p53-dependent apoptosis and enhances drug sensitivity of human non-small cell lung cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2236-2242.	0.8	2
2862	Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas. , 2020, , 235-261.		0
2863	Analysis of Ensemble Feature Selection for Correlated High-Dimensional RNA-Seq Cancer Data. <i>Lecture Notes in Computer Science</i> , 2020, , 525-538.	1.0	2
2864	Genetics of Lung Cancer. <i>Respiratory Medicine</i> , 2020, , 87-103.	0.1	0
2865	Metachronous Isolated Contralateral Lung Metastasis from Pulmonary Adenosquamous Carcinoma with EGFR Mutation. <i>Acta Medica (Hradec Kralove)</i> , 2020, 63, 141-144.	0.2	2
2866	Role of downregulated ADARB1 in lung squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2020, 21, 1517-1526.	1.1	4
2867	The Pharmacogenomics "Side-effect" of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2060-2071.	0.9	1
2870	Identification of Key Genes Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma by Bioinformatics Analysis. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2020, 4, 335.	0.1	0
2871	Liver kinase B1 correlates with prognosis and epithelial-mesenchymal transition of resectable early stage non-small cell lung cancer. <i>Translational Cancer Research</i> , 2020, 9, 639-646.	0.4	3
2872	Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner subconsensuses of lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 9058-9077.	1.3	7
2873	Lung Cancer Computational Biology and Resources. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a038273.	2.9	1
2874	Molecular Pathology of Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037812.	2.9	8
2875	The current and future roles of genomics. , 0, , 79-94.		0
2876	Molecular pathology. , 0, , 95-118.		2
2877	Achievements in targeted therapies. , 0, , 215-233.		0
2878	Can we expect progress from targeted therapy of SCLC?. , 0, , 234-246.		0
2879	Distributions associated with simultaneous multiple hypothesis testing. <i>Journal of Statistical Distributions and Applications</i> , 2020, 7, .	1.2	1

#	ARTICLE	IF	CITATIONS
2880	Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. <i>Methods in Molecular Biology</i> , 2021, 2194, 187-221.	0.4	0
2882	Immune cell landscape analysis reveals prognostic immune cells and its potential mechanism in squamous cell lung carcinoma. <i>PeerJ</i> , 2020, 8, e9996.	0.9	3
2884	Molecular determinants of lung cancer metastasis to the central nervous system. <i>Translational Lung Cancer Research</i> , 2013, 2, 273-83.	1.3	15
2886	Apoptotic agents. <i>Translational Lung Cancer Research</i> , 2013, 2, 238-43.	1.3	3
2887	Necitumumab: a new therapeutic option for squamous cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2014, 3, 382-3.	1.3	6
2888	The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 15-7.	1.3	2
2889	Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2013, 2, 101-11.	1.3	10
2890	Involvement of Notch1/Hes signaling pathway in ankylosing spondylitis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2737-45.	0.5	4
2891	Do oncogenic drivers exist in squamous cell carcinoma of the lung?. <i>Oncology</i> , 2013, 27, 906, 913-4.	0.4	1
2892	Novel Application of Junction Trees to the Interpretation of Epigenetic Differences among Lung Cancer Subtypes. <i>AMIA Summits on Translational Science Proceedings</i> , 2015, 2015, 31-5.	0.4	0
2893	The promise of lung master protocol for squamous cell carcinoma: one trial to rule them all, one trial to find them?. <i>Annals of Translational Medicine</i> , 2015, 3, 219.	0.7	2
2894	The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2016, 5, 106-9.	1.3	5
2895	Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?. <i>Translational Lung Cancer Research</i> , 2016, 5, 95-7.	1.3	7
2896	PRECISION MEDICINE: DATA AND DISCOVERY FOR IMPROVED HEALTH AND THERAPY. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2016, 21, 243-8.	0.7	4
2900	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. <i>Anticancer Research</i> , 2015, 35, 669-76.	0.5	5
2905	The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 388-391.	0.2	0
2907	Genomics of adult and pediatric solid tumors. <i>American Journal of Cancer Research</i> , 2018, 8, 1356-1386.	1.4	14
2909	Associations of miR-605 rs2043556 polymorphism with the susceptibility and overall survival of lung cancer in Chinese non-smoking females. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 438-447.	0.5	2

#	ARTICLE	IF	CITATIONS
2912	Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. <i>Pathologica</i> , 2020, 112, 138-152.	1.3	2
2913	Recent advances in lung cancer genomics: Application in targeted therapy. <i>Advances in Genetics</i> , 2021, 108, 201-275.	0.8	5
2914	A549/DDP derived exosomes can affect cisplatin chemosensitivity via transporting CXCR4 to A549 cells. <i>Biocell</i> , 2022, 46, 711-720.	0.4	0
2915	Social Disparities in Thoracic Surgery Database Research. <i>Thoracic Surgery Clinics</i> , 2022, 32, 83-90.	0.4	1
2916	Prognostic Value of Telomeric Zinc Finger-Associated Protein Expression in Adenocarcinoma and Squamous Cell Carcinoma of Lung. <i>Medicina (Lithuania)</i> , 2021, 57, 1223.	0.8	1
2917	Deregulation of AKT/mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 425-433.	1.5	3
2918	Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition. <i>Science Advances</i> , 2021, 7, eabk1023.	4.7	43
2919	NTCU induced pre-malignant and malignant stages of lung squamous cell carcinoma in mice model. <i>Scientific Reports</i> , 2021, 11, 22500.	1.6	3
2920	p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 3363.	1.8	6
2921	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. <i>BMC Cancer</i> , 2021, 21, 1225.	1.1	0
2922	Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer. <i>British Journal of Cancer</i> , 2022, 126, 1244-1252.	2.9	17
2923	TMEM116 is required for lung cancer cell motility and metastasis through PDK1 signaling pathway. <i>Cell Death and Disease</i> , 2021, 12, 1086.	2.7	11
2924	Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. <i>Oncology Reports</i> , 2021, 47, .	1.2	3
2925	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. <i>Nature Cancer</i> , 2021, 2, 1224-1242.	5.7	37
2926	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	5.8	24
2928	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. <i>Frontiers in Oncology</i> , 2021, 11, 750657.	1.3	32
2929	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. <i>Frontiers in Immunology</i> , 2021, 12, 790119.	2.2	7
2930	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. <i>Molecular Cancer</i> , 2022, 21, 4.	7.9	28

#	ARTICLE	IF	CITATIONS
2931	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. <i>BMC Cancer</i> , 2022, 22, 46.	1.1	6
2932	Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer. <i>Cell Calcium</i> , 2022, 102, 102527.	1.1	5
2933	Risk assessment model and nomogram established by differentially expressed lncRNAs for early-stage lung squamous cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 5304-5314.	0.4	4
2934	Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. <i>Pathologica</i> , 2020, 112, 138-152.	1.3	5
2935	Stress Testing Pathology Models with Generated Artifacts. <i>Journal of Pathology Informatics</i> , 2021, 12, 54.	0.8	9
2936	RNA N6-Methyladenosine Regulators Contribute to Tumor Immune Microenvironment and Have Clinical Prognostic Impact in Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 650499.	1.1	1
2937	NRF2: KEAPing Tumors Protected. <i>Cancer Discovery</i> , 2022, 12, 625-643.	7.7	60
2938	Evaluation of the Prognostic Value of Long Noncoding RNAs in Lung Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
2939	Genetic alteration and PD-L1 expression profiles of Chinese patients with lung squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 231, 153761.	1.0	0
2940	CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 830.	1.8	8
2941	Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. <i>Journal of Translational Medicine</i> , 2022, 20, 30.	1.8	22
2942	The role of ROS in tumour development and progression. <i>Nature Reviews Cancer</i> , 2022, 22, 280-297.	12.8	453
2943	KRAS and MET in non-small-cell lung cancer: two of the new kids on the “drivers” block. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662110660.	1.0	6
2944	Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. <i>Cell Death and Differentiation</i> , 2022, 29, 1552-1568.	5.0	18
2945	Bayesian Sparse Spiked Covariance Model with a Continuous Matrix Shrinkage Prior. <i>Bayesian Analysis</i> , 2022, 17, .	1.6	3
2946	Identification of differentially distributed gene expression and distinct sets of cancer-related genes identified by changes in mean and variability. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, iqab124.	1.5	6
2947	Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2100344.	1.5	1
2948	Inflammation and Myeloid Cells in Cancer Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 759691.	1.8	12

#	ARTICLE	IF	CITATIONS
2949	Neurofibromin and suppression of tumorigenesis: beyond the GAP. <i>Oncogene</i> , 2022, 41, 1235-1251.	2.6	13
2950	Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 780655.	1.3	12
2951	The role of splicing factor PRPF8 in breast cancer. <i>Technology and Health Care</i> , 2022, 30, 293-301.	0.5	3
2952	Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	5
2953	Biomarkers in Pulmonary Carcinomas. , 2022, , 99-128.		2
2954	Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells. <i>Scientific Reports</i> , 2022, 12, 972.	1.6	11
2955	A Survey of Machine Learning Approaches Applied to Gene Expression Analysis for Cancer Prediction. <i>IEEE Access</i> , 2022, 10, 27522-27534.	2.6	20
2956	^{63}Ni regulates a common landscape of enhancer associated genes in non-small cell lung cancer. <i>Nature Communications</i> , 2022, 13, 614.	5.8	13
2957	Cetuximab and vemurafenib plus FOLFIRI(5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2022, 163, 152-162.	1.3	7
2958	A comprehensive and current review on the role of flavonoids in lung cancer“Experimental and theoretical approaches. <i>Phytomedicine</i> , 2022, 98, 153938.	2.3	22
2959	Regulation of Hippo signaling by metabolic pathways in cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119201.	1.9	15
2960	IKK α -deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
2961	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
2962	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-10). <i>Lung Cancer</i> , 2022, 166, 107-113.	0.9	3
2963	The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 982-988.	3.6	21
2966	Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring <i>KEAP1</i> and <i>NFE2L2</i> . <i>Journal of Cancer</i> , 2022, 13, 1512-1522.	1.2	0
2967	Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 188-188.	0.7	13
2968	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations. <i>International Journal of Genomics</i> , 2022, 2022, 1-17.	0.8	1

#	ARTICLE	IF	CITATIONS
2969	Identifying pathways regulating the oncogenic p53 family member p63 provides therapeutic avenues for squamous cell carcinoma. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 18.	2.7	4
2970	A cancer graph: a lung cancer property graph database in Neo4j. <i>BMC Research Notes</i> , 2022, 15, 45.	0.6	4
2971	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types. <i>Frontiers in Genetics</i> , 2021, 12, 806386.	1.1	14
2972	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies. <i>Clinical Epigenetics</i> , 2022, 14, 31.	1.8	18
2973	Low Expression of ZNF154 is Related to Poor Prognosis in Gastric Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 659-672.	0.9	4
2974	Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 781903.	1.3	3
2975	MicroRNA-200a-3p and GATA6 are abnormally expressed in patients with non-small cell lung cancer and exhibit high clinical diagnostic efficacy. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 281.	0.8	3
2976	Two Faces of Nrf2 in Cancer. , 0, , .		0
2977	Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis. <i>Thoracic Cancer</i> , 2022, , .	0.8	4
2978	A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 2790-2800.	1.3	7
2979	Profiling of diverse tumor types establishes the broad utility of VHL-based ProTacs and triages candidate ubiquitin ligases. <i>iScience</i> , 2022, 25, 103985.	1.9	17
2980	Cell Painting predicts impact of lung cancer variants. <i>Molecular Biology of the Cell</i> , 2022, 33, mbcE21110538.	0.9	25
2981	Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 856132.	1.3	2
2982	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. <i>European Respiratory Journal</i> , 2022, 60, 2200380.	3.1	34
2983	Multifaceted Roles of the KEAP1-NRF2 System in Cancer and Inflammatory Disease Milieu. <i>Antioxidants</i> , 2022, 11, 538.	2.2	24
2984	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.	1.0	11
2986	In Silico Bioinformatics Followed by Molecular Validation Using Archival FFPE Tissue Biopsies Identifies a Panel of Transcripts Associated with Severe Asthma and Lung Cancer. <i>Cancers</i> , 2022, 14, 1663.	1.7	2
2987	Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling. <i>Oncogene</i> , 2022, 41, 2326-2339.	2.6	3

#	ARTICLE	IF	CITATIONS
2989	Molecular Genetic Mechanisms in Cancers of Keratinocytic Origin. , 0, , .		1
2990	BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer. Antioxidants, 2022, 11, 661.	2.2	6
2991	Integrated Analysis of Transcriptomic and Genomic Data Reveals Blood Biomarkers With Diagnostic and Prognostic Potential in Non-small Cell Lung Cancer. Frontiers in Molecular Biosciences, 2022, 9, 774738.	1.6	3
2992	The Diagnostic Utility of Cell-Free DNA from Ex Vivo Bronchoalveolar Lavage Fluid in Lung Cancer. Cancers, 2022, 14, 1764.	1.7	3
2993	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
2994	KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. Journal of Thoracic Oncology, 2022, 17, 751-757.	0.5	21
2995	Targeting ferroptosis as a vulnerability in cancer. Nature Reviews Cancer, 2022, 22, 381-396.	12.8	644
2997	Updated Prognostic Factors in Localized NSCLC. Cancers, 2022, 14, 1400.	1.7	28
2998	Rapid FEV1 Decline and Lung Cancer Incidence in South Korea. Chest, 2022, 162, 466-474.	0.4	4
2999	Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. Journal of Clinical Medicine, 2022, 11, 1461.	1.0	20
3000	Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for <scp>OSMR</scp> and <scp>YAP</scp> signalling. Journal of Pathology: Clinical Research, 2022, 8, 279-293.	1.3	1
3001	Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 780650.	1.3	12
3002	Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 3478.	1.8	25
3003	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
3004	Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer, 2022, 167, 87-97.	0.9	11
3005	Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer. Cancers, 2022, 14, 1813.	1.7	4
3006	Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors. Journal of Thoracic Oncology, 2022, 17, 477-480.	0.5	2
3007	NRF2 drives an oxidative stress response predictive of breast cancer. Free Radical Biology and Medicine, 2022, 184, 170-184.	1.3	8

#	ARTICLE	IF	CITATIONS
3008	Anti-cancer peptide-based therapeutic strategies in solid tumors. Cellular and Molecular Biology Letters, 2022, 27, 33.	2.7	49
3009	FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy. Frontiers in Oncology, 2022, 12, 846744.	1.3	3
3010	Machine learning application in personalised lung cancer recurrence and survivability prediction. Computational and Structural Biotechnology Journal, 2022, 20, 1811-1820.	1.9	25
3011	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. Nature Communications, 2022, 13, 1811.	5.8	21
3012	Role and regulation of autophagy in cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166400.	1.8	52
3013	Attention Based Deep Multiple Instance Learning Approach for Lung Cancer Prediction using Histopathological Images. , 2021, 2021, 2852-2855.		6
3014	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer, 2021, 21, 1322.	1.1	7
3015	Novel cancer subtyping method based on patient-specific gene regulatory network. Scientific Reports, 2021, 11, 23653.	1.6	6
3016	<i>KLF5</i> , a Novel Therapeutic Target in Squamous Cell Carcinoma. DNA and Cell Biology, 2021, 40, 1503-1512.	0.9	0
3017	A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. Nature Communications, 2021, 12, 7139.	5.8	12
3018	Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers, 2021, 13, 6168.	1.7	5
3019	KRAS Mutations in Squamous Cell Carcinomas of the Lung. Frontiers in Oncology, 2021, 11, 788084.	1.3	14
3021	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open, 2021, 6, 100328.	2.0	15
3022	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	5.8	16
3023	A novel classification method for NSCLC based on the background interaction network and the edge-perturbation matrix. Aging, 2022, 14, 3155-3174.	1.4	2
3024	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine, 2022, 14, 39.	3.6	22
3025	DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clinical Epigenetics, 2022, 14, 50.	1.8	9
3026	Tumors and tumor-like conditions of the lung. , 2015, , 1335-1427.		0

#	ARTICLE	IF	CITATIONS
3096	Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. <i>Modern Pathology</i> , 2022, 35, 1383-1397.	2.9	17
3097	A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. <i>Nature Communications</i> , 2022, 13, 2206.	5.8	146
3114	The changing world of oncology drug development-A global pharmaceutical company's perspective. <i>Chinese Clinical Oncology</i> , 2014, 3, 20.	0.4	6
3116	Deubiquitination and Stabilization of PD-L1 by USP21.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12763-12774.	0.0	0
3117	Differential Gene Expression Analysis of the Most Relevant Genes for Lung Cancer Prediction and Sub-type Classification. <i>Lecture Notes in Computer Science</i> , 2022, , 182-191.	1.0	0
3118	PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy. <i>Cell and Bioscience</i> , 2022, 12, 50.	2.1	9
3119	The Significance of Tumor Microenvironment Score for Breast Cancer Patients. <i>BioMed Research International</i> , 2022, 2022, 1-27.	0.9	3
3120	Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic. <i>Current Oncology</i> , 2022, 29, 3171-3186.	0.9	2
3121	Pharmacogenomic Cluster Analysis of Lung Cancer Cell Lines Provides Insights into Preclinical Model Selection in NSCLC. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2022, 14, 712-721.	2.2	1
3122	Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor. <i>Cancers</i> , 2022, 14, 2174.	1.7	2
3123	Survival Outcomes and Treatment Patterns in Patients with NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	2
3124	Clinical-molecular prospective cohort study in Non-Small Cell Lung Cancer (PROMOLE study): a comprehensive approach to identify new predictive markers of pharmacological response. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	5
3126	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1071-1083.	0.5	2
3128	Recent Advances of Autophagy in Non-Small Cell Lung Cancer: From Basic Mechanisms to Clinical Application. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	8
3129	Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5346.	1.8	11
3130	Prediction of lung cancer risk in Chinese population with genetic-environment factor using extreme gradient boosting. <i>Cancer Medicine</i> , 2022, 11, 4469-4478.	1.3	7
3131	Genetic variants in <i>DDO</i> and <i>PEX5L</i> in peroxisome-related pathways predict non-small cell lung cancer survival. <i>Molecular Carcinogenesis</i> , 2022, 61, 619-628.	1.3	2
3132	Human Papillomavirus-Related Carcinomas of the Sinonasal Tract. <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 291-302.	0.2	3

#	ARTICLE	IF	CITATIONS
3133	Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression. <i>Cancer Research</i> , 2022, 82, 2520-2537.	0.4	9
3134	GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling. <i>Cancer Letters</i> , 2022, 538, 215692.	3.2	9
3135	Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung – Determination and validation of optimal prognostic cut-offs. <i>Lung Cancer</i> , 2022, 169, 1-12.	0.9	5
3136	Charted Territory: Evidence from Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical Industry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3138	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
3139	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. <i>Oncogene</i> , 2022, 41, 3423-3432.	2.6	7
3140	Transcriptome analysis reveals high tumor heterogeneity with respect to re-activation of stemness and proliferation programs. <i>PLoS ONE</i> , 2022, 17, e0268626.	1.1	0
3142	Molecular Signatures of <i>KRAS</i> -Mutated Lung Adenocarcinoma: Analysis of Concomitant <i>EGFR</i> , <i>ALK</i> , <i>STK11</i> , and PD-L1 Status. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211020.	0.7	2
3143	Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
3144	Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. <i>OncoTargets and Therapy</i> , 0, Volume 15, 571-584.	1.0	1
3145	Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. <i>Free Radical Biology and Medicine</i> , 2022, 187, 92-104.	1.3	5
3146	Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma. <i>Molecular Carcinogenesis</i> , 2022, 61, 776-786.	1.3	2
3147	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. <i>Current Oncology</i> , 2022, 29, 3748-3758.	0.9	7
3148	<i>PSC</i> subtyping based on <i>TTF1</i> and p40 expression reveals distinct molecular characteristics and therapeutic strategies. <i>International Journal of Cancer</i> , 2022, 151, 717-729.	2.3	2
3149	Structural and Functional Thymic Biomarkers Are Involved in the Pathogenesis of Thymic Epithelial Tumors: An Overview. <i>Immuno</i> , 2022, 2, 408-429.	0.6	0
3150	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. <i>Biomedicines</i> , 2022, 10, 1313.	1.4	9
3151	A computational approach to generate highly conserved gene co-expression networks with RNA-seq data. <i>STAR Protocols</i> , 2022, 3, 101432.	0.5	1
3152	Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	20

#	ARTICLE	IF	CITATIONS
3154	An 8-Gene Signature for Classifying Major Subtypes of Non-Small-Cell Lung Cancer. <i>Cancer Informatics</i> , 2022, 21, 117693512211007.	0.9	5
3155	Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
3156	NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6748.	1.8	12
3157	Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3158	Vaccines for immunoprevention of DNA mismatch repair deficient cancers. , 2022, 10, e004416.		21
3159	Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations. <i>Genomics</i> , 2022, , 110401.	1.3	6
3160	Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	4
3161	Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. <i>Oncogene</i> , 2022, 41, 3640-3654.	2.6	17
3162	Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1381-1392.	1.9	0
3163	Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2022, 23, 457-466.	1.1	12
3164	CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma. <i>Molecular Therapy</i> , 2022, 30, 3341-3357.	3.7	4
3165	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	3.4	117
3166	Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1302-1314.	1.3	10
3167	Deciphering associations between three RNA splicing-related genetic variants and lung cancer risk. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	1
3168	Prognostic significance of PD-L1 expression and CD8+ TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 2224-2234.	0.6	3
3169	Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3216.	1.7	4
3170	tert-Butylhydroquinone-induced formation of high-molecular-weight p62: A novel mechanism in the activation of Nrf2-Keap1. <i>Cell Biology International</i> , 2022, 46, 1345-1354.	1.4	3
3171	Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues. <i>Nature Communications</i> , 2022, 13, .	5.8	11

#	ARTICLE	IF	CITATIONS
3172	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4981-4997.	0.9	14
3173	What we have learnt from Drosophila model organism: the coordination between insulin signaling pathway and tumor cells. <i>Heliyon</i> , 2022, 8, e09957.	1.4	2
3174	Creatine riboside is a cancer cell-derived metabolite associated with arginine auxotrophy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	4
3175	Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. <i>Genome Medicine</i> , 2022, 14, .	3.6	20
3176	APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma. <i>Lung Cancer</i> , 2022, , .	0.9	1
3177	Identification of metastasis-related long non-coding RNAs in lung cancer through a novel tumor mesenchymal score. <i>Pathology Research and Practice</i> , 2022, , 154018.	1.0	2
3178	Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. <i>Cancers</i> , 2022, 14, 3472.	1.7	1
3179	Histologically resolved multiomics enables precise molecular profiling of human intratumor heterogeneity. <i>PLoS Biology</i> , 2022, 20, e3001699.	2.6	6
3180	Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping. <i>Computers in Biology and Medicine</i> , 2022, 148, 105832.	3.9	7
3181	A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3183	Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway. <i>British Journal of Cancer</i> , 2022, 127, 1214-1225.	2.9	16
3184	CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2022, 45, 324-334.	1.2	8
3185	Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	3
3186	Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma. <i>Cancers</i> , 2022, 14, 3671.	1.7	5
3187	Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3188	DiNAMIC.Duo: detecting somatic DNA copy number differences without a normal reference. <i>Bioinformatics</i> , 2022, 38, 4415-4417.	1.8	0
3189	Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells. <i>JCI Insight</i> , 2022, 7, .	2.3	9
3190	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	10

#	ARTICLE	IF	CITATIONS
3191	Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
3192	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. <i>Cancers</i> , 2022, 14, 4103.	1.7	14
3193	The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	46
3195	Targeting <scp>YAP1</scp>/<scp>TAZ</scp> in nonsmallâ€cell lung carcinoma: From molecular mechanisms to precision medicine. <i>International Journal of Cancer</i> , 2023, 152, 558-571.	2.3	10
3196	Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation. <i>Current Oncology</i> , 2022, 29, 5855-5868.	0.9	1
3197	Genetic, metabolic and immunological features of cancers with <scp>NRF2</scp> addiction. <i>FEBS Letters</i> , 2022, 596, 1981-1993.	1.3	5
3198	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. <i>Lung Cancer</i> , 2022, 172, 19-28.	0.9	9
3199	Strategies for understanding the role of cellular heterogeneity in the pathogenesis of lung cancer: a cell model for chronic exposure to cigarette smoke extract. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
3200	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. <i>Lung Cancer</i> , 2022, 172, 154-159.	0.9	5
3201	Panâ€cancer landscape of abnormal ctDNA methylation across human tumors. <i>Cancer Genetics</i> , 2022, 268-269, 37-45.	0.2	0
3202	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
3203	A Novel ER Stress Mediator TMTC3 Promotes Squamous Cell Carcinoma Progression by Activating GRP78/PERK Signaling Pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 4853-4868.	2.6	8
3204	Genomic Alterations in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
3205	Node-aligned Graph Convolutional Network for Whole-slide Image Representation and Classification. , 2022, , .		19
3206	Cancer Subtyping via Embedded Unsupervised Learning on Transcriptomics Data. , 2022, , .		3
3207	Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3208	Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. <i>Communications Biology</i> , 2022, 5, .	2.0	4
3209	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	1.7	5

#	ARTICLE	IF	CITATIONS
3210	Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
3211	NRF2: A crucial regulator for mitochondrial metabolic shift and prostate cancer progression. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	6
3212	Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 1544.	1.1	2
3213	Utilization of cytologic cell blocks for targeted sequencing of solid tumors. <i>Cancer Medicine</i> , 2023, 12, 4042-4063.	1.3	3
3214	Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. <i>Science Immunology</i> , 2022, 7, .	5.6	15
3215	Ubiquitination-mediated molecular pathway alterations in human lung squamous cell carcinomas identified by quantitative ubiquitinomics. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
3217	Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function <i>NOTCH1</i> -Mutant Head and Neck Cancer. <i>Oncologist</i> , 2022, 27, 1004-e926.	1.9	6
3218	Hunting for Novel Routes in Anticancer Drug Discovery: Peptides against Sam-Sam Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10397.	1.8	6
3219	Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 4444-4456.	0.4	2
3220	FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10506.	1.8	4
3221	A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	3
3222	Role of autophagy in liver diseases. <i>Current Opinion in Physiology</i> , 2022, , 100594.	0.9	0
3223	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	3
3224	Analyzing integrated network of methylation and gene expression profiles in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3226	A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 4126-4138.	0.4	7
3228	Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications. <i>Cancers</i> , 2022, 14, 4653.	1.7	1
3229	Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. <i>Nature Cancer</i> , 2022, 3, 1026-1038.	5.7	115
3230	Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2

#	ARTICLE	IF	CITATIONS
3231	Novel NRF2-activated cancer treatments utilizing synthetic lethality. <i>IUBMB Life</i> , 2022, 74, 1209-1231.	1.5	7
3232	Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. <i>Nature Communications</i> , 2022, 13, .	5.8	13
3233	Significance of NRF2 in physiological and pathological conditions an comprehensive review. <i>Archives of Biochemistry and Biophysics</i> , 2022, 730, 109417.	1.4	15
3234	Somatic mutation variant analysis in rural, resectable non-small cell lung carcinoma patients. <i>Cancer Genetics</i> , 2022, 268-269, 75-82.	0.2	2
3235	Iron in Cancer Progression: Does BACH1 Promote Metastasis by Altering Iron Homeostasis?. <i>Sub-Cellular Biochemistry</i> , 2022, , 67-80.	1.0	1
3236	Histologic transformation in lung cancer: when one door shuts, another opens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211305.	1.4	3
3237	The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. <i>Cancers</i> , 2022, 14, 5305.	1.7	3
3239	Cancer-associated Notch receptor variants lead to O-fucosylation defects that deregulate Notch signaling. <i>Journal of Biological Chemistry</i> , 2022, 298, 102616.	1.6	5
3242	A TNFR1-UBCH10 axis drives lung squamous cell carcinoma dedifferentiation and metastasis through a cell-autonomous signaling loop. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
3243	The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells. <i>Cancer Medicine</i> , 2023, 12, 5688-5702.	1.3	9
3244	Gene Screening in High-Throughput Right-Censored Lung Cancer Data. <i>Onco</i> , 2022, 2, 305-318.	0.2	0
3245	Squamous cell lung cancer: Current landscape and future therapeutic options. <i>Cancer Cell</i> , 2022, 40, 1279-1293.	7.7	22
3247	Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 2064-2078.	1.3	3
3248	Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure. <i>Translational Lung Cancer Research</i> , 2022, 11, 2022-2039.	1.3	1
3249	Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. <i>Journal of the National Cancer Institute</i> , 2023, 115, 29-42.	3.0	7
3250	Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2023, 21, 36-50.	1.5	3
3251	Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. <i>Cancer Research Communications</i> , 2022, 2, 1487-1496.	0.7	2
3252	Esophageal Cancer Genetics and Clinical Translation. <i>Thoracic Surgery Clinics</i> , 2022, 32, 425-435.	0.4	3

#	ARTICLE	IF	CITATIONS
3253	Identification of alternative transcripts of NSD1 gene in Sotos Syndrome patients and healthy subjects. <i>Gene</i> , 2023, 851, 146970.	1.0	3
3254	A semi-supervised multi-task learning framework for cancer classification with weak annotation in whole-slide images. <i>Medical Image Analysis</i> , 2023, 83, 102652.	7.0	17
3255	The Role of DNA Methylation and DNA Methyltransferases in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 317-348.	0.8	7
3256	Thymic Carcinoma Versus Lung Squamous Cell Carcinoma. , 2022, , 113-118.		0
3257	Construction and Validation of Early Warning Model of Lung Cancer Based on Machine Learning: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211367.	0.8	0
3258	Metastatic Urothelial Carcinoma Versus Squamous Cell Carcinoma. , 2022, , 107-112.		0
3259	KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3260	Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer. <i>Cell Reports</i> , 2022, 41, 111596.	2.9	7
3261	A Clinician's Guide to Bioinformatics for Next-Generation Sequencing. <i>Journal of Thoracic Oncology</i> , 2023, 18, 143-157.	0.5	9
3262	Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
3263	Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. <i>Genome Medicine</i> , 2022, 14, .	3.6	13
3264	Prediction of Lung Cancer Survival Based on Multiomic Data. <i>Lecture Notes in Computer Science</i> , 2022, , 116-127.	1.0	0
3265	Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy. <i>European Journal of Medicinal Chemistry</i> , 2023, 246, 115009.	2.6	2
3266	Exploring structural effects in a new class of NRF2 inhibitors. <i>RSC Medicinal Chemistry</i> , 2023, 14, 74-84.	1.7	1
3267	Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. <i>Computers in Biology and Medicine</i> , 2023, 152, 106347.	3.9	4
3268	Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma. <i>Medicine (United States)</i> , 2022, 101, e31798.	0.4	0
3269	Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease. <i>Antioxidants</i> , 2022, 11, 2345.	2.2	77
3270	PROTAC therapy as a new targeted therapy for lung cancer. <i>Molecular Therapy</i> , 2023, 31, 647-656.	3.7	13

#	ARTICLE	IF	CITATIONS
3272	Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3273	Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3274	Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. <i>Clinical Lung Cancer</i> , 2023, 24, e126-e133.	1.1	2
3275	Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
3276	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103891.	2.0	6
3277	KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. <i>Cancer Cell</i> , 2023, 41, 88-105.e8.	7.7	12
3278	Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report. <i>Thoracic Cancer</i> , 0, , .	0.8	2
3279	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3280	High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population. <i>Journal of Thoracic Disease</i> , 2023, 15, 101-111.	0.6	2
3281	Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 814-831.	1.3	0
3282	Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	2
3283	Secular-Trend Analysis of the Incidence Rate of Lung Squamous Cell Carcinoma in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1614.	1.2	0
3284	Identification of 2,4,5-trisubstituted-2,4-dihydro-3H-1,2,4-triazol-3-one-based small molecules as selective BRD9 binders. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115018.	2.6	3
3285	Prediction of lung cancer metastasis by gene expression. <i>Computers in Biology and Medicine</i> , 2023, 153, 106490.	3.9	3
3286	Somatic variant detection from multi-sampled genomic sequencing data of tumor specimens using the ith.Variant pipeline. <i>STAR Protocols</i> , 2023, 4, 101927.	0.5	3
3287	Hierarchical Categorical Generative Modeling for Multi-omics Cancer Subtyping. , 2022, , .		1
3288	Data-Driven Identification of Targets for Fluorescence-Guided Surgery in Non-Small Cell Lung Cancer. <i>Molecular Imaging and Biology</i> , 0, , .	1.3	1
3289	The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2023, 24, 165-174.	1.1	2

#	ARTICLE	IF	CITATIONS
3290	Bioinformatic analysis of single-cell RNA sequencing dataset dissects cellular heterogeneity of triple-negative breast cancer in transcriptional profile, splicing event and crosstalk network. <i>Clinical and Translational Oncology</i> , 2023, 25, 1856-1868.	1.2	3
3291	Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	17
3292	Tumor immunology. , 2023, , 245-452.		0
3293	Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
3294	<i>NFE2L2</i> Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. <i>Cancer Research</i> , 2023, 83, 861-874.	0.4	16
3296	A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
3297	High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts. <i>Translational Lung Cancer Research</i> , 2023, .	1.3	0
3298	Investigation of the function of the novel tumor marker BEND5 in lung adenocarcinoma based on data mining and in vitro analysis. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	0
3299	ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. <i>Gynecologic Oncology</i> , 2023, 171, 59-66.	0.6	2
3300	LncRNA HHIP-AS1 suppresses lung squamous cell carcinoma by stabilizing HHIP mRNA. <i>Life Sciences</i> , 2023, 321, 121578.	2.0	2
3301	Ethnic differences in lung cancer: “we can differ and still unite around common goals.” <i>Respiratory Investigation</i> , 2023, 61, 355-356.	0.9	0
3302	Risk factors and actionable molecular signatures in COVID-19-associated lung adenocarcinoma and lung squamous cell carcinoma patients. <i>Computers in Biology and Medicine</i> , 2023, 158, 106855.	3.9	0
3303	Clinical Research Progress of Carrilizumab in Patients with Lung Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 12191-12197.	0.0	0
3304	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0
3305	Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition. <i>International Journal of Biological Macromolecules</i> , 2023, 230, 123428.	3.6	3
3306	Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals <i>TP53</i> Aneuploidy-driven Metabolic Reprogramming. <i>Cancer Research Communications</i> , 2023, 3, 281-296.	0.7	0
3307	Integrative multi-omics networks identify PKC δ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. <i>Nature Cancer</i> , 2023, 4, 181-202.	5.7	19
3308	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. <i>AME Medical Journal</i> , 0, 8, 6-6.	0.4	1

#	ARTICLE	IF	CITATIONS
3309	Inflammasome-independent NLRP3 function enforces ATM activity in response to genotoxic stress. <i>Life Science Alliance</i> , 2023, 6, e202201494.	1.3	1
3311	A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 718-730.	0.5	8
3312	Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment. <i>National Science Review</i> , 2023, 10, .	4.6	6
3313	Mutational and Transcriptional Characterization Establishes Prognostic Models for Resectable Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 0, Volume 15, 147-163.	0.9	2
3314	Microsatellite instability-related prognostic risk score (MSI-pRS) defines a subset of lung squamous cell carcinoma (LUSC) patients with genomic instability and poor clinical outcome. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
3315	Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4209.	1.8	2
3316	Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	1
3317	Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. <i>Journal of Clinical Medicine</i> , 2023, 12, 1711.	1.0	1
3318	Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100486.	0.6	0
3319	Destruction of the cellular antioxidant pool contributes to resveratrol-induced senescence and apoptosis in lung cancer. <i>Phytotherapy Research</i> , 2023, 37, 2995-3008.	2.8	6
3320	Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma. <i>Cell Reports</i> , 2023, 42, 112212.	2.9	12
3321	Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer. <i>Biomolecules</i> , 2023, 13, 477.	1.8	5
3322	FAM193A is a positive regulator of p53 activity. <i>Cell Reports</i> , 2023, 42, 112230.	2.9	2
3323	Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE. <i>ELife</i> , 0, 12, .	2.8	1
3324	Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
3326	Statistical Methods for Integrative Clustering of Multi-omics Data. <i>Methods in Molecular Biology</i> , 2023, , 73-93.	0.4	0
3327	Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. <i>Breast Cancer</i> , 0, , .	1.3	1
3329	Molecular Pathology of Lung Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
3330	Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	0
3331	Mitigation of Cardiovascular Disease and Toxicity through NRF2 Signalling. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6723.	1.8	3
3332	A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
3333	Malignant and borderline mesothelial tumors of the pleura. , 2024, , 755-792.		1
3334	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. <i>Nature Genetics</i> , 2023, 55, 807-819.	9.4	18
3335	Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review. <i>British Journal of Anaesthesia</i> , 2023, 131, 26-36.	1.5	2
3336	Genomicâ€“transcriptomic evolution in lung cancer and metastasis. <i>Nature</i> , 2023, 616, 543-552.	13.7	44
3337	The evolution of lung cancer and impact of subclonal selection in TRACERx. <i>Nature</i> , 2023, 616, 525-533.	13.7	62
3338	DNA-Methylomeâ€“Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 3051-3064.	3.2	3
3339	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. <i>Cancer Discovery</i> , 2023, 13, 1572-1591.	7.7	13
3340	Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. <i>Cancer Research</i> , 2023, 83, 1953-1967.	0.4	7
3341	FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung. <i>Cancer Research</i> , 2023, 83, 1443-1458.	0.4	0
3342	NFR2/ABC transporter axis in drug resistance of breast cancer cells. <i>Molecular Biology Reports</i> , 2023, 50, 5407-5414.	1.0	5
3343	<i>TP53</i> mutations predict poor response to immunotherapy in patients with metastatic solid tumors. <i>Cancer Medicine</i> , 2023, 12, 12438-12451.	1.3	2
3344	Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
3345	Progress of Lung Cancer Genomic Epidemiology in China. , 2022, , 243-259.		0
3352	Methylation and hydroxymethylation in cancer. , 2023, , 11-37.		0
3358	Cancers bronchopulmonaires. , 2023, , 195-197.		0

#	ARTICLE	IF	CITATIONS
3361	Transforming Diagnosis and Therapeutics Using Cancer Genomics. <i>Cancer Treatment and Research</i> , 2023, , 15-47.	0.2	1
3384	Chromosome 12. , 2023, , 371-394.		0
3399	Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
3424	Molecular Carcinogenesis of Lung Cancer. , 2023, , 1-21.		0
3441	Decoding the tumor microenvironment with spatial technologies. <i>Nature Immunology</i> , 2023, 24, 1982-1993.	7.0	6
3455	Decoding the basis of histological variation in human cancer. <i>Nature Reviews Cancer</i> , 0, , .	12.8	1